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Abstract
Neuropathic pain is defined as pain arising as a result of damage to or
dysfunction of the nervous system and is often resistant to opiate analgesics, making it
difficult to treat using conventional therapies. Underlying the development of this
chronic pathological pain state is a process of neuronal plasticity termed central
sensitisation, involving changes from the spinal to the cortical levels of the central
nervous system. Central sensitisation may result in thermal hyperalgesia and
mechanical and cold allodynia which are commonly found in this condition. Neurons
in the dorsal horn undergo plastic changes during central sensitisation, markedly
altering their response profile to sensory stimulation. Glutamate is the major
excitatory neurotransmitter at synapses between primary afferents and spinal dorsal
horn neurons and plays a vital role in the generation of neuronal plasticity. Several
key receptors are involved in altering the sensitivity of these neurons, including
ionotropic and metabotropic glutamate receptors and peptidergic receptors.
This study was designed to investigate the role of AMPA, NMDA, mGlu
group I and VPAC2 receptors (Rs) in the generation of neuropathic pain. Firstly, the
behavioural reflex responses of naive rats to intrathecal administration of low doses of
these receptor agonists, singly or in combinations were investigated. Combinations of
two or more agonists caused increased behavioural responses to thermal and
mechanical stimuli. The combination of AMPA with mGluR group I and VPAC2 R
agonists, showed a synergistic effect whereas other combinations were less than
additive.
Expression of AMPA R GluRl and GluR2 subunits in the superficial dorsal
horn was studied using confocal immunofluorescence. In the chronic constriction
injury (CCI) model of neuropathic pain both the number of GluRl-immunopositive
cell bodies and the level of GluRl expression within cells decreased significantly in
lamina II of the dorsal horn, ipsilateral to the injury. In contrast, there was no change
in GluR2 expression or the degree of colocalisation of GluRl and GluR2 subtypes
within individual cells following CCI.
The subcellular distribution of GluRl subunits was also noted to change
significantly as a result of CCI. GluRl subunits were found to redistribute distally into
neuronal processes in lamina II cells ipsilateral to CCI and also in response to acute
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intrathecal AMPA treatment. This redistribution may reflect an increase in the number
of GluRl-containing receptors associated with synaptic sites.
The relationship between the presynaptic marker protein, Bassoon and GluRl -
immunopositive cells was investigated, showing a significant increase in the number
of Bassoon immunopositive puncta associated with each GluRl-immunopositive cell
ipsilateral to nerve injury. The subcellular redistribution of GluRl subunits caused by
CCI was reversed upon behavioural recovery and also by intrathecal administration of
a combination of antagonists to NMDA R, mGluRl/5 and VPAC2 R, whereas an
AMPA R antagonist alone had no effect.
These results suggest that AMPA Rs are important in the central sensitisation
underlying neuropathic pain. However, it is clear that several receptors are involved in
triggering maximal behavioural responses, and potential therapeutic interventions may
be more effective if designed to target more than one receptor type. There is also
evidence to suggest that AMPA Rs may have differing roles dependant upon their
subtype composition, so subtype-specific antagonists may potentially be useful in
treatment of neuropathic pain.
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Chapter 1: Introduction to pain processing
Pain is defined as "an unpleasant sensory and emotional experience associated
with actual or potential tissue damage or expressed in terms of such damage"
(Merskey and Bogduk, 1994). Nociception is the term used for a purely sensory event,
devoid of the emotional content of pain perception, consisting of the transduction of a
noxious stimulus in the periphery and its transmission to the cerebral cortex via the
spinal cord.
Physiological pain is an adaptive process, allowing for recovery and healing of
an injury by causing immobility of the damaged part and avoidance of further painful
stimuli. The sensation of pain ceases once the inflammatory process abates or the
noxious stimulus is removed. However, if pain continues once the healing process is
complete, or is out of proportion to the degree of tissue injury, this is considered to be
a pathological pain state. Nociceptive processing is not a 'hard wired' system; signal
modulation and neuronal plasticity may occur at any stage of the pain pathway.
Noxious stimuli from injured tissue may lead to long-term changes in nociception and
pain perception. In human subjects, these changes result in altered sensitivity to
cutaneous stimuli. These plastic changes are termed hyperalgesia and allodynia
(Treede et al„ 1992), (Willis, 1992).
Hyperalgesia manifests as an increased response to painful stimuli and is
described as primary or secondary. Primary hyperalgesia refers to altered nociceptive
responses from the area of tissue damage. This is characterised by both thermal and
mechanical hyperalgesia. Secondary hyperalgesia refers to the decreased pain
threshold experienced in unharmed areas adjacent to damaged tissue. This
phenomenon may be triggered experimentally by a number of noxious stimuli
including thermal skin injury, mechanical trauma, UV light, freezing or local
electrical stimulation. Different modalities of noxious input, such as heat or
mechanical stimuli, may be sensitised independently.
Allodynia is the perception of normally innocuous stimuli, such as brushing or
fine touch, as noxious. These unpleasant, excessive sensory responses to injury may
persist for prolonged periods after tissue healing has occurred, or the noxious stimulus
has been removed. Underlying these sensory changes are processes termed peripheral
and central sensitisation (Woolf, 1983). Peripheral sensitisation results from release of
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inflammatory mediators at the site of injury and causes a reduced firing threshold in
peripheral nociceptors. Central sensitisation is an expression of increased excitability
of multireceptive or wide dynamic range (WDR) neurons (Mendell, 1966) in the
spinal cord (Baranauskas and Nistri, 1998), (Woolf, 1996). Secondary neurons in the
dorsal horn show a reduction in threshold so that there is a response to previously sub
threshold stimuli (Simone et ah, 1989). Spatial and temporal summation of afferent
action potentials results in the perception of pain. An increase in receptive field size
promotes spatial summation, as demonstrated in vivo in the rat hindpaw (Cook et ah,
1987). In human subjects, low threshold A(1 fibre inputs (such as stroking the skin
with a brush) take on the characteristics of noxious stimuli and are perceived as
painful.
Pathological pain states may be divided into those caused by inflammatory
mechanisms and those caused by damage to the peripheral- (PNS) or central nervous
systems (CNS). The latter neuropathic form of chronic pain is the subject of the
current study. There is good evidence to demonstrate the occurrence of central
sensitisation after nerve injury(Bennett and Xie, 1988), (Liu et ah, 2000).
1.1 Neuronal plasticity, long term potentiation (LTP) and wind-up
During the development of the prolonged sensitised states associated with
neuropathic pain, neurons may display plasticity, altering their function, chemical
profile or structure (Woolf and Salter, 2000). In addition to changes within neurons,
synaptic connections between them also demonstrate plastic changes (Julius and
Basbaum, 2001).
Long-term changes in neuronal activity have been studied for some years in
the hippocampal region of the brain, where they are thought to mediate learning and
memory. In the early 1970s, it was noted that brief trains of high-frequency electrical
stimulation (50-100 stimuli at 100Hz or more) to monosynaptic excitatory pathways
in the hippocampus caused a rapid increase in synaptic strength lasting hours or days,
which was termed LTP (Bliss and Lomo, 1973).
In addition to induction of plasticity by high frequency stimuli in the
hippocampus, low frequency stimulation (0.3-20Hz) electrical C fibre stimulation, or
cutaneous stimulation of noxious intensity, resulted in an increased number of action
potential spikes per stimulus in a subset of dorsal horn interneurons. This effect was
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first noted and termed wind-up by Mendell and Wall in 1965 (Mendell and Wall,
1965). Wind-up is an artificially generated process occurring only whilst the train of
low frequency stimulation continues. This phenomenon has been investigated using a
number of techniques, including recording from extracellular and intracellular
electrodes, whole cell patch techniques, and by recording the action potential response
from ventral roots (Herrero et ah, 2000). Although wind-up is not a physiological
process, and LTP occurs only under conditions of very high frequency electrical
stimulation, it has been suggested that these processes share some similarities with
mechanisms underlying the development of central sensitisation in the spinal cord,
leading to hyperalgesia and allodynia (Baranauskas and Nistri, 1998), (Ji et al., 2003).
1.2 Peripheral transduction of sensory information
Sensory information from the external environment is received by the skin and
transduced into electro-chemical activity (action potentials) in primary afferent nerve
fibres by a wide variety of cutaneous receptors. Subgroups of receptors are activated
by specific types of stimulus including heat, cold, fine touch, pressure, vibration,
stretch and tissue pH. Primary afferent fibres enter the central nervous system and
terminate at the first synapse in the dorsal hom (DH) of the spinal cord forming a
highly organised somatotopic map of peripheral structures (Swett and Woolf, 1985).
1.2.1 Peripheral nerve fibres
Cutaneous afferent fibres are subdivided into three main groups depending
upon their size and conduction velocity. The largest, most rapidly conducting fibres
measure greater than 10pm in diameter, conduct impulses at 30-100ms"1 and are
termed Ap fibres. These myelinated fibres are thought to transmit fine touch and
proprioceptive information. Smaller myelinated fibres measuring 2-6pm in diameter
are termed A5. These fibres have conduction velocities varying between 12 and
30ms"1 and transmit innocuous and noxious sensory information. The nociceptive
information carried by A5 fibres results in a sensation which has been termed 'first
pain' as it usually occurs rapidly after stimulation and is sharp in character. The
smallest fibres, termed C fibres, are unmyelinated and measure 2-6pm in diameter,
with conduction velocities in the range of 0.5-2.0ms"1. These slow transmission fibres
largely carry nociceptive information leading to a sensation, which has been termed
'second pain', as it has a relatively slow onset and burning character (Yaksh, 1986).
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Histochemistry of dorsal root ganglion (DRG) cells has revealed two main types of C
fibre neurons. One group comprising 40 - 45% of all DRG neurons in the adult mouse
express tropomyosin-related kinase A (trk A) receptors for nerve growth factor
(NGF). The majority of these cells also coexpress calcitonin gene-related peptide
(CGRP) and substance P (SP) (Snider and McMahon, 1998). The other group express
a-D-galactosyl-binding lectin (IB4) and the P2X3 ATP-gated ion channel (references
in (Julius and Basbaum, 2001)).
1.2.2 Cutaneous receptors
There are a number of different peripheral receptors involved in the
transduction of cutaneous stimuli. In general, receptors triggered by low threshold
innocuous stimuli are associated with specific sensory modalities, whereas a stimulus
of sufficient strength may trigger a response in a nociceptor no matter what its
modality.
Non-nociceptive cutaneous receptors respond specifically to innocuous
mechanical, thermal and chemical stimuli. Cutaneous mechanoreceptors are usually
associated with myelinated primary afferent fibres. Rapidly adapting receptors are
known as Meissner or Pacinian corpuscles and respond to light touch, vibration and
pressure. Slow adapting receptors are of two types, Merkel cells and Ruffini
corpuscles, which respond to stretch (Willis and Coggeshall, 1991). Hairy skin also
has specific receptors associated with hair follicles and responsive to hair bending and
movement (Brown and Iggo, 1967), (Lynn and Carpenter, 1982). Skin thermo- and
mechanoreceptors have also been identified which are associated with C fibres and
respond to cooling and innocuous mechanical stimulation (Bessou et al., 1971).
Cold and warm stimuli activate different receptors depending on the intensity
of the stimulus. Innocuous cool sensation is mediated by receptors associated with a
population of C and A8 fibres responding to stimuli in the 15-30°C range (Bessou and
Perl, 1969). Mild warmth (30-37°C) would seem to trigger a subset of receptors
associated with C fibres (Iggo, 1959).
1.2.3 Nociceptors
Nociceptors respond to stimuli of sufficient intensity to potentially result in
tissue damage. The concept of such a receptor is not new, and was first suggested
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almost 100 years ago (Sherrington, 1906). These high threshold receptors are less well
differentiated in terms of structure and specificity of response than their non-
nociceptive counterparts. Peripheral nociceptors consist of unencapsulated nerve
endings attached to unmyelinated C fibres or small diameter myelinated AS fibres.
Cell bodies of these nociceptive afferents lie within the dorsal root ganglia (DRG).
Studies based on anaesthetised monkeys, using heat and mechanical noxious stimuli,
revealed two basic types of nociceptive afferents: C fibres responsive to heat and
mechanical stimuli and AS fibres responsive to heat and mechanical stimuli
(mechano- / heat-sensitive C fibre units, CMH, mechano- / heat-sensitive A fibre
units, AMH) (references in Chapter 3 (Yaksh, 1986)). These afferent fibres show a
monotonic response to increasing stimuli of noxious intensity. C fibre polymodal
nociceptors have been shown to respond to various high threshold stimuli in a non¬
specific manner including heat, high threshold mechanical and chemical stimulation
(Bessou and Perl, 1969) and in some cases intense cold (Cervero and Iggo, 1980),
(Willis and Coggeshall, 1991), (Henley, 1993), (Simone and Kajander, 1996), (Shi,
2001). In addition to the populations of nociceptors described, there are also 'silent'
nociceptors which do not respond to any form of stimulus until sensitised by tissue
injury (Bessou and Perl, 1969), (Schmidt et al., 1995).
Recordings of action potentials from unmyelinated C fibres have been made
from the peroneal nerve of healthy human subjects using microneurography (Weidner
et al., 1999). This study found a number of C fibre types, including sympathetic
efferents, CMH units, mechano-insensitive C units most of which responded to heat
stimuli (heat-responsive C units, CH), and a few that responded to capsaicin alone
(mechano- and heat-insensitive C units, CMiHi). Mechano-insensitive units were
found to have significantly slower conduction velocity.
Noxious heat transduction
It has been demonstrated that 45% of small and medium nociceptor fibres
grown in culture from rat dorsal root ganglia (C and type II A8 fibres) responded to
moderate heat stimuli (45°C), whereas only 5-10% responded to intense heat (52°C)
(type I A8 fibres) (Nagy and Rang, 1999). It is now clear that C and type II A8
neurons express the vanilloid receptor (VR-1), which transduces heat sensation
(Caterina et al., 1997). The vanilloid receptors VR-1 and VRL-1 are members of the
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transient receptor potential (TRP) family of ion channels, consisting of six trans¬
membrane domains with a hydrophobic loop between the fifth and sixth domains.
VR-1 is ten times more permeable to calcium than monovalent cations and is
activated by capsaicin or its analogue resiniferatoxin and blocked by the antagonists
capsazepine and ruthenium red. This receptor responds to noxious heat and its
responses are modulated by hydrogen ion concentration (references in (McCleskey
and Gold, 1999)), (Caterina et al., 1999). Mutant mice lacking the VR-1 receptor are
largely insensitive to moderate heat stimuli but respond normally to intense heat
stimuli, which may be transduced by the VRL-1 receptor.
Cold transduction
The molecular mechanisms that transduce cold stimuli have been less clearly
elucidated and it has proved difficult to define what degree of cold may be considered
noxious. It has been demonstrated that cooling DRG cells in culture to 20°C permits
calcium entry into the cells (Reid and Flonta, 2001). However, it was not clear
whether cold was having a non-specific effect on many receptors, or acting via a
single 'cold-receptor'. Insights into the mechanism of cold transduction originate from
the use of pharmacological agents, such as menthol, that elicit a cooling sensation.
Using this cooling substance, a menthol receptor has been cloned from trigeminal
sensory neurons that is also activated by thermal stimuli in the cool to cold range.
This cold- and menthol-sensitive receptor (CMR1) is a member of the TRP family of
excitatory ion channels and responds to cold in the region of 8°C to 28°C (McKemy et
al., 2002). A further related channel, TRPA1 has also been identified that responds to
lower temperatures (<18°C) (Story et al., 2003). The CMR1 receptor was found
expressed on small diameter neurons in the trigeminal and dorsal root ganglia. So it
would appear that TRP channels detect temperatures over a wide range, and are the
principal sensors of thermal stimuli in the mammalian peripheral nervous system.
Noxious chemical transduction
In addition to physical stimuli such as heat, cold and pressure, the local tissue
environment may also trigger nociceptive responses. After tissue damage, many
chemical products are released. This inflammatory soup includes extracellular protons
and adenosine triphosphate (ATP), arachidonic acid and its metabolites, serotonin,
bradykinin and nerve growth factor (NGF). Nociceptive neurons express receptors
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paired with most of these mediators such as the trk A receptor for NGF, the
bradykinin BK2 receptor, the 5HT3 receptor for serotonin and the P2X3 receptor for
ATP (McCleskey and Gold, 1999). In addition to this dramatic change in the local
environment, nociceptors themselves may release SP when activated by noxious
stimuli or via antidromic activation of the peripheral nerve, which may also modulate
the release of inflammatory mediators from surrounding tissues (Moskowitz et ah,
1983), (Levine etal., 1993).
It has been suggested that extracellular ATP may play a role in nociception in
the periphery. ATP would appear in the extracellular space only after cell lysis in
injured tissue. Interest in ATP as a mediator of acute nociception developed when it
was found that injection of ATP into inflamed skin causes pain in humans (Bleehen
and Keele, 1977). Several subtypes of ATP receptor have now been cloned and some
appear to be localised on nociceptive afferents. These nucleotide receptors can be
divided into ionotropic forms (P2X1.7) and metabotropic forms (P2Y) which are
linked to a number of signalling pathways including phospholipase C (PLC)
activation (Krishtal et ah, 1988), (North and Barnard, 1997).
Local tissue acidity plays a key role in peripheral nociception, (McCleskey
and Gold, 1999), (Mamet and Voilley, 2002). Ischaemia, infection and inflammation
all lead to a decrease in local tissue pH, which may be as low as 5.4. Steen et al have
demonstrated that a subset of C fibres sensitive to mechanical and heat stimuli
respond to pH by firing in a dose-dependant manner to increasing hydrogen ion
concentration. Threshold levels were found to range from pH 6.9 to 6.1 and mean
maximum discharge was at pH 5.2 (Steen et ah, 1992).
Hydrogen ions may modulate the response of some receptors (VR-1) and may
directly activate others. The acid-sensing ion channel (ASIC) family of cation
channels have been shown to respond to pH (Krishtal and Pidoplichko, 1981). These
receptors have various roles in different species and tissues, but all are specifically
permeable to sodium and may be blocked by the loop diuretic drug, amiloride. It is
not entirely clear which receptors are involved in the response to acidity, but the
ASIC1 channel is closed at a physiological pH of 7.4, shows a transient response if
the local pH drops below 7.0 and a prolonged response below pH 6.0 (Bevan and
Yeats, 1991), (McCleskey and Gold, 1999).
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Noxious mechanical transduction
No transducer protein for mechanical stimuli has yet been isolated, but some
studies suggest it may be a member of the mammalian degenerin (MDEG) ion
channel family (Waldman and Lazdunski, 1998), (Chelur et al., 2002). These
receptors are a subset of the ASIC family. Nematode studies have identified several
degenerins, including MEC-4 and MEC-10. These receptors are expressed on
mechanoreceptor neurons of the nematode and are both required for touch sensation.
MEC-6 has been more recently identified and colocalises with MEC-4, augmenting
amiloride-sensitive sodium currents produced by MEC-4/-10 by a factor of 200
(Chelur et ah, 2002). It has been suggested that the MEC-4/-6/-10 complex constitutes
a stretch-activated channel. The mammalian equivalent may play a role in mechanical
nociception.
1.3 Central transmission of sensory information
The first synapse in the nociceptive pathway occurs in the dorsal horn of the
spinal cord. This region acts as a gateway to the CNS for nociceptive information and
has been the subject of the present study. Second order neurons vary in their input
specificity and response to stimuli. Their response profile may be altered dramatically
by the development of central sensitisation, and they are influenced by complex
intrinsic and descending modulatory mechanisms, which will be discussed below. The
dorsal horn neurons may project to the brainstem via a number of distinct ascending
tracts described below (Treede et al., 1992).
Pain information processing also occurs at a cortical level, and the advent of
functional MRI scanning has increased our knowledge of these higher brain functions
in human subjects. In healthy human volunteers, pain intensity- related
haemodynamic changes have been identified in a widespread, bilateral brain system
including the primary (SI) and secondary (SII) somatosensory cortices, insular,
cingulate, and frontal cortical areas, as well as thalamus, amygdala, and midbrain
(Porro, 2003). Data from anatomical and electrophysiological studies show that these
cortical regions receive direct nociceptive thalamic input. The rostral agranular insular
cortex (RAIC) has recently been identified as a site where neurochemical changes,
can alter nociceptive thresholds in awake animals. The connectivity of the RAIC
suggests it is involved in multiple aspects of pain behaviour including motivational /
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affective components and sensorimotor integration of nociceptive processing (Jasmin
et al., 2004).
1.3.1 Anatomy of the spinal cord dorsal horn
The spinal cord consists of a 'butterfly-shaped' region of grey matter arranged
around a central canal, surrounded by white matter. Rexed suggested an anatomical
division of the spinal cord grey matter into nine laminae based on their
cytoarchitechtonic characteristics, comprising the dorsal and ventral horns, and a tenth
lamina surrounding the central canal (Rexed, 1952). All afferent sensory information
from the skin surface passes into the dorsal horn, which comprises Rexed's laminae I
to V. This laminar arrangement of the dorsal horn remains remarkably consistent
between mammalian species (Molander et al., 1984).
Peripheral receptors of differing sensitivities tend to terminate in specific
regions, with low-threshold mechanoreceptors terminating in laminae III and IV and
high- threshold nociceptors in laminae I, II and V. Unmyelinated nociceptor C fibres
terminate predominantly in lamina II (Willis and Coggeshall, 1991). Fine calibre
myelinated A8 fibres from the skin may terminate within superficial laminae, or
deeper in lamina V, whereas afferents from visceral organs or muscle project to
mainly lamina V. Large myelinated Ap fibres terminate deeper in laminae III and IV
of the dorsal horn (Willis and Coggeshall, 1991). It was suggested that this highly
specific division of afferent inputs into different regions of the dorsal hom reflected
the relationship between a low-intensity stimulus and an innocuous sensation and a
noxious stimulus and pain.
In addition to this laminar arrangement, the central terminals of primary
afferent neurons also form an ordered topographic map of the skin surface in the
dorsal horn of the spinal cord (Swett and Woolf, 1985), (Doubell and Mannion, 1999).
1.3.2 Cytoarchitecture
The three superficial laminae of the dorsal horn contain many small cells and a
few larger ones in laminae I and III. Whilst neurons in laminae I and III may project
to the brain, most lamina II neurons arborize locally (Willis and Coggeshall, 1991).
Unlike neurons in several other areas of the CNS, it would appear that there is little
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relationship between cell morphology and function in the dorsal horn (references in
(Todd and Spike, 1993)).
Lamina I is the thin outermost zone of the dorsal hom containing relatively
few small (5x5pm) and large (15x15pm) cells. Many of these cells are projection
neurons joining the spinothalamic tract (STT) and spinomesencephalic tract (SMT),
(Menterey et ah, 1982), (Todd et al., 2000), (Todd, 2002). There are four main
morphological cell types in this lamina, although many are atypical in appearance.
The dendrites of fusiform, flattened and pyramidal cells remain within lamina I,
whereas those of multipolar cells may enter lamina II or III (Lima and Coimbra,
1986).
Lamina II is known as the 'substantia gelatinosa' due to its appearance under a
light microscope. This layer lies ventral to lamina I and consists of an outer zone
(lamina II0) containing densely packed small cells (5x5pm) and a less compact inner
zone (lamina If). Neurons within this lamina conform to two structural types, islet
cells and stalked cells. Islet cells have dendrites that spread rostrocaudally within
lamina II with axons that remain close to the cell body. Stalked cells are found in
outer lamina II and have dendrites which fan out ventrally and axons which pass
dorsally into lamina I (Todd and Lewis, 1986), (Todd, 1988). Very few (-1%) lamina
II neurons project to the brainstem, whilst some project into lamina I or have
extensive local connections (Willis et al., 1979).
Lamina III contains larger and less tightly packed cells. There are two
structural types: those which resemble lamina II islet cells, and others resembling
inverted stalked cells with dorsally directed dendrites (Powell and Todd, 1992).
Primary afferents of large hair follicles, Pacinian corpuscles and rapidly adapting
mechanoreceptors terminate in lamina III. Second order neurons send dendrites from
lamina III to laminae I and IV. Lamina III also contains cells of origin of the
spinocervical tract (SCT) and the postsynaptic dorsal column (PSDC) tract (Brown et
al., 1981).
Lamina IV is a thick layer containing large scattered cells measuring
10x15pm, often with dendrites projecting into lamina I, II and III. This dendritic
distribution allows lamina IV cells to receive a direct primary afferent input from
fibres that enter the superficial layers as well as indirectly mediated inputs. Significant
numbers of larger cells also project to the SCT and PSDC. Lamina V forms the
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narrowest part of the dorsal horn and contains the largest cells (15x20pm), many of
which join the ascending STT.
1.3.3 Neurotransmitters and peptides within the superficial dorsal horn
The neurotransmitter systems of the dorsal horn have been widely studied, as
their pharmacological manipulation may lead to the development of novel analgesic
drugs. As the present study involves the superficial laminae of the dorsal hom (I -
III), deeper structures will not be discussed. Large numbers of inhibitory and
excitatory transmitters and peptides have been isolated within the outer three laminae
of the dorsal horn, some of which are considered below.
The inhibitory neurotransmitter y-aminobutyric acid (GABA) is abundant in
the superficial dorsal horn. Early immunohistochemical studies used antibodies
directed against glutamic acid decarboxylase (GAD), an essential enzyme in the
synthetic pathway of GABA. Samples were also treated with colchicine to inhibit
axoplasmic transport of the enzyme and allow labelling of cell bodies. These studies
revealed GAD within larger cells in outer and inner lamina II. Utilising antibodies to
GABA, it was found that 28% of cells in lamina I contained this neurotransmitter,
31% in lamina II and 46% in lamina III (Todd and Sullivan, 1990). Within lamina II,
large islet cells contained GABA whereas small cells did not (Spike and Todd, 1992).
GABA also coexists with the calcium-binding protein parvalbumin in 60% of cells
and this has been taken as a surrogate marker of GABAergic cells in several studies
(Antal et al., 1991). In addition, a proportion of GABAergic cells contain the co
transmitter glycine. Of these cells, 33% contained glycine in lamina I, 43% in lamina
II and 64% in lamina III (Todd and Sullivan, 1990). There is evidence for the
existence of descending GABAergic cells from Lissaur's Tract and the medulla, but
the majority are intrinsic to the DH, as spinal cord transection did not decrease the
level of GABA within the DH significantly (Rizzoli, 1968). Many GABAergic cells
make presynaptic, axo-axonic connections with primary afferents, acting to inhibit
sensory inputs (Levy, 1977).
There are also dorsal hom cells containing acetylcholine (ACh), which has an
inhibitory action via its muscarinic receptors (Urban et ah, 1989). This inhibitory
neurotransmitter will not be considered further.
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L-glutamate is the major excitatory neurotransmitter within the dorsal horn
and is found in the majority of neurons in laminae I and II (Miller et ah, 1988).
Several studies have substantiated a role for glutamate as a neurotransmitter in
primary afferent neurons and in ascending somatosensory pathways (references in
(Broman, 1994)). Glutamate and its receptors will be discussed in greater depth
below.
Other substances likely to be involved in somatosensory neurotransmission
include the neuropeptides and nucleotides such as ATP. Many different peptides have
been detected in primary afferent neurons with unmyelinated or thinly myelinated
axons, and are thus likely to be directly involved in primary afferent
neurotransmission. Some neurons giving rise to ascending somatosensory pathways,
primarily those with cell bodies in the dorsal horn, are also immunoreactive for
peptides. These peptides are briefly reviewed below.
Tachykinins are a group of related neuropeptides derived from the precursors
preprotachykinin I and II (PPT I and PPT II). SP, neurokinin A (NK A), and
neuropeptides K and y are derived from PPT I, whereas neurokinin B (NK B) is
derived from PPT II. Immunohistochemical analysis has provided an insight into the
distribution of these peptides within the dorsal horn, but antisera tend to cross react.
Tachykinin immunopositive fibres have been demonstrated in laminae I - III,
generally decreasing in number with increasing depth, many of which would appear to
be primary afferents (Rusa et al., 1986). Many cell bodies have also been shown to
contain tachykinins and colchicine treatment revealed large cells in lamina I and
smaller cells in laminae II and III (RibieroDaSilva et al., 1991). In situ hybridisation
histochemistry (ISHH) revealed neurons expressing PPT I in laminae I and II and
neurons expressing PPT II in a band within lamina III (Warden and Young, 1988).
More recently, application of specific antisera to NK B and SP has revealed that these
tachykinins can coexist within individual axons, suggesting that a subset of cells may
express both PPT I and II (Too and Maggio, 1991). Tachykinins have also been
shown to colocalise with calcitonin gene-related peptide (CGRP), galanin and
cholecystokinin (CCK) within primary afferents (Tuchscherer and Seybold, 1989),
(Battaglia and Rustioni, 1992). Some STT projection neurons in lamina I also contain
tachykinins.
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The endogenous opioids are also present within nerve fibres in the superficial
dorsal horn, largely within laminae I and II. The cell bodies of these fibres mostly lie
within lamina II (Todd and Spike, 1992), (Todd et ah, 1992b). There are several types
of endogenous opioids derived from two precursor peptides. Endorphin and dynorphin
are derived from preprodynorphin (PPD). The enkephalins may be subdivided further
into Met- and Leu-enkephalin; the Met- form is derived solely from preproenkephalin
(PPE), whereas the Leu- form may derive from PPE or PPD (Standaert et al., 1986).
Dynorphin- and enkephalin- immunoreactive perikarya in lamina I of the
dorsal horn represent neurons with extensive local collateral connections, which are
the main source of a long ascending projection to the parabrachial nucleus in the rat.
Furthermore, lamina I opioid-containing neurons may receive SP-immunoreactive
primary sensory afferents. (Standaert et al., 1986). This finding underlies the
importance of these cells in sensory processing, as the pontine parabrachial nucleus,
which has been implicated in nociceptive as well as antinociceptive processes,
expresses high levels of opioid receptors and is reciprocally connected with the spinal
cord dorsal horn.
Endogenous opioids are often coexpressed with other peptides in the dorsal
horn. Within lamina II, 50% of cells containing enkephalin were also tachykinin
immunopositive (this represents 95% of cells containing SP) (Senba et al., 1988).
Metenkephalin and somatostatin have also been shown to coexist in cell bodies and
nerve terminals in the dorsal horn (Todd and Spike, 1992). Enkephalin and GABA
may also coexist in cells in laminae II and III (Todd et al., 1992b).
Dynorphin mRNA has been demonstrated in laminae I and II of the dorsal
horn in rat, cat and monkey spinal cord. In rats the immunoreactive fibres would seem
to be distributed within inner lamina I and outer and inner lamina II and, after
colchicine treatment, the cell body staining matches this pattern (Cho and Basbaum,
1989). In keeping with its likely role in nociceptive processing, the axons of some
dynorphin containing cells within lamina I extend to the parabrachial midbrain areas
and some to the nucleus of the solitary tract. In addition, levels of this opioid have
been shown to increase within the dorsal horn in response to peripheral inflammation
(Ruda et al., 1988). Preprodynorphin mRNA and dynorphin peptide are increased
after various chronic noxious stimuli such as CCI and peripheral inflammation (Cho
and Basbaum, 1988). In these conditions, there is an increase in opioid levels in local
lamina I neurons and spinal mesencephalic neurons. It has been suggested this is
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significant in bringing about the increase in spinal cord excitability seen in these
conditions (Dubner and Ruda, 1992). In addition to enkephalin, dynorphin is also
coexpressed with SP in some cells in the dorsal horn or in descending neurons
(Tuchscherer and Seybold, 1989).
Neurotensin is a tridecapeptide which acts to excite dorsal horn neurons when
applied iontophoretically, but produces antinociception when administered
intrathecally (references in (Furst, 1999)). Fibres containing this neuropeptide are
found in lamina I and II in two bands. Cell bodies are found in ventral lamina II and
dorsal lamina III (references in (Todd and Spike, 1993)). The majority of these axons
contain the glutamate transporter molecule VGLUT2 and are probably glutamatergic
(Todd et ah, 1994), (Todd et al., 2003). Cells containing neurotensin do not seem to
contain GABA and 75% contain calbindin (Todd et al., 1992a).
Cells containing somatostatin do not express GABA and would seem to
represent a different population from those containing neurotensin. These cells also
express VGLUT2 and arborize locally within dorsal lamina II and lamina I (Todd et
al., 2003). These small cells have cell bodies within ventral lamina II and lamina III
and may represent excitatory interneurons (Todd et al., 1994).
Fibres containing vasoactive intestinal polypeptide (VIP) are found within
laminae I and II. Most of these fibres regress with primary afferent sectioning,
suggesting that they arise peripherally. After colchicine treatment, some cell bodies
containing VIP are found in laminae I and II. Some of the lamina I cells have been
shown to have processes extending to the midbrain (Leah et al., 1988).
Finally, while some fibres within laminae I and II have been shown to contain
galanin, most degenerate following spinal cord section suggesting that they arise from
descending neurons (Melander et al., 1986). It has been demonstrated that these
peptide-containing neurons originate at least in part in the locus coeruleus (Holets et
al., 1988).
f .3.4 The electrophysiological responses of dorsal horn neurons to stimuli
It is possible to classify dorsal horn cells according to their
electrophysiological response to peripheral stimuli. Three major groups exist,
depending upon their response to noxious stimulation. Class I neurons do not respond
to noxious stimulation and are involved in the transmission of innocuous information
via low-threshold A-fibres (Dubner and Bennett, 1983). Class II neurons respond to
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both innocuous and noxious cutaneous stimuli and are termed multireceptive or wide
dynamic range (WDR) neurons (Mendell, 1966). These cells may respond to
stimulation of all types of primary afferent from C fibres to Ap fibres (reviewed in
(Besson and Chaouch, 1987)) and are most commonly found in laminae IV-VI.
Neurons of the WDR type may show tonic activity without stimulation and have a
graded response across their receptive fields. Some are inhibited by Ap fibre input at
the periphery, whereas others respond positively to all stimuli across their receptive
fields (Cervero and Iggo, 1980), (Iggo et al., 1985). Class III, nocispecific neurons
respond to input from myelinated and unmyelinated nociceptive afferents only
(Cervero et al., 1976). These neurons have relatively small receptive fields and
display little spontaneous activity. Nocispecific neurons tend to occur in lamina I and
include projection neurons. A fourth group, consisting of proprioceptive neurons will
not be considered here.
It has been demonstrated that 74% of lamina I neurons are nociceptive
specific. The remaining 26% were shown to be wide dynamic range class II neurons.
It was demonstrated that application of an AMPA R antagonist resulted in an
inhibition of electrically evoked responses, whereas application of an NMDA
antagonist had no effect. This suggests that transmission of nociceptive information is
mediated in part by AMPA Rs rather than NMDA Rs (Seagrove et al., 2004).
1.3.5 Projection of dorsal horn neurons
In addition to this functional classification, dorsal horn neurons may also be
grouped according to their axon projections. The vast majority of dorsal horn neurons
are interneurons, which may be excitatory, or inhibitory. Projection neurons enter
ascending spinal tracts and convey sensory information to higher centres. Inhibitory
interneurons may synapse with primary afferents or post-synaptically with dorsal horn
neurons. This inhibitory influence can be seen on lamina III / IV neurons, which have
been shown to receive synapses from local GABAergic interneurons (Todd, 2002)
and on a subset of lamina I projection neurons which also receive a dense inhibitory
input (Puskar et al., 2001).
Projection neurons from lamina I send axons to a number of brain regions
which are known to be involved in nociception, including the caudal ventrolateral
medulla (CVLM), the parabrachial area, periaqueductal grey area (PAG) and
thalamus (Willis and Coggeshall, 1991), (Craig, 1995), (Gauriau and Bernard, 2004).
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These neurons have been shown to be highly excitable and to display unique firing
patterns (Ruscheweyh et ah, 2004).
Up to 80% of lamina I projection neurons express the SP receptor, NKi (Todd
et ah, 2002). These cells are likely to have a pro-nociceptive function, as their ablation
in chronic inflammatory and neuropathic pain states led to a marked reduction in
hyperalgesia but no change in innocuous sensory transmission (Mantyh et al., 1997),
(Nichols et al., 1999). In addition to cells expressing NKi, lamina I contains a number
of large cells lacking this receptor, which may have an inhibitory function. These cells
contain high levels of the glycine receptor-associated protein gephyrin and are found
close to GABA containing terminals (Puskar et al., 2001). There is evidence that a
population of cells within laminae III and IV expressing the NKi receptor (Nairn et
al., 1997), project to the CVLM and parabrachial area (Todd, 2002), and may also
target lamina I projection neurons (Sakamoto et al., 1999).
In addition to this complex local circuitry within the dorsal hom, there are also
descending fibre tracts, which have a significant modulatory affect on the dorsal horn
output. For example, the descending serotonergic axons from the medullary raphe
nuclei have been found to exhibit inhibitory influence over lamina I and lamina III/IV
projection neurons (Todd, 2002). It can be seen that signal modulation by local
intemeurons may affect both the input to and output from the dorsal horn, and these
cells have been implicated in models of pain and analgesia.
1.3.6 Ascending tracts
The anatomy of the fibre tracts from the dorsal hom to the brainstem is
considered below. These tracts are described with reference to the rat; other
mammalian species may show variations in their relative importance.
Spinothalamic tract (STT)
The spinothalamic tract conveys sensory information from the contralateral
dorsal hom to thalamic nuclei. Although mostly concerned with transmission of
noxious mechanical sensory information, temperature and innocuous mechanical
stimuli may also be conveyed (Giesler et al., 1976). Cells of origin of this tract can be
found in laminae I, II, IV and V (Todd et al., 2000), (Todd, 2002). These excitatory
pro-nociceptive neurons within lamina I also receive synapses from local inhibitory
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interneurons, as well as descending input from inhibitory fibre tracts (Polgar et al.,
2002).
Spinomesencephalic tract (SMT)
The SMT projects from cells in laminae I, V and VI to the mesencephalic
tegmentum region including the periaqueductal grey area. It is likely that the
contribution from lamina I cells is nocispecific (Menetrey et ah, 1982).
Dorsal column pathways
This ascending tract can be divided into the postsynaptic dorsal column system
(PSDC) and the spinocervical tract (SCT). The PSDC originates in laminae III and IV
and projects ipsilaterally to the gracile and cuneate nuclei of the medulla via the
dorsal funiculus. This tract conveys a multitude of sensory modalities including
pressure, cooling, pinch and hair movement as well as nociceptive information
(Angaut-Petit, 1975). The SCT originates from cells in laminae IV to VII and projects
ipsilaterally to the lateral funiculus. Some fibres of this tract pass into the PSDC or
cross the midline to run contralaterally in the ventral funiculus (Cao et ah, 1993).
Most neurons of the SCT respond to innocuous hair movement, however, many are
multireceptive and can also respond to nociceptive stimulation (Fleetwood-Walker et
ah, 1988).
1.3.7 Endogenous inhibitory modulation
As suggested above, there are local and descending mechanisms within the
CNS designed to modulate nociceptive transmission. Melzack and Wall first designed
a model to describe the functioning of such an intrinsic inhibitory mechanism in their
gate control theory of pain (Melzack and Wall, 1965). They proposed that spinal
nociceptive transmission could be inhibited by non-nociceptive large diameter
myelinated A(3 fibre inputs acting on second order neurons via spinal inhibitory
interneurons. The inhibitory influence of cutaneous stimulation of large A fibres on C
fibre- and noxious stimulation-evoked excitation of dorsal horn neurons has been well
demonstrated (Woolf and Wall, 1982), (Besson and Chaouch, 1987). Although many
additional receptors and transmitters have since been discovered, the gate theory
remains relevant to our current understanding of nociception (Dickenson, 2002).
Local inhibitory mechanisms may be augmented by descending inhibitory pathways
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from the brain, damping down nociceptive transmission (Besson and Chaouch, 1987),
(Polgar et al., 2002).
Tonic descending modulation
Several brain-stem regions are known to be involved in the descending control
of nociceptive transmission. Two key regions would appear to be the medullary
nucleus raphe magnus (NRM) and adjacent structures of the rostral ventromedial
medulla (RVM). The NRM provides a major descending serotonergic input to the
dorsal horn laminae I, II and V (Basbaum and Fields, 1984), (Polgar et al., 2002). In
addition, electrical stimulation of this region has been shown to produce analgesia.
It has been suggested that RVM cells are tonically active during mild sensory
stimulation, inhibiting nociceptive transmission from the periphery. However, intense
noxious stimulation may cause the release of GABA onto RVM cells, which in turn
suppresses activity in this pathway and removes descending inhibition on dorsal horn
cells, allowing transmission of nociceptive input via the dorsal horn (Gilbert and
Franklin, 2001). The RVM may also be activated via opioid-mediated mechanisms
involving higher brain centres such as the amygdala (McGaraughty and Heinricher,
2002).
The locus coeruleus (LC) also plays a role in modulating nociceptive
transmission, via its actions on the parafascicular neurons (PF) of the thalamus (Zhang
et al., 1997). The LC exerts two opposing effects on nociceptive transmission.
Descending noradrenergic fibres from the LC to spinal cord play a predominantly
inhibitory role, and ascending fibres may facilitate the responsiveness of the PF to
noxious input.
Noradrenaline has been shown to cause hyperpolarization of lamina II cells
when applied to the spinal cord, and to induce an outward current by G- protein-
mediated activation of potassium channels through 0C2 adrenoceptors, thereby
producing an antinociceptive effect (Sonohata et al., 2004). From this brief summary,
it can be seen that descending modulation of nociceptive transmission involves
complex interactions between several brain and spinal cord regions.
The endogenous opioid system
Exogenous opioids have been used as effective analgesics in man for over one
thousand years. These drugs have been shown to be effective when administered by
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virtually every route, but intrathecal opioids have been shown to be particularly
effective at very low concentrations, suggesting that receptors may be concentrated in
the CNS, including the spinal cord. Three members of the opioid receptor family have
been cloned: the delta-opioid receptor (DOR) (Evans et ah, 1992), the mu-opioid
receptor (MOR) (Chen et ah, 1993) and the kappa-opioid receptor (KOR) (Meng et
al„ 1993).
Opioid receptors have been found in the superficial dorsal horn, both on
primary afferents and secondary interneurons (Atweh and Kuhar, 1977). The highest
concentrations of receptors in the spinal cord are around the C fibre termination zone
in lamina I and in the substantia gelatinosa. In the rat spinal cord, 70% of opioid
receptors are of the mu type, 24% delta and 6% kappa (Besse et al., 1990).
Endogenous ligands for these receptors have been identified, and opioid peptides such
as dynorphin and enkephalin are present at synapses within the dorsal horn (Willis
and Coggeshall, 1991). These findings provide evidence for the role of the
endogenous opioids in nociceptive processing. The antinociceptive action of these
compounds has been confirmed in electrophysiological studies, where iontophoretic
application of opioids to lamina II of the dorsal horn produced inhibition of neuronal
responses to noxious peripheral stimulation (Fleetwood-Walker et al., 1988).
The endogenous cannabinoid system
This recently discovered endogenous inhibitory system is currently under
intense investigation due to the relative efficacy of natural and synthetic cannabinoid
compounds in providing analgesia in conditions such as multiple sclerosis and
neuropathic pain (Robson, 2001). The two identified cannabinoid receptors, CB] and
CB2 (Pertwee, 1997), (Pertwee, 1998) have been shown to be present in the peripheral
and central nervous system, particularly in areas associated with nociceptive
processing such as the superficial laminae of the spinal dorsal horn. CBi receptors in
particular, have been reported to be located on spinal interneurons in the outer part of
lamina II (Farquhar-Smith et al., 2000). The antinociceptive role of endogenous
cannabinoids has been demonstrated in behavioural (Lichtman and Martin, 1997),
(Smith and Martin, 1992) and electrophysiological studies of acute pain (Drew et al.,
2000). In addition to the antinociceptive role of cannabinoids alone, CB] and MORs
have been shown to colocalise in lamina II interneurons, and could potentially act in a
synergistic manner (Salio et al., 2001).
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1.4 Animal models of chronic pain leading to spinal sensitisation
Progress in pain research has been aided by the use of animal models of
human pain conditions. Simple tests of acute nociception such as the tail flick, hot
plate test were used to develop analgesic drugs. More recently, complex models of
persistent inflammatory or neuropathic pain have been developed. The majority of
these models reflect relevant clinical conditions in man and leave the animal in
relatively good health with the minimum of distress.
Measuring the behavioural responses of animals to painful stimuli also
presents difficulties. It is clearly not possible to assess the character of the pain
experienced by animal subjects (eg: stabbing, burning, shooting pain and so on).
Aversive behaviour such as vocalising, biting or scratching can be measured in certain
circumstances, but nociceptive responses are often too subtle to result in such clear
behavioural changes. Generally, spinal reflexes have been utilised in studies of pain
mechanisms in animals and man. The magnitude of the nocifensive hindpaw flexor
reflex to electrical stimulation or to physiological stimuli, has been positively
correlated to the activity of spinal dorsal horn neurons (Schouenborg and Sjolund,
1983). This reflex is subject to local and descending modulation and can be used to
investigate responses to a number of experimental interventions. Changes in the
latency and magnitude of the nocifensive response can be measured relatively easily,
providing a graded behavioural response to stimuli perceived as increasingly noxious.
A number of behavioural tests have been developed to assess different sensory
modalities. Heat hyperalgesia has been assessed using an apparatus developed by
Hargreaves to measure the latency of hindpaw withdrawal from a calibrated heat
stimulus (Hargreaves et al., 1988) (see Figure 3.1). Mechanical allodynia can be
assessed using von Frey filaments (or pressure analgesymeter). These calibrated fibres
flex at a given force and produced a graded, non-noxious pressure stimulus. In the
presence of mechanical allodynia (characteristic of some neuropathic pain states), this
usually innocuous stimulus will cause paw withdrawal. Cold allodynia is assessed
using a cold water bath and noting the presence and duration of limb withdrawal from
the cold stimulus.
Both inflammatory and neuropathic chronic pain models have been developed.
Briefly, the rat model of inflammatory chronic pain utilises peripheral injection of
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irritants such as formalin or Freund's adjuvant (Walker et al., 1999). These models
result in mechanical and thermal hyperalgesia with a large peripheral component.
Neuropathic pain would seem to have a somewhat different mechanism to
chronic pain caused by inflammatory processes and leads to mechanical allodynia
and, in some models, cold allodynia and thermal hyperalgesia (see section 1.9).
The model adopted for the current study was developed by Bennett (Bennett
and Xie, 1988). It is known as the sciatic chronic constriction injury (CCI) model.
Four loose chromic ligatures are tied around the sciatic nerve (see section 4.2.1).
Spontaneous pain, allodynia and protective posture are all demonstrated to a variable
degree after surgery. The de novo development of cold allodynia is also a marked
feature of this model. These behavioural changes manifest within 36 hours of the
nerve constriction, are most pronounced 10-14 days after induction of the injury and
can last for up to three months.
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1.5 Receptors and neurotransmitters involved in nociception
Peripheral stimuli of sufficient intensity to trigger action potentials in primary
afferent fibres result in the release of a variety of neurotransmitters and neuropeptides
from the presynaptic nerve terminals in the spinal dorsal horn. After crossing the
synaptic cleft, these neurotransmitters bind to the postsynaptic receptors on dorsal
horn cells where they result in changes in the conductance of the postsynaptic
membrane.
The major excitatory amino acid neurotransmitter released from primary
afferents is thought to be L-glutamate (Watkins and Evans, 1981). Electrical nerve
stimulation causes glutamate release by terminals of both myelinated and
unmyelinated axons, suggesting that this neurotransmitter has an important role to
play in both nociception and transmission of non-noxious information (Davies et al.,
1979). L-glutamate has subsequently been identified as an important excitatory amino
acid neurotransmitter for fibres transmitting mechanical, chemical and thermal stimuli
from the periphery (Gerber and Randic, 1989), (King and Lopez-Garcia, 1993).
Several subtypes of glutamate receptor have been identified in both the superficial and
deep dorsal horn. These can be broadly subdivided into ionotropic ligand-gated ion
channels and metabotropic receptors, which are coupled to various second messenger
systems through GTP-binding proteins (Willis and Coggeshall, 1991).
In addition to the glutamatergic systems discussed above, peptides also play an
important role in neurotransmission and neuromodulation. The current study was
designed to investigate the interaction between key neurotransmitter systems in the
development of neuropathic pain. These systems will be discussed in detail below,
with emphasis on the role of the a-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA) receptor for glutamate (see section 1.9).
1.5.1 Ionotropic glutamate receptors
The ionotropic glutamate receptors (iGluR) have been divided into two major
groups depending upon their pharmacological response characteristics to various
agonists (Young and Fagg, 1990). These are the N-methyl-D-aspartate (NMDA), and
the non-NMDA iGluRs. Non-NMDA Rs are further subdivided into AMPA and
kainate receptors. AMPA R subunits have been demonstrated in neurons of the
superficial laminae of the dorsal horn (Furuyama et al., 1993), (Henley, 1993), (Tolle
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et al., 1993), (Popratiloff et al., 1996), and NMDA receptors (NMDA Rs) have been
shown to be located throughout the brain and spinal cord particularly in the superficial
dorsal horn (Cotman and Monaghan, 1985), (Greenamyre et al., 1985), (Monaghan
and Cotman, 1985).
There is a great deal of evidence to support the critical role of NMDA and
AMPA Rs in nociceptive processing and in the neuronal plasticity underlying
processes such as memory, learning and the development of chronic pain states
(Coderre et al., 1993). Activation of NMDA Rs may play an important role in
neuronal plasticity and specifically in the development of central sensitisation (Woolf
and Thompson, 1991). Recent studies have demonstrated a more significant role for
AMPA Rs in synaptic plasticity than had been previously appreciated (Luscher et al.,
1999), (Luscher and Frerking, 2001), and this receptor is considered in more detail
below (see section 1.6).
NMDA receptors
During non-noxious stimulation, A fibres release glutamate from pre-synaptic
end plates and excitatory postsynaptic potentials (EPSPs) are generated in the dorsal
horn neuron by activation of non-NMDA glutamate receptors. In this situation the
NMDA R calcium channels remain blocked by magnesium ions in a voltage-
dependant manner. Once the stimulus is removed, action potentials cease and no
further signal transduction occurs. During acute pain transmission, NMDA Rs are
largely inactive due to channel blockade by magnesium ions (Nishiyama, 2000).
Prolonged noxious stimuli, however, cause a release of glutamate from A8 and
C fibres which may be sufficient to activate NMDA receptors. NMDA receptor
activation may occur when the dorsal horn neuron is sufficiently depolarised (by
alternative glutamate receptors or alternative mechanisms), or the receptor is
phosphorylated via second messenger systems triggered by activation of non-NMDA
glutamate and peptide receptors. When NMDA receptors are activated by removal of
the magnesium block, there is an increase in calcium flux through the postsynaptic
membrane with a prolonged channel opening time. The channel blockade of NMDA
Rs by magnesium ions may be removed by progressive depolarisation of the cell
membrane or by reducing the receptor affinity for the ion by, for example,
conformational change following its phosphorylation. Thus, glutamate produces a fast
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excitatory potential when acting at the AMPA R site and a long synaptic potential
when acting at the NMDA receptor site.
The NMDA receptor is distributed throughout the dorsal and ventral horns of
the spinal cord (Furuyama et ah, 1993). It is an ionotropic glutamate receptor,
permeable to calcium and sodium ions. The receptor is a tetramer of NR1 and NR2A-
D subunits (Dingledine et al., 1999). Following the induction of central sensitisation,
binding of L-glutamate to this receptor allows calcium and sodium to enter the cell,
triggering further depolarisation and activation of calcium dependent processes
(Davies and Lodge, 1987). The activation of NMDA receptors appears to be central to
the generation of prolonged states of nociception. The hyperalgesia occurring
following the induction of sensitised states in a number of experimental paradigms
was attenuated by intrathecal administration of NMDA receptor antagonists. These
results suggest that NMDA receptor activation may contribute to the mechanical
hyperalgesia that follows peripheral tissue inflammation (Ren and Dubner, 1993) and
peripheral mononeuropathy (Tal and Bennett, 1993), (Tal and Bennett, 1994). Human
studies have demonstrated that the NMDA antagonist ketamine may be effective in
the treatment of various chronic pain conditions, but the evidence for its efficacy is
moderate or weak and side effects may preclude its use (Hocking and Cousins, 2003).
The NMDA receptor also plays a central role in other processes involving
neuronal plasticity, such as LTP, necessary for spatial learning and memory formation
in the hippocampus (Morris et al., 1986). NMDA receptor-dependent LTP is
considered to share some similarities with processes occurring in central sensitisation
of the spinal cord in hyperalgesic pain states (Dougherty et al., 1992), (Sandkuhler,
2000), (Rueter et al., 2003). However, there are clearly significant mechanistic
differences between the two processes. Sensitisation in neuropathic pain is a
heterosynaptic process, triggered by relatively low frequency input from more than
one source, whereas LTP requires high frequency neuronal stimulation (Ji et al.,
2003). An LTP-like event can be triggered in spinal cord slices, using high frequency
stimulation, but this is not seen in intact cord in the presence of segmental and
descending modulation (Sandkuhler and Liu, 1998).
In addition to the role of the NMDA R in LTP in the hippocampus, application
of NMDA R antagonists also attenuated the increased responses seen following wind-
up of a subset of dorsal horn interneurons by low frequency C fibre stimulation, or
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cutaneous stimulation of noxious intensity (Woolf and Thompson, 1991), (King and
Lopez-Garcia, 1993).
The effect of glutamate binding to the NMDA receptor may be modulated by a
regulatory glycine binding site (Kleckner and Dingledine, 1988). Glycine appears to
be important in regulating a number of NMDA receptor-mediated responses, and may
act as a co-agonist. Activation of the GlyNMDA site would also appear to be an
essential component of the NK1 receptor facilitation of dorsal horn neuronal
responses towards NMDA receptor agonists (Heppenstall and Fleetwood-Walker,
1997b). GlyNMDA site antagonists have been shown to suppress the enhanced
responses of spinal neurons resulting from repetitive C fibre stimulation (Dickenson
and Aydar, 1991). In vivo, blockade of the GlyNMDA (glycines receptor (Kleckner and
Dingledine, 1988)) site using the antagonist 7-chlorokynurenate, has been shown to
inhibit NMDA-induced thermal hyperalgesia in the rat (Kolhekar et al., 1994).
AMPA receptors
AMPA Rs are considered extensively in section 1.6.
Kainate receptors
Until recently, this family of ionotropic glutamate receptors has been difficult
to study due to a lack of specific agonists and antagonists. Available agents tended to
cross-react with AMPA iGluRs. Kainate receptors incorporating the GluR5 subunit
are present at high levels on small diameter primary afferent neurons thought to
mediate nociceptive inputs. Procter et al investigated the effect of GluR5 agonists and
antagonists on nociceptive stimuli in single cells, hemisected rat spinal cords and
intact mice (Procter et al., 1998). It was found that the GluR5 agonist had a small
effect in reducing C fibre-mediated reflexes in a spinal cord preparation, but had no
analgesic effect in vivo.
Using spinal cord slices from knockout mice, GluR5 or GluR6 subunits were
found to either suppress or facilitate glutamatergic excitatory transmission in the
substantia gelatinosa. Kainate treatment had a biphasic effect in the absence of GABA
inhibition, with facilitation apparent at a low concentration (30 nM) and depression at
a higher concentration (3 pM). This suggests that kainate receptors are involved in bi¬
directional regulation of excitatory synaptic transmission in the dorsal hom lamina II
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region, and that these actions may be of importance for nociception (Youn and
Randic, 2004).
1.5.2 Metabotropic glutamate receptors
The metabotropic glutamate receptors (mGluRs) form a family of eight
subtypes (Pin and Duvoisin, 1995). They are divided functionally in to three groups:
group I metabotropic receptors (mGluRl and mGluR5) are concentrated in the
superficial dorsal hom of the spinal cord (Jia et al., 1999). Some of these receptors
can be further sub-divided into splice variants for example (mGluRla-d and
mGluR5a-b), with varying physiological roles (Tanabe et al., 1992), (Joly et al.,
1995). Antisera to mGluR5 detected marked immunoreactivity within laminae I and II
of the dorsal hom, and autonomic regions in rat spinal cord. Relatively fewer
mGluRla were found in laminae I and II, the majority of these receptors being
localised to the deep dorsal hom (laminae III-V), and the ventral hom (laminae VI-
IX). Somatic motoneurons expressed mGluRla. The mGluRlb appeared to be
localised to lamina X around the central canal, and in the ventral hom (Alvarez et al.,
2000).
The group I mGluRs are coupled to Gq/i i proteins and activate protein kinase C
(PKC) in addition to releasing calcium from intracellular stores and possibly
increasing intracellular cyclic adenosine 3',5'-monophosphate (cAMP) (Abe et al.,
1992), (Aramori and Nakanishi, 1992). All these functions lead to an increase in
cellular excitability and are likely to underlie the role group I metabotropic glutamate
receptors are thought to play in various forms of synaptic plasticity including LTP in
the hippocampus, wind-up and the development of chronic pain states.
Group II and III mGluRs are negatively coupled to adenylate cyclase via Gj/0
proteins (De Blasi et al., 2001). Presynaptic group II receptors (mGluR2 and 3)
decrease glutamate release. Group III mGluRs are involved in varied processes:
mGluR6 is found only in the retina and plays a role in the amplification of visual
inputs. The remainder of group III receptors; mGluR4, 7 and 8 are also found at
presynaptic sites. The group II and III mGluRs will not be discussed further here.
Group I metabotropic glutamate receptors and nociception
Application of mustard oil peripherally to rats selectively activates C fibres
and brings about a state of sustained activation in dorsal hom neurons (Munro et al.,
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1993). The importance of mGluR receptor activation in nociception has been
demonstrated in vivo by reversal of DH neuron mustard oil evoked sensitisation using
iontophoretic application of L-l-amino-3-phosphonopropanoic acid (L-AP3), a
selective mGluR antagonist (Young et al., 1995). It was also found that cyclothiazide
(CTZ), a selective mGluRl antagonist, markedly reduced the electrophysiological
response of DH neurons to mustard oil but not to brushing (Young et al., 1997). This
study provides evidence that mGluRl plays an important role in nociceptive
transmission, particularly after prolonged noxious input.
The effect of removal of mGluRl by antisense ablation on single cell
electrophysiological responses to stimulation has also been studied (Young et al.,
1998). Multireceptive neurons in the dorsal horn of mGluRl-ablated animals showed
a normal response to innocuous stimuli, but a markedly reduced response to mustard
oil and the specific mGluRl/5 agonist 3,5-dihydroxyphenylglycine (DHPG). In
parallel to the electrophysiological changes, it was noted that the rats demonstrated a
marked analgesia to thermal stimuli on behavioural testing. Once again, this provides
evidence for the role of mGluR group I in nociception.
DHPG has also been shown to cause spontaneous nociceptive behaviour
(SNB) and mechanical hyperalgesia when given via the intrathecal (IT) route to naive
rats, whereas the non-specific mGluR agonist trans-1-aminocyclopentane-1,3-
dicarboxylic acid (ACPD) caused less SNB and a specific mGluR5 agonist trans-
azetidine-2,4-dicarboxylic acid (t-ADA) produced no SNB. This suggests a more
significant role for mGluRl than for mGluR5 in acute nociception (Fisher and
Coderre, 1996).
The role of mGluR5 in a number of pain states was investigated using the
specific antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) (Walker et al.,
2001). MPEP given intrathecally resulted in some reversal of mechanical hyperalgesia
in chronic inflammation using a Freund's Adjuvant model at 24hrs post injection. In
acute inflammation, MPEP had a moderate effect on mechanical hyperalgesia, but no
effect on oedema. In a sciatic nerve ligation model of neuropathic pain, no effect was
found on mechanical hyperalgesia, suggesting that the mGluR5 has a more significant
role in inflammation than in neuropathic pain.
In contrast to these findings, intrathecal treatment with the specific mGluR5
antagonist SIB 1757 was effective in reversing thermal hyperalgesia in a spinal nerve
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ligation (SNL) model of neuropathic pain at a low dose of 0.01 pg but only showed a
partial dose-dependant reversal of mechanical hyperalgesia (Dogrul et al., 2000).
It has been suggested that the relative efficacy of mGluR5 antagonists in
ablating thermal but not mechanical hyperalgesia in nerve injury emphasizes the
possibility that differing mechanisms exist for each of these abnormal pain states. In
addition, antibody ablation of mGluRl and mGluR5 had little effect on reducing
nociceptive behaviour caused by noxious heat or chemical irritation (with formalin).
However, these antibodies were effective in reducing cold allodynia after sciatic nerve
constriction induced neuropathic pain (Fundytus et al., 1998). It has recently been
suggested that the role of mGluR5 in neuropathic pain is mediated via modulating
apoptotic cell death (de Novellis et al., 2004). However, the relative importance of
this process in neuropathic pain is not yet clear as reports vary widely as to the degree
of cell death occurring, and a recent carefully conducted study revealed no differential
loss of GABAergic inhibitory cells (Polgar et al., 2003), (see section 1.11.4).
1.5.3 Neuropeptides
Various neuropeptides are synthesised in DRG neurons and are often co-
released with glutamate from peripheral afferent terminals causing a variety of
synergistic effects on postsynaptic dorsal horn cells. As they may play an important
role in the development of sensitised states within the CNS, they are considered in
some detail below.
Levels of peptide receptors and their ligands alter markedly after peripheral
nerve injury, both in the dorsal root ganglion and spinal cord. In large-diameter
neurons, neuropeptide Y (NPY) and cholecystokinin increase, whereas levels of
calcitonin gene-related polypeptide are reduced. In small diameter nociceptive
neurons in the DRG, levels of SP, CGRP and somatostatin decrease, while levels of
vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase-activating peptide
(PACAP) and galanin markedly increase (Hokfelt et al., 1994).
Substance P
Substance P is a member of the tachykinin family and is expressed by a
significant proportion of small diameter primary afferent neurons, neurons within the
superficial spinal dorsal horn and small diameter nocispecific DRG neurons (Hokfelt
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et al., 1975), (Ju et al., 1987). This peptide is an endogenous ligand for the neurokinin
1 (NKi) receptor.
The NKi receptor has been shown to be expressed by approximately 80% of
lamina I neurons projecting to the thalamus, periaqueductal grey matter, lateral
parabrachial area and caudal ventrolateral medulla (Todd et al., 2000). It would
therefore seem likely that NKi-expressing cells are involved in several aspects of
nociceptive processing. The effects of NKi expressing projection neurons on
brainstem structures may be modulated by descending serotonergic inhibitory
pathways, which have been shown to form connections with these cells in the
superficial dorsal horn (Polgar et al., 2002).
Evidence for the pro-nociceptive role of SP has been provided using a variety
of experimental techniques. When given intrathecally, SP caused a reduction in the
latency of the tail-flick response to peripheral stimuli in nai've rats (Yashpal et al.,
1982) and triggered biting and scratching behaviours in mice that may be indicative of
pain sensation (Hylden and Wilcox, 1981), (Courteix et al., 1993).
The SP tachykinin receptor NKi is linked to second messenger systems via G
proteins and its activation leads to a prolonged depolarising effect on secondary
neurons. It has been suggested that this prolonged activation of second order neurons
by SP may lead to central sensitisation, as antagonists to the NKi receptor have been
shown to block cumulative depolarisation and hence wind-up (Baranauskas and
Nistri, 1996), (Baranauskas and Nistri, 1998). However, NKi antagonists have not
been shown to be generally effective in reducing neuronal responses to brief noxious
stimulation in rats (Fleetwood-Walker et al., 1990), (Yamamoto and Yaksh, 1992).
These results would suggest that SP and NKi receptors might play a more prominent
role in sustained noxious states. This suggestion is supported by the finding that
noxious mechanical and severe thermal stimuli specifically evoked SP release from
primary afferents using microdialysis techniques and antibody probes (Kuraishi et al.,
1989), (Duggan and Furmidge, 1994), (Duggan et al., 1995). Noxious stimuli
resulting in tissue damage were also shown to result in a significantly greater release
of SP than less intense stimuli. In addition, ablation of SP containing neurons in the
superficial dorsal horn in vivo resulted in marked attenuation of behavioural responses
to highly noxious stimuli, but left responses to mild noxious stimuli intact (Mantyh et
al., 1997).
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It is known that the effect of glutamate on the dorsal horn neuron may be
modulated by co-released SP which coexists with this neurotransmitter in dorsal root
ganglion (DRG) neurons and primary afferent terminals (Battaglia and Rustioni,
1988), (Debiasi and Rustioni, 1988). Electrophysiological studies have demonstrated
that iontophoretic application of SP may enhance NMDA receptor-induced activity of
spinothalamic tract (STT) neurons (Dougherty and Willis, 1990), (Dougherty and
Willis, 1991), and rat dorsal horn neurons (Cumberbatch et al., 1995). This NK]
receptor facilitation of the NMDA receptor can be blocked by GlyNMDA site
antagonists (Heppenstall and Fleetwood-Walker, 1997a), (Heppenstall and
Fleetwood-Walker, 1997b). These results suggest that there is a clear interaction
between the glutamatergic NMDA receptor, glycine and SP in the transmission of
nociceptive information.
These studies suggest that SP is involved in nociception in situations where
tissue damage occurs and inflammatory mediators are released. In addition to this
role, SP has recently been implicated in the generation and maintenance of
neuropathic pain, as pre-emptive intrathecal administration of the NKi receptor
antagonist L-732 138 has been shown to prevent the development of mechanical and
cold allodynia following CCI (Cahill and Coderre, 2002). It would therefore appear
that an NKi antagonist would be an effective analgesic drug in chronic pain states.
Unfortunately, such compounds have been shown to be largely ineffective in clinical
trials in humans, possibly due to the existence of multiple alternative pathways that
may potentially activate iGluRs in the development of chronic pain states.
Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating
polypeptide
These polypeptides are widely expressed within the CNS of a variety of
species (Yaksh et al., 1988). VIP and PACAP are present throughout the spinal cord
of the cat and rat, with increasing concentration towards the caudal end (Gibson et al.,
1981), (Yashpal et al., 1991). Nerve fibres immunopositive for these compounds are
concentrated in laminae I and II, an area known to be important in the transmission of
nociceptive information (Cervero and Iggo, 1980), (Moller et al., 1993). Recently,
PACAP mRNA expression has been demonstrated in neurons in laminae I and II of
the DH. Interestingly, increased expression of PACAP was seen in ventral horn
neurons, in response to sciatic nerve transection, suggesting a role for PACAP in
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repair or regeneration of motor neurons (Pettersson et al., 2004). The wide distribution
of VIP and PACAP within the CNS, in particular in primary sensory neurons of the
spinal dorsal horn, suggests a possible role for these peptides in the transmission of
somatosensory information.
VIP and PACAP are recognised by a family of three receptors. As these two
peptides share a relatively high degree of sequence homology, they may combine with
the same receptor binding sites (Harmar and Lutz, 1994). The PACi receptor is
relatively specific for PACAP, whereas the VPAQ and VPAC2 Rs have similar
binding affinity for both agonists (Hosoya et al., 1992), (Ishihara et al., 1992). These
receptors each consist of seven trans-membrane domains and are coupled to
stimulatory Gs proteins, increasing cAMP levels on activation (Spengler et al., 1993),
(Dickinson and Fleetwood-Walker, 1999).
Intrathecal application of VIP has been shown to facilitate spinal cord reflex
excitability in rats (Hokfelt et al., 1987), (WiesenfeldHallin, 1989), (Xu and
WiesenfeldHallin, 1991). Despite this demonstration of the role of VIP in acute
nociception, this peptide is expressed at very low levels in DRG neurons and in
lamina I and lamina II neurons of the spinal dorsal horn in the normal state (Gibson et
al., 1981), (Knyiharcsillik et al., 1991), (Moller et al., 1993), (Noguchi et al., 1993).
Intrathecal application of the VIP antagonist (Ac-Tyr*, D-Phe~)-GRF(l-29)-NH2 did
not prevent C fibre stimulation induced reflex facilitation in normal animals
(WiesenfeldHallin et al., 1990), (Xu and WiesenfeldHallin, 1991). These studies
suggest that endogenous VIP does not appear to play a significant role in the C fibre-
induced spinal sensitisation under normal conditions.
Following nerve injury, however, the situation would appear to be rather
different, with characteristic changes occurring in the expression of various
neuropeptides in the DRG and DH (Hokfelt et al., 1994). In small diameter,
nociceptive neurons in the DRG, levels of SP, CGRP and somatostatin decrease,
whereas VIP and PACAP increase (WiesenfeldHallin et al., 1990). These results
suggest that there may be a switch in the significance of various neuromodulator
substances following peripheral nerve injury, with the role of major excitatory
neuropeptide transferring from SP in the nai've animal to VIP in the sensitised state.
PACAP levels in the DRG increase early following injury and return to resting
levels after one to two weeks (Zhang et al., 1995), whereas VIP levels increase late in
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the superficial dorsal horn and remain elevated (Nahin et ah, 1994), (Zhang et ah,
1995b). The marked difference in the time course of these changes suggests that
PACAP and VIP may play a role in the induction and maintenance of a sensitised
state respectively.
It has been demonstrated that iontophoretic spinal application of a specific
VPAC2 R antagonist inhibited the neuronal response to sustained noxious input from
the application of mustard oil, but had no effect on the response to innocuous brushing
in the nai've animal. In neuropathic animals, VPACi, VPAC2 and PACi R antagonists
had no effect on innocuous sensory transmission (Dickinson et ah, 1999).
Spinal application of agonists to the VPACi, VPAC2 and PACi Rs resulted in
increased firing of DH neurons in nai've animals. After the induction of neuropathy
(CCI), the response to VPACi and PACi R agonists was not increased, whereas the
response to the VPAC2 R agonist Ro 25-1553 was dramatically augmented (Dickinson
et ah, 1999). These findings suggest that the VPAC2 R may play a specific role in the
transmission of noxious stimuli in neuropathic pain.
The role of PACAP has been less well elucidated. Intrathecal delivery of
PACAP-38, activating both VPAC and PAC Rs, has been shown to reverse thermal
hyperalgesia in mice at low doses and causes biting and scratching pain related
behaviour at higher doses, suggesting that this peptide may have a complex role in the
spinal cord, dependant upon its concentration (Narita et al., 1996). In contrast to these
studies in mice, intrathecal PACAP-27 produced a significant and long-lasting
suppression of C fibre-evoked flexion reflex in the rat (Zhang et al., 1993). In
addition, intrathecal PACAP also reduced spontaneous pain behaviours in the rat
following formalin inflammation of the hind paw (Yamamoto and Tatsuno, 1995).
The role of PACAP remains unclear, therefore, and may alter depending upon the
background state of the nociceptive system and the drug dosage. Interspecies
differences may further complicate the situation.
Blockade of the VPAC2 R would seem to have a specific effect in suppressing
neuronal responses to prolonged noxious input in both normal and nerve-injured rats,
suggesting that this receptor may mediate noxious sensory transmission, particularly
after sensitising nerve injury (Dickinson et al., 1999). This finding highlights a role
for specific VPAC2 R antagonists as potential analgesics in intractable neuropathic
pain.
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Calcitonin gene-related peptide (CGRP)
This peptide is an important mediator of nociceptive transmission. CGRP is
found in 30% of all unmyelinated C fibre primary afferents and A8 fine myelinated
fibres, and is down regulated in large dorsal root ganglia (DRG) neurons following
axotomy (Levine et al., 1993), (Hokfelt et al., 1994). Noxious thermal and mechanical
stimulation of primary afferents has been shown to trigger CGRP release into the
superficial dorsal horn (Morton and Hutchison, 1990). The majority of CGRP positive
DRG neurons also contain SP (Battaglia and Rustioni, 1988). These two compounds
are co-released and CGRP modulates the effect of SP, inhibiting SP endopeptidase
and potentiating its effect (Mao et al., 1992c).
The role of CGRP in various pain conditions has been investigated using
CGRP(8-37), a truncated form of CGRP that binds to the CGRP receptor with similar
affinity to the endogenous ligand but does not activate the receptor and thus acts as a
highly selective CGRP receptor antagonist. Mechanical hyperalgesia following
intradermal injection of capsaicin in rats has been reversed using CGRP(8-37) applied
via a microdialysis catheter into the dorsal horn (Sun et al., 2003). This study suggests
that CGRP may play a role in inflammatory hyperalgesia.
This peptide has also been implicated in the maintenance of neuropathic pain.
In a rat model of mononeuropathy after left common sciatic nerve constriction, CGRP
immunoreactivity was significantly decreased in the DH of the spinal cord and DRG
ipsilateral to injury. In the same study, intrathecal CGRP(8-37) induced a significant
bilateral increase in hindpaw withdrawal latency to both thermal and mechanical
stimulation in both neuropathic and nai've animals (Yu et al., 1996). Interestingly, the
analgesic effect of CGRP blockade using CGRP(8-37) was less marked in rats
following nerve injury, suggesting that the contribution of CGRP and its receptors to
transmission of presumed nociceptive information appears to be reduced in the sciatic
nerve constriction model. In addition to peripheral nerve injury, intrathecal CGRP(8-
37) was effective in alleviating mechanical and thermal allodynia in a dose-dependent
manner in a model of chronic central neuropathic pain after spinal hemisection
(Bennett et al., 2000).
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1.5.4 Inhibitory and neuromodulatory peptides
Neuropeptide Y (NPY)
In the resting state, NPY is not expressed by DRG neurons (Lundberg et al.,
1983). However, following axotomy, (Wakisaka et al., 1991), (Kashiba et al., 1994),
(Malmberg et al., 1997) or CCI of the sciatic nerve (Nahin et al., 1994), (Munglani et
al., 1995) its expression increases in large diameter neurons. However, there are also
many NPY-positive fibres innervating the superficial dorsal horn, which originate
both locally and from supraspinal descending tracts (Wakisaka et al., 1991).
In a study of neuropathic pain following spinal nerve injury in rats,
administration of anti-NPY antiserum into the nucleus gracilis ipsilateral to nerve
injury reversed tactile, but not thermal, hypersensitivity. These data suggest that nerve
injury-induced tactile hypersensitivity may be mediated by upregulated NPY via large
fibre input into the nucleus gracilis (Ossipov et al., 2002).
In inflammation, intrathecal NPY has been shown to reduce thermal
hyperalgesia on the side ipsilateral to carrageenan or CFA injection in a dose
dependant manner, with only a small effect on the contralateral side. The effect of
NPY may be inhibited by administration of an antagonist at the NPY Y1 receptor, but
not by an NPY Y2 receptor antagonist. These data suggest that spinal Y1 receptors
contribute to the inhibitory effects of NPY on thermal hypersensitivity in the rat
(Taiwo and Taylor, 2002). However, NPY expression does not appear to alter in
inflammatory states, in contrast to the marked effects of neuropathy (Wakisaka et al.,
1992).
It would seem that the role of NPY in nociception is far from clear: inhibition
of this peptide in the nucleus gracilis results in decreased mechanical hyperalgesia in
neuropathy, and activation of the Y1 receptor decreases thermal hyperalgesia in
inflammation. It is likely that differing NPY receptors have differing modulatory roles
within different regions of the CNS.
y-Aminobutyric acid (GABA) and glycine
An important role for GABA in sensory processing is suggested by both
electrophysiological and behavioural studies, which indicate an inhibitory function in
the transmission of noxious stimuli. Neurons containing GABA and glycine exert
tonic inhibitory effects on excitatory dorsal horn inputs (Curtis et al., 1970),
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(Zieglgansberger and Sutor, 1983). Both ionotropic GABAa receptors and
metabotropic GABAb receptors are expressed on neurons in the superficial DH (Price
et al., 1984), (Bowery et al., 1987). Activation of GABAb receptors leads to inhibition
of presynaptic neurotransmitter release and to inhibition of postsynaptic neuronal
activity (references in (Bowery et al., 1993) and (Bowery, 1993)).
GABAb receptors clearly play a role in neuropathic pain, as treatment with
agonists to this receptor subtype resulted in reduction in mechanical allodynia
following partial sciatic ligation and a dose dependant reduction in thermal
hyperalgesia following CCI, with little effect on inflammatory hyperalgesia (Patel et
al., 2001), (Franek et al., 2004).
Following unilateral sciatic nerve ligation in the mouse, intraperitoneal
injection of muscimol (GABAa agonist) or baclofen (GABAb agonist) induced a
dose-related thermal antinociception in both intact and ligated animals (Zarrindast and
Mahmoudi, 2001). Activation of GABAa receptors using intrathecal muscimol has
also been shown to prevent the long-lasting potentiation of dorsal horn neuron
electrophysiological responses usually seen after tetanic stimulation in rats with
chronic constriction injury (Miletic et al., 2003).
It has been suggested that loss of GABAergic inhibition within the dorsal horn
may be required for the development of spinal central sensitisation and this
mechanism is discussed further below (see section 1.11.4), (Ibuki et al., 1997),
(Moore et al., 2002).
Galanin
Galanin is a 29-amino-acid neuropeptide normally expressed at very low
levels in sensory and sympathetic neurons (Ju et al., 1987), (Baranowski et al., 1994),
(Ma and Bisby, 1997). It is widely distributed in the CNS, and is concentrated both in
the superficial dorsal horn of the spinal cord and within primary afferent fibres (Kar
and Quirion, 1995).
Following peripheral nerve injury, galanin is strongly upregulated in small and
medium diameter unmyelinated neurons in the DRG, which commonly co-express SP
and CGRP (Hokfelt et al., 1987), (Villar et al., 1989). It has been suggested that
galanin up regulation is important in the development of central sensitisation (Kerr et
al., 2001).
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The effects of intrathecal galanin on behaviour are complex and variable,
seemingly dependant on the endogenous levels of galanin, the drug dose, and the type
of experimental model (Xu et al., 2000). In general, an inhibitory effect on
neuropathic pain was noted (Liu and Hokfelt, 2002). It is possible that this peptide
plays a neuromodulatory role, as it antagonises the excitatory effects of CGRP and SP
when used as an intrathecal pre-treatment (Xu et al., 1990), (WiesenfeldHallin et al.,
1991b). In addition to damping down the excitatory effects of pro-nociceptive
peptides (Ferhat et al., 1996), galanin also inhibits the analgesic effect of morphine on
noxious thermal and mechanical stimuli in na'ive animals (WiesenfeldHallin et al.,
1991a).
As might be expected from its up-regulation following nerve injury, galanin
would seem to play a more significant role in modulating nociception in rats with
spinal nerve ligation. There was a marked inhibition of up to 80% of responses to both
physiological and electrical stimuli in SNL rats following intrathecal galanin
administration. This suggests that the inhibitory role of galanin may become more
significant following nerve injury (Flatters et al., 2002).
Somatostatin (SOM)
Somatostatin is a neuropeptide expressed by small diameter primary afferent
neurons, which do not express SP (Nagy and Hunt, 1982) and in lamina II cells of the
dorsal horn (Hokfelt et al., 1976). Its role in nociception is not entirely clear.
Intrathecal SOM application has been reported to increase the excitability of the
spinal cord neurons following mechanical and thermal stimuli (WiesenfeldHallin,
1985). In contrast to this finding, intrathecal and epidural application of somatostatin
in humans results in analgesia, however concerns regarding neurotoxicity have limited
its use via these routes. Receptors for this peptide are also found peripherally, and
their activation reduces both inflammatory pain and the activity of sensitised
nociceptors in rats (Carlton et al., 2001). It may be that SOM has a neuromodulatory
effect, controlling the release of other neurotransmitters, and so may act in a




AMPA Rs are involved in the fast transmission of noxious and innocuous
stimuli (Procter et al., 1998), (Stanfa and Dickenson, 1999). These receptors mediate
the majority of monosynaptic excitatory postsynaptic potentials (EPSPs) in the dorsal
horn evoked by C fibres. Activation of these receptors results in a change in the
potential of the postsynaptic membrane towards depolarisation. Summation of a
number of these EPSPs may lead to the triggering of an action potential in the target
neuron.
1.6.1 Structure
The four AMPA R subunits were first sequenced in 1990 and termed the
GluR-A-D subunits (Keinanen et al., 1990), (reviewed in (Hollmann and Heinemann,
1994) ). The GluR-A molecule appeared to have 100% sequence homology with the
putative kainate receptor (termed GluR-Kl) sequenced the previous year (Hollmann
et al., 1989). Evidence from X-ray crystallography of partly homologous bacterial
potassium channels, and electrophysiological studies of mutant channel conductance
suggests that the AMPA R is a tetramer of four subunits with their pore regions facing
the centre to produce an ion channel (Robert et al., 2001), (references in (Bredt and
Nicoll, 2003)). The complete receptor consists of combinations of subunits, termed
GluRl-4. Each subunit consists of a large extracellular N-terminal region (400 amino
acids) followed by a membrane-spanning a helix, then a second hydrophobic domain
which dips into the membrane from the cytoplasmic side and forms the pore. Beyond
the pore there is a further transmembrane section followed by extracellular loop, a
final transmembrane a helix and the cytoplasmic C terminal tail. The two
extracellular modules SI and S2 may form the glutamate-binding domain (see Figure
1.1b).
AMPA Rs exist in two splice variants: flip and flop, causing sequence
variation just before the fourth transmembrane domain. GluR2 mRNA is edited at the
Q/R site (before the third transmembrane domain) by a sequence specific RNA
editase, ADAR2. The unedited form (containing Q) is permeable to calcium; the
edited form (containing R) is not. The majority of receptors undergo editing at this
point. GluR2, 3 and 4 mRNA is edited at the R/G site immediately before the flip/flop
sequence, resulting in an increase in the rate of recovery from desensitisation. The
majority of these three GluR subtypes are edited in this manner in the adult. Receptor
desensitisation to a glutamate stimulus depends on the receptor subunit composition.
The R7G editing site and the flip/flop cassettes in AMPA R subunits contribute to a
great extent in receptor desensitisation and recovery rates. The flop forms of the
subunits desensitise more rapidly in response to glutamate than flip forms (Dingledine
et al., 1999), (see Figure 1.1a). Flip variants predominate before birth and remain
expressed at high levels into adulthood. Flop variants increase in number from
postnatal day eight, and reach the same levels as flip by adulthood in the rat.
1.6.2 Anatomical location
The AMPA R is found in most areas of the central nervous system. The
subunit composition of each receptor varies with its location as well as synaptic
activity. In rat neostriatal cells, for example, 50% of dendritic spines were
immunopositive to GluRl and GluR2/3 (Bernard et ah, 1997).
The superficial dorsal horn of the spinal cord is of particular relevance to
nociceptive processing and contains significant numbers of AMPA Rs, particularly
GluRl and GluR2. These receptor subunits have been shown to be expressed solely in
neurons rather than glia (Todd et ah, 1998), and were localised to synaptic densities in
lamina II on electron micrography (Tachibana et ah, 1994). Most studies have
demonstrated that GluRl labelling was generally more superficial than GluR2/3,
which was found at low levels in lamina I and in larger amounts in lamina II and III
(Tolle et ah, 1993), (Popratiloff et ah, 1996), (Coggeshall and Carlton, 1997). The
GluR2 subunit protein and mRNA is present in greater amounts than GluRl in the
superficial dorsal horn, and tends to be more evenly distributed through the outer
three laminae when investigated using in situ hybridisation (ISHH) and
immunocytochemistry (ICC) (Furuyama et ah, 1993). GluRl subunits tend to be
localised in neurons in lamina I and outer lamina II (Tolle and et al, 1993), (Yung,
1998). Subunits GluRl, 2/3 are also found in the spinothalamic tract cells, soma and
dendrites (Ye and Westlund, 1996). In vivo, it would seem that GluRl and GluR2
subunits are largely isolated to separate bands in the dorsal hom of the spinal cord,
with some overlap within lamina II. Both subunits may occur within individual cells,
however (Zhang et ah, 1995a).
The other AMPA subunits, GluR3 and 4 are expressed at much lower levels in
the superficial dorsal horn. GluR3 is expressed at moderate levels throughout the
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outer three laminae, whereas GluR4 is almost undetectable. In the ventral horn, levels
of GluR3/4 immunostaining were high in motor neurons, whereas GluRl/2 staining
was moderate to weak (Furuyama et ah, 1993), (Tolle and et al, 1993).
On a subcellular level, post embedding immunogold electron microscopy has
revealed clustering of AMPA R subunits at synaptic sites in the dorsal horn
(Popratiloff et al., 1996). GluRl and GluR2/3 subunits were found between 30nm
outside and 40nm inside the postsynaptic membrane of asymmetric synapses. The
AMPA R subunits were post-synaptic to two types of central bouton, termed CI and
C2 (RibeiroDaSilva and Coimbra, 1982). The CI terminals were associated with
unmyelinated primary afferents and GluRl subunits, and the C2 with small
myelinated afferents and GluR2/3. Although the majority of AMPA Rs are
postsynaptic, some presynaptic AMPA Rs have been demonstrated in lamina II of the
dorsal horn, in a spinal cord slice preparation of developing post natal day 9 (P9) rats,
playing an inhibitory role by triggering primary afferent depolarisation when bound to
their ligand (Lee et al., 2002).
In other CNS regions, the distribution of AMPA R subunits has shed some
light on their possible function. Using immunocytochemistry combined with electron
microscopy, the subcellular distributions of different AMPA R subunits in the rat
caudal nucleus of the solitary tract were found to be mostly distinct. GluR2/3 was
found at pre- and postsynaptic sites, and in astrocytic glia; while GluRl was found
primarily in small dendrites and spines. Using subtype-specific antibodies, GluRl and
GluR2 were occasionally colocalised in large dendrites. This study demonstrates that
within the nucleus of the solitary tract, single (large) neurons may contain both GluRl
and GluR2, but there is apparently differential trafficking of GluRl to potential sites
for synaptic plasticity (ie: small dendrites and dendritic spines) (Aicher et al., 2002).
Unlike other AMPA R subunits, GluR2 undergoes glycosylation with high mannose
content, possibly delaying its transit through the endoplasmic reticulum (ER). This
ensures that there is a large intracellular pool of GluR2 subunits available for
assembly (references in (Bredt and Nicoll, 2003)).
The subcellular location of AMPA Rs has been investigated in hippocampal
cell culture using a number of biochemical techniques. Proteolysis of surface
receptors by chymotrypsin, cross-linking of surface receptors, and biotinylation of
surface receptors all demonstrated similar results. It was found that 60-70% of total
53
GluRl protein and 40-50% of total GluR2/3 protein was expressed on the surface of
hippocampal neurons (Hall and Soderling, 1997).
Although a high proportion of receptors may be expressed on the cell surface,
they may not be located at dendritic sites where they would affect synaptic function. It
has been shown that 71% of GluRl subunits are localised intracellularly in dendritic
shafts, 20% on the dendritic shaft surface, 8% in spines and only 3% in postsynaptic
densities (Shi et al., 1999).
The movement of GluR2 subunits on the surface of cultured hippocampal cells
was investigated in an elegant study using latex-bead labelling of AMPA Rs. Cell
surface GluR2 subunits would appear to meander randomly, possibly as a result of
diffusion, until anchored at peri-synaptic sites. Localised increases in calcium
concentration, as found at sites of synaptic activity, resulted in the accumulation of
receptors at the cell surface and their immobilisation (Borgdorff and Choquet, 2002).
The subcellular location of GluRl and GluR2 subunits has not been investigated in
adult rat dorsal horn in vivo.
1.6.3 Developmental changes
The expression of AMPA R subunits alters during development. In the adult
rat, the majority of GluRl labelling was found in the neuropil of dorsal hom lamina II
and in small cell bodies and proximal processes. In postnatal day 7 (P7) animals,
numerous neurons were labelled with very long tapering processes in most regions of
spinal grey matter (Jakowec et al., 1995). The subcellular location of receptor subunits
also varies as the animal matures. In the neonatal rat hippocampus, most GluRl is
intracellular with little at spines or synapses (Shi et al., 1999). By postnatal day 9, 30-
40% of GluRl and 2 remains intracellular. In the adult, cell surface receptor
expression is greater than 85% for GluRl and greater than 80% for GluR2 (Grosshans
et al., 2002). These figures suggest a greater proportion of receptors may be expressed
on the cell surface of hippocampal cells than was previously thought, however, it is
not known whether these figures reflect the surface expression of receptors in vivo in
the dorsal horn (Hall and Soderling, 1997).
In early development AMPA Rs are diffusely distributed in the dendrite, but
later become localised at post-synaptic sites. Within individual neurons, the density of
AMPA Rs in dendritic spines has been shown to vary throughout spine development.
Early small spines are rich in NMDA R but lack AMPA R, perhaps representing silent
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synapses, which are electrophysiological^ inactive (Durand et ah, 1996). As the
spines enlarge, the AMPA R content increases, allowing for depolarisation and
activation of the NMDA calcium channels at these synapses, causing them to become
functional (Takumi et ah, 1999).
1.6.4 Calcium permeability
Calcium permeable AMPA Rs form a subgroup of receptors that may play a
significant role in the synaptic plasticity involved in the development of chronic pain
states (Sorkin et al., 2001). These receptors may potentially alter synaptic strength by
• • 9+ •
providing the appropriate Ca signal to activate second messenger systems (Gu et al.,
• • • 9+
1996). Using kainate induced cobalt uptake in spinal cord slices, Ca permeable
AMPA Rs can be identified (Pruss et al., 1991). The uptake of cobalt was prevented
by selective AMPA antagonism (using GYKI 53655 a selective non-competitive
AMPA antagonist) demonstrating that kainate was acting as a ligand at the AMPA R.
In addition, treatment with Joro spider toxin (JsTx) a specific antagonist of calcium
permeable AMPA Rs and kainate receptors, prevented cobalt loading. Taken together,
* • • 9+
these two findings demonstrate that cobalt loading is occurring through Ca
9 i
permeable AMPA Rs only (Engelman et al., 1999). In rat pups, Ca permeable
AMPA Rs were found in lamina I and outer lamina II with heavier labelling towards
the lateral edge of the dorsal horn (Engelman et al., 1999).
The presence of the GluR2 subunit determines calcium permeability
(Burnashev et al., 1992). AMPA Rs lacking GluR2 have permeability ratios
approaching Pca/PNa = 3. Inclusion of GluR2 subunits markedly decreases calcium
permeability (Hollmann and Heinemann, 1994). This feature of the receptor maps to a
single arginine residue in the pore-forming region of the GluR2 subunit, which is a
glutamine in GluRl, 3 and 4. This residue is coded as glutamine (Q) in GluR2
genomic DNA, it is converted to arginine (R) by post-transcriptional mRNA editing.
This editing of the 'Q/R' site occurs in 99% of GluR2 mRNAs (Seeburg et al., 1998),
(Seeburg, 2002). AMPA Rs with high and low calcium conductivity have been
demonstrated within a single retinal ganglion cell demonstrating that individual cells
may express more than one type of AMPA R subunit combination (Zhang et al.,
1995a). There is evidence that the subunit composition of the receptors can rapidly
alter in an activity-dependant manner. Using cerebellar cells, Liu and Cull-Candy
2_j_demonstrated a rapid and lasting change in the subunit composition and Ca
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permeability of AMPA Rs following stimulation. Repeated activation of Ca
permeable AMPA Rs caused a rapid reduction in Ca2+ permeability and increased
incorporation of GluR2 into AMPA subunits (Liu and Cull-Candy, 2000).
The functional role of Ca2+ permeable AMPA Rs
Calcium permeable AMPA Rs would seem to play a role in central
sensitisation in pathological pain states, as blockade of these receptors with the
specific non-competitive agent Joro spider toxin (JsTx) prevented mechanical
hyperalgesia following thermal injury (Sorkin et al., 1999). The mechanism of action
of these receptors in modulating nociception is likely to be complex, however, as
• • 2"bthere is evidence supporting the expression of Ca permeable AMPA Rs on
inhibitory interneurons and neurons projecting to the brainstem. Cells containing
GABA are generally taken to have an inhibitory role, whereas those expressing the SP
receptor NK] include projection neurons to the spinothalamic tract, which may be
• • O j
pronociceptive. Some Ca permeable AMPA Rs were expressed with GABA and
some with NKi in embryonic dorsal horn cell culture (Albuquerque et al., 1999).
In situ studies have also demonstrated that some NKi positive dorsal horn cells
coexpressed Ca2+ permeable AMPA Rs by cobalt uptake (13 of 38 cells surveyed)
(Engelman et al., 1999). As 30% of lamina I neurons project to brainstem regions
involved in pain processing (Bice and Beal, 1997) and approximately 80% of lamina I
STT cells express NKi (Marshall et al., 1996), at least some projection neurons also
express calcium permeable AMPA Rs (Engelman et al., 1999). This suggests that
these receptors may play a role in the transmission and modulation of ascending
nociceptive information.
In contrast to the above, Spike et al discovered that 78% of dorsal horn
neurons with GluRl-immunoreactivity were GABA- immunoreactive, and some of
these were also glycine- immunoreactive. Almost all of the GluR2/3- immunoreactive
neurons were not GABA- or glycine- immunoreactive (Spike et al., 1998). This
finding was supported by Albuquerque et al., who found that 39% of dorsal horn
•j |
neurons expressing Ca permeable AMPA Rs were also GABA-immunopositive. In
the same paper, it was noted that the great majority of cells expressing the calcium
binding proteins calbindin and calretinin, which were potentially excitatory
interneurons, did not express Ca2+ permeable AMPA Rs (Albuquerque et al., 1999).
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It would seem that a high proportion of GABAergic cells also express GluRl
9~P • • •
subunits and Ca permeable AMPA Rs. The majority of NKi positive cells would
also appear to express calcium permeable AMPA Rs. However a significant number
of potential excitatory interneurons expressing the calcium binding proteins calbindin
and calretinin do not express Ca permeable AMPA Rs. From the above evidence,
• • • 9-P
the majority of cells expressing Ca permeable AMPA Rs would seem to play an
inhibitory role in the neural circuitry of the dorsal horn. However, a significant
minority of neurons expressing this receptor subtype may have a modulatory or
excitatory role in nociceptive transmission.
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Figure 1.1 a) Alternative splicing and editing of AMPA R subunits. The flip/flop and C-terminal
splice variants are depicted schematically. The transmembrane regions are shown as boxes
M1 to M4. The Q/R and R/G editing sites are also shown. Adapted from (Dingledine et al.,
1999). b) Diagrammatic representation of the molecular structure of an AMPA R subunit
within the cytoplasmic membrane. The extracellular N-terminal domain is denoted NTD, and
the two extracellular domains S1 and S2 are shown binding to the glutamate ligand. M1 to M4
domains are depicted as grey cylinders and an arc. Four such subunits combine to form a
functional receptor, c) Diagrammatic representation of AMPA R cycling to and from the
synaptic membrane. The cycling loop on the left represents the activity dependent insertion of
'long tailed' AMPA Rs containing the GluR1 subunit. The right hand loop represents the
constitutive cycling of 'short tailed' receptors into synapses already containing AMPA Rs.
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1.7 Neuronal plasticity in neuropathic pain
The neuronal plasticity occurring in chronic pain is the result of a process of
peripheral and central sensitisation. The potential mechanisms involved in these
processes are discussed below, with emphasis on the role of the AMPA R in
neuropathic pain.
1.8 Peripheral sensitisation
Peripheral sensitisation is characterised by changes in nociceptor function
including decreased threshold, increased response to supra-threshold stimuli and
spontaneous activity. These changes in the primary afferent neuron are triggered by
the release of inflammatory mediators at the site of injury (Dray et al., 1994).
Arachidonic acid metabolites such as prostaglandin E2 (PGE2), bradykinin and nerve
growth factor are released in inflammation and tissue injury and act on G-protein
coupled receptors or tyrosine kinase receptors on nociceptor terminals. Second
messenger systems may result in the phosphorylation of receptors on the nociceptor
terminal altering their kinetics or increasing their sensitivity to ligand binding (Julius
and Basbaum, 2001). This aspect of neuronal plasticity will not be considered further
in this study.
1.9 Central sensitisation and the AMPA receptor
Central sensitisation has been defined as an immediate-onset activity-
dependent increase in the excitability of nociceptive neurons in the dorsal horn as a
result of and outlasting an intense peripheral noxious stimulus, tissue injury or nerve
damage (Woolf, 1996), (Baranauskas and Nistri, 1998), (Ji et al., 2003). Changes
occurring in spinal dorsal horn neurons include increased excitability, hyper
responsiveness to afferent input and increased after discharges (Palecek et al., 1992),
(Laird and Bennett, 1993), (Sotgiu et al., 1995).
AMPA ionotropic glutamate receptors have long been known to be involved in
the transmission of acute nociceptive and innocuous signals (King and Lopez-Garcia,
1993). Iontophoretic treatment with AMPA results in depolarisation of dorsal horn
wide dynamic range neurons in rats. These electrophysiological responses may be
antagonised by systemically administered competitive and non-competitive AMPA
antagonists (the quinoxalinedione NBQX and the 2,3-benzodiazepine GYKI 53655).
Both NBQX and GYKI 53655 dose- dependently reduced responses to peripheral
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innocuous touch and noxious heat stimuli and to AMPA (Budai and Larson, 1994),
(Cumberbatch et al., 1994). Similar findings were also revealed in a study of STT cell
responses in a primate model. Blockade of non-NMDA receptors resulted in a marked
decrease in the responses of STT neurons to all stimuli (Dougherty et ah, 1992).
There is also evidence for the involvement of AMPA Rs in mediating acute
thermal pain. Intrathecal AMPA antagonist treatment resulted in an antinociceptive
effect in a rat hot plate model of acute noxious thermal stimulation, which proved to
be strongly synergistic with the antinociceptive effect of opioids (Nishiyama et ah,
1998). There is evidence, therefore from several species and using
electrophysiological and behavioural techniques to suggest that the AMPA R plays a
role in acute nociceptive and non-nociceptive sensory transmission. The function of
this receptor in mediating chronic pain and central sensitisation in the spinal cord is
not as clear, however.
The wide range of functional and structural changes occurring in neurons and
synapses in central sensitisation result from multiple intracellular signalling
mechanisms activated by the neurotransmitter glutamate, and neuromodulators such
as SP, brain-derived neurotrophic factor (BDNF) and other peptides. Once
sensitisation has been established, even low levels of ongoing stimulation will allow it
to persist (Gracely et ah, 1992), (Liu et ah, 2000).
Central sensitisation may occur immediately, as in electrophysiological
stimulation studies (Cook et ah, 1987). This form of sensitisation does not require
protein synthesis and is therefore termed transcription-independent or classical
activity-dependent central sensitisation. Other forms of immediate-onset,
transcription-independent plasticity may occur in the spinal cord under certain
conditions and these are termed wind-up and LTP. These processes are considered
only briefly. Later stages of central sensitisation involving protein synthesis are
termed transcription-dependent and may be further divided into activity-dependent
and activity-independent (driven by inflammation, for example) (Ji et ah, 2003).
There is strong evidence that a combination of loss of function of inhibitory
mechanisms such as local GABAergic interneurons (Moore et ah, 2002) and an
increase in excitatory mechanisms, such as mGluR mediated activation of the NMDA
R (Ji et ah, 2003), occurs in central sensitisation. The AMPA R may play a role in
both aspects of central sensitisation and is the focus of this study, particularly with
reference to potential mechanisms of neuropathic pain.
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It is known that NMDA antagonists reduce spontaneous pain and thermal
hyperalgesia in a CCI model of peripheral neuropathy in the rat (Mao et ah, 1992b).
However, it was also found that intrathecal treatment with the non-NMDA R
antagonists HA966 or CNQX beginning prior to nerve ligation (pre-injury treatment)
reduced thermal hyperalgesia in CCI rats after nerve ligation. However, this treatment
was ineffective once hyperalgesia was established. In contrast, a single treatment with
the NMDA antagonist MK 801 was effective even when hyperalgesia had developed.
These findings suggest that non-NMDA R may initiate thermal hyperalgesia
following nerve injury, which is then maintained by NMDA R activation (Mao et al.,
1992a). In addition to its role in neuropathic thermal hyperalgesia, co-activation of
non-NMDA iGlu receptors and mGlu receptors has been shown to produce
mechanical hyperalgesia in a study based on a behavioural paradigm (Meller et al.,
1993).
In contrast to the NMDA receptor, the AMPA R has not been considered as a
likely therapeutic target in the management of chronic pain, as non-specific AMPA R
blockade results in loss of non-noxious somatosensory transmission as well as
nociception. However, recent studies targeting two very different aspects of AMPA R
pharmacology have revealed the potential of highly specific agents in alleviating
hyperalgesia in models of neuropathic and inflammatory pain. The role of
intracellular adapter proteins and calcium permeable subtypes of the AMPA R has
been highlighted by these findings. Using a rat model of neuropathic pain (CCI,
(Bennett and Xie, 1988)), thermal hyperalgesia was alleviated by blocking the
interaction between the GluR2 receptor and the intracellular adapter proteins GRIP
(glutamate receptor interacting protein) and PICK1 (protein interacting with C kinase
1) (Garry et al., 2003b). In addition, intrathecal administration of Joro spider toxin
(JsTx), a calcium permeable AMPA R antagonist, blocked thermal injury-induced
mechanical allodynia in a rat behavioural paradigm (Sorkin et al., 1999). This
antagonist also prevented the induction of thermal hyperalgesia and mechanical
allodynia given one hour after carrageenan injection into the rat hindpaw, providing
evidence for the role of calcium permeable AMPA Rs in acute and chronic
inflammatory pain. However, JsTx had no effect on spontaneous pain behaviour after
subcutaneous formalin injection, on allodynia after spinal nerve ligation, or when
given three hours after carrageenan (Sorkin et al., 2001).
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It is clear, therefore, that AMPA Rs play a role in the central sensitisation
underlying both inflammatory and neuropathic chronic pain. Receptors containing the
GluRl or GluR2 subunit are expressed at high levels in the superficial dorsal hom and
would seem to be particularly important in these processes.
1.9.1 Activity dependent central sensitisation
In the initial stages of immediate onset central sensitisation, two processes are
important: alteration in ion channel / receptor activity due to post-translational
receptor modification and trafficking of receptors to the synaptic membrane (Woolf
and Salter, 2000). These mechanisms are discussed below with reference to the
AMPA R.
1.9.2 AMPA receptor phosphorylation
Evidence suggests that the post-translational processing of receptors, such as
phosphorylation of key amino acids, is an important step in the development of
central sensitisation (Woolf and Salter, 2000). The release of neurotransmitters and
neuromodulators from the presynaptic cell results in the activation of ligand-gated ion
channels (NMDA, AMPA and kainate), G-protein coupled mGluRs, the SP receptor
NKi and tyrosine kinase receptors trkB and Eph. Activation of kinases leads to
phosphorylation of various receptor proteins altering their structure and function. In
addition, trafficking of AMPA Rs to and from the cell membrane has been shown to
play an important role in LTP and potentially in central sensitisation in the spinal
cord, but as yet there is no direct evidence to support this possibility.
Several protein kinases are involved in the development of central
sensitisation, including protein kinases A, C, and G (PKA, PKC and PKG) and
calcium / calmodulin-dependent protein kinase II (CaMK II). Blockade of PKC
activity has been shown to inhibit the generation of a sensitised state after intradermal
capsaicin injection, in primate STT cells (Lin et al., 1996). PKC may be activated by
ligand binding to G-protein linked membrane receptors such as the mGluRs (Schoepp
and Conn, 1993), (Schoepp et al., 1999). PKC may then act to increase NMDA
channel opening and reduce the voltage dependant Mg2+ block of this receptor (Chen
and Huang, 1992).
The central processes occurring in inflammation and neuropathic pain share
some similarities, however significant differences exist. There is evidence to suggest a
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differential role for protein kinase A (PKA) and protein kinase C (PKC) in
inflammatory and neuropathic pain. Mutant mice lacking the RI|3 subunit of PKA
express normal behavioural responses to acutely noxious stimuli. However, pain
behaviour in response to inflammation is markedly reduced in these animals. The
PKCy isoform of PKC is a calcium dependant kinase, found in the CNS. Mice lacking
this kinase also demonstrate normal responses to acutely noxious stimuli, but do not
develop thermal hyperalgesia or mechanical allodynia after partial sciatic nerve
section. This would suggest a specific role for PKA in the development of central
sensitisation in response to prolonged inflammatory stimulation, and for PKCy in the
development of neuropathic pain (references in (Petersen-Zeitz and Basbaum, 1999)).
CaMK II is found throughout the central nervous system. It regulates calcium
signalling in synaptic transmission by phosphorylating various proteins, including
neuronal membrane receptors and intracellular transcription factors. There is an
increased expression and phosphorylation of CaMK II in rat spinal dorsal horn
neurons after noxious stimulation by intradermal injection of capsaicin (Fang et al.,
2002). Inhibition of this kinase by intrathecal administration of a specific blocker has
been shown to prevent the enhanced electrophysiological responses of spinal
nociceptive neurons and the typical changes in exploratory behaviour to capsaicin
treatment (references in: (Ji et al., 2003)). Retrograde labelling techniques
demonstrated that CaMK II is expressed in STT neurons, and was therefore likely to
be involved in the transmission of nociceptive information (Fang et al., 2002).
There is evidence to suggest that CaMK II exerts its effects on the nociceptive
pathway via the phosphorylation of the GluRl subunit of the AMPA R. It has been
demonstrated that CaMK II phosphorylation of GluRl enhances AMPA-mediated
synaptic transmission by increasing the single channel conductance of existing AMPA
Rs and attracting new AMPA Rs to the synapse (Soderling and Derkach, 2000). Two
phosphorylation sites have been discovered at the C-terminus of the GluRl subunit.
8T1 • ...
CaMK II phosphorylates GluRl at Ser resulting in a 40% potentiation in the peak
current through GluRl homomeric channels, and PKA at Ser which accompanies
the surface insertion of GluRl (Roche et al., 1996), (Ehlers, 2000). However,
insertion of GluRl receptors at synapses has not yet been shown to contribute to
central sensitisation in the spinal cord (Ji et al., 2003).
Rapid, early phosphorylation of GluRl has been demonstrated after
intradermal capsaicin treatment. Levels of phospho-GluRl (at Ser845 and Ser831 sites)
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in the spinal cord, as determined by Western Blot and immunohistochemical analysis,
increased significantly from 5 minutes to at least 60 minutes post capsaicin treatment.
The level of GluRl protein itself did not alter after treatment (Fang et al., 2003). This
very early activation of GluRl phosphorylation in inflammation, mediated by PKA
and CaMK II, may initiate many of the changes seen in the later stages of central
sensitisation.
Recent studies have provided evidence to suggest that CaMK II may also play
a role in neuropathic pain. Blockade of CaMK II activity in wild type mice prevented
the development of behavioural reflex sensitisation following CCI injury (Garry et al.,
2003a).
1.9.3 AMPA receptor trafficking
AMPA Rs mediate fast excitatory neurotransmission and it is clear that AMPA
R concentration at the post-synaptic density (PSD) must be closely regulated, as the
number of these iGluRs expressed at this site is a major determinant of postsynaptic
excitability. Silent synapses in the dorsal horn do not transmit fast post-synaptic
responses and may be activated by the recruitment of AMPA Rs (Wall, 1977), (Li and
Zhuo, 1998). Activation of such synapses by AMPA R recruitment may play an
important part in the generation of sensitisation in the spinal cord. After induction of
LTP, it was noted that AMPA R-mediated EPSPs increased but NMDA R-mediated
events did not, suggesting that the changes in neuronal excitability seen in this
paradigm may to be due to the inclusion of increased functional AMPA Rs at the
synapse (Muller et al., 1988).
AMPA Rs have been shown to be inserted and removed from the cell
membrane by mechanisms common to many receptors, proteins and neurotransmitters
(Man et al., 2000). There is currently little direct evidence to suggest that AMPA R
trafficking occurs in central sensitisation in neuropathic pain, however it is likely that
a similar process may take place in dorsal horn neurons.
Electrophysiological studies utilizing hippocampal CA1 pyramidal cell
cultures have demonstrated that blocking membrane insertion of vesicles decreases
AMPA R EPSPs, suggesting that active AMPA Rs were being removed from the
synapse, but the insertion of new receptors had been blocked. Conversely, when
endocytosis was prevented using GDPpS to block the GTPase activity of dynamin,
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AMPA mediated EPSPs increased in amplitude by 100% over time. This suggests that
functional AMPA Rs were being delivered to the synapse, but their removal by a
process requiring endocytosis had been blocked. In both studies, NMDA currents
were unaffected (Luscher et al., 1999).
Once delivered to the membrane, AMPA Rs would appear to move freely until
they reach synaptic areas where they become tethered. In order to maintain a stable
receptor population at the synapse, clathrin-dependant internalisation also occurs to
balance the process of adding new receptors to the membrane. The free moving pool
of receptors may act as a further reservoir for inclusion into synapses. Several proteins
are involved in the processes of endocytosis, which may internalise AMPA Rs. These
have been reviewed by Jarousse and Kelly and will not be considered in detail here
(Jarousse and Kelly, 2001). The possible mechanisms of AMPA R trafficking are
outlined in Figure 1.1c.
There is evidence to suggest that AMPA Rs are continuously cycled to and
from the membrane without stimulation, some 7% of surface GluRl were
constitutively internalised within ten minutes. Binding of ligands to AMPA Rs causes
a more rapid redistribution, with 46% of GluRl subunits being internalised within 10
minutes of AMPA stimulation (Carroll et al., 1999), (Luscher and Frerking, 2001).
Activation of the NMDA R has also been shown to trigger AMPA R internalisation in
cultured kidney cells, via activation of calcineurin and dephosphorylation of GluRl at
a PKA phosphorylation site. Thus, the phosphorylation state of GluRl at the PKA site
may determine the fate of internalised AMPA RS (Luscher and Frerking, 2001).
Calcineurin is likely to play a significant role in receptor internalisation, as it is known
to dephosphorylate a number of proteins involved in endocytosis, including the key
protein dynamin.
In addition to AMPA R internalisation by iGluR ligand binding, there is
evidence to suggest that the group I mGluR agonist DHPG may trigger GluRl and
GluR2 subunit internalisation in cultured hippocampal neurons (Snyder et al., 2001).
Mechanisms unrelated to glutamate receptors may also play a role in AMPA R
internalisation. It has been demonstrated that AMPA Rs also undergo internalisation
by a GluR2-dependant mechanism in response to insulin, suggesting that there may be
more than one mechanism for receptor internalisation (Man et al., 2000). Finally,
calcium entry into the cell is required for at least some forms of AMPA R
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internalisation, as this process is markedly inhibited by the L-type calcium channel
blocker nimodipine (Lin et al., 2000).
Study of the insertion of AMPA Rs into the post-synaptic membrane has
proved to be difficult, as most stimulation protocols applied to cultured cells lead to
receptor internalisation. In the resting state in cultured CA1 hippocampal neurons, the
majority of GluRl are not associated with synaptic sites. Shi et al demonstrated that
tetanic stimulation of these cells leads to delivery of receptors to the spines and
clustering of receptors within dendrites (Shi et al., 1999). Time-lapse two-photon laser
scanning microscopy revealed that tetanic stimulation of cultured neurons caused
delivery of fluorescent-tagged GluRl subunits to the spines and clustering of
receptors within the dendritic shaft. These events were prevented by NMDA R
antagonism. This suggests a mechanism for delivery of GluRl-containing AMPA Rs
to dendritic spines involving increased synaptic activity and activation of NMDA Rs.
From the above summary, it can be seen that AMPA Rs may control the
effectiveness of synaptic transmission by trafficking into and out of the synapse. This
may be of great relevance to the induction of sensitised states in the hippocampus and
spinal cord. It is also clear that AMPA R trafficking involves interaction with a
number of other key receptors and proteins, some of which are considered below.
1.9.4 Protein-protein interactions of the AMPA receptor
There is increasing evidence to suggest that numerous proteins interacting
with AMPA R subunits play an important role in the generation of sensitised states
such as neuropathic pain (Garry and Fleetwood-Walker, 2004). The most significant
protein interaction module that can associate with the AMPA R is known as the PDZ
(PSD-95, Discs-large, ZO-1) domain (see Figure 1.1a, b). The PDZ domain is a 90
amino-acid structure, which often binds to the extreme C-terminal end of proteins.
Thus far, over 100 proteins within the human genome have been found to contain
PDZ domains. The first to be discovered was postsynaptic density protein-95 (PSD-
95), which associates with the extreme C-terminal end of the NR2 subunit of the
NMDA R.
In the hippocampus, the majority of AMPA Rs contain either GluRl / GluR2
subunits, or GluR2 / GluR3 subunits in combination. The subunits exist in two forms
with long and short cytoplasmic C terminal tails, the former have a PDZ motif and the
latter do not. GluRl always has a long tail and GluR3 a short one. The tails of GluR2
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and 4 may be either long or short, depending on alternative splicing. The length of the
tail, and therefore the presence of a PDZ motif would seem to be important in
determining the delivery of these receptors to synapses. Long-tail receptors
(incorporating GluRl subunits with a PDZ motif) require synaptic activity for
delivery to spines, whereas short tailed AMPA Rs (consisting of the short form of
GluR2) are continuously cycled to and from synapses (Shi et ah, 2001), (references in
(Bredt and Nicoll, 2003)).
The AMPA R subunits GluRl and GluR2 interact with different protein
groups, which may shed light on their specific roles in receptor trafficking. AMPA Rs
containing the GluRl subunit and lacking GluR2 may have a high degree of calcium
permeability and their inclusion in active synapses may be important in synaptic
strengthening and neuropathic sensitisation in the dorsal horn (Gu et al., 1996), (see
section 1.6.4).
AMPA Rs containing GluRl subunits are added to synapses during neuronal
plasticity; requiring an interaction between GluRl and PDZ domain proteins in a
CaMK II-dependant mechanism (Hayashi et al., 2000). The GluRl subunit binds via
its C-terminal tail to the postsynaptic density protein SAP-97, and interacts with actin-
associated protein 4.IN, which has been shown to increase AMPA R density at
postsynaptic sites in cell cultures (Shen et al., 2000), (Rumbaugh et al., 2003). It has
become apparent that trafficking of GluRl subunits is highly regulated with distinct
stages of exocytosis and synaptic insertion (Luscher and Frerking, 2001), (Passafaro
et al., 2001), (Shi et al., 2001).
The GluR2 subunit is expressed at high levels in the superficial dorsal horn
and interacts with a number of key proteins (Jakowec et al., 1995). Several of the
proteins interacting with GluR2/3 have been the subjects of recent study, including:
GRIP; PICK1; ABP (AMPA R binding protein) (Srivastava et al., 1998) and NSF (N-
ethylmaleimide-sensitive fusion protein).
PICK1, originally identified as a protein kinase Ca binding protein, may serve
to bring this kinase close to the AMPA R in the plasma membrane resulting in the
removal of the GluR2 subunit from the synapse (Xia et al., 1999), (Perez et al., 2001).
Mutation of the GluR2 subunit at a single amino acid site (S880A) interferes
with GRIP / ABP binding and results in decreased AMPA clustering at the membrane,
suggesting that ABP and / or GRIP are required to stabilise the receptor at the PSD
(Osten et al., 2000). This study supports the theory that phosphorylation of GluR2 at
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the Ser 880 site by PKC results in a form of subunit that does not bind GRIP and is
released from the membrane.
Recently, it has been demonstrated that blockade of the interaction between
GRIP / PICK1 and GluR2 results in a marked attenuation of the thermal hyperalgesia
seen after induction of reflex sensitisation by CCI. Specific blockade of PICK1
interactions had a similar effect. Both interventions had limited effect on mechanical
allodynia, however. This study demonstrates the importance of GluR2 / PICK1
interaction in the maintenance of thermal hyperalgesia in neuropathic pain (Garry et
al„ 2003b).
Ligand binding to the AMPA R is known to cause receptor intemalisation.
Previously, GRIP has been demonstrated at the PSD and in the cytosol (Wyszynski et
al., 1998), (Dong et al., 1999). Topical application of AMPA to the spinal cord caused
GRIP and PICK1 to leave the membrane fraction and enter the cytosol. This was
prevented by blockade of clathrin-mediated endocytosis, suggesting that GRIP,
PICK1 and GluR2 are internalised in response to AMPA stimulation (Garry et al.,
2003b).
The GluR2 and GluR4 subunits also bind NSF, an ATPase involved in
membrane fusion, which may mediate trafficking or membrane fusion of vesicles
containing GluR2. Binding to NSF stabilizes the AMPA R subunit at the membrane
(Nishimune et al., 1998), (Osten et al., 1998). Blockade of the interaction between
NSF and GluR2 resulted in a marked attenuation of the thermal hyperalgesia seen
after CCI-induced reflex sensitisation (Garry et al., 2003b).
It has also been demonstrated that blockade of GluR2 / NSF interaction
resulted in a decrease in AMPA R EPSCs. Ligand-induced intemalisation of AMPA
Rs was also increased by N-ethylmaleimide blockade of the NSF-GluR2 interaction
(Luscher et al., 1999). This study suggests that AMPA Rs constantly cycle to and
from the membrane. Interruption of either the endocytosis or insertion of vesicles
appears to alter the number of functional AMPA Rs at the cell surface and hence the
currents transmitted by AMPA R stimulation.
1.9.5 Additional AMPA R-interacting proteins
Some synaptic proteins interact with AMPA Rs irrespective of their subtype
composition. In addition to the PDZ binding domains, AMPA Rs contain other
binding sites, such as the N-terminal domain (NTD), which binds proteins such as the
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extracellular neuronal activity-regulated pentraxin (Narp) (O'Brien et al., 1999).
Binding of GluRl, 2 or 3 subunits to Narp has been shown to increase clustering and
surface expression of AMPA Rs at excitatory synapses (O'Brien et al., 2002). The
NTD may have other, as yet undiscovered functions, as over expression of this region
of GluR2 subunits induces the formation of dendritic spines in cultured hippocampal
cells (Passafaro et al., 2003).
Another synaptic protein known as stargazin, a member of a family of similar
transmembrane AMPA R regulatory proteins (TARPs) interacts with GluRl, 2 and 4
(Tomita et al., 2003). This protein, first discovered in the ataxic mutant stargazer
mouse binds via its C-terminal tail to PSD-95 in addition to AMPA Rs.
PSD-95 seems vital in determining the number of AMPA Rs at synaptic sites,
whereas stargazin seems to determine their position relative to the cell surface. At
least 50% of AMPA Rs containing the GluR2 subunit would appear to be localised
beneath the cell membrane in hippocampal neurons, many within vesicles measuring
50-300nm containing GRIP and PICK1 (Lee et al., 2001). This pool of receptors can
be recruited to the surface by over-expression of stargazin (Chen et al., 2000). Over
expression of PSD-95 results in increased expression of AMPA Rs at the cell surface
and increased AMPA transmission (El Hussein et al., 2000).
Recent evidence suggests that PSD-95 may have a specific role in the
establishment and maintenance of sensitisation in neuropathic pain. Mutant mice
expressing an abnormal variant of the multivalent adaptor protein PSD-95 in the
dorsal horn of the spinal cord failed to develop the NMDA receptor-dependent
hyperalgesia and allodynia seen in the CCI model of neuropathic pain. In contrast to
this finding, normal inflammatory nociceptive behaviour was noted following the
injection of formalin. In wild type mice, CaMK II associates with NMDA Rs in the
generation of central sensitisation via a PSD-95 protein link. It would seem that
disruption of CaMK II docking to the NMDA receptor may be important in the lack of
neuropathic behavioural reflex sensitisation in PSD-95 mutant mice (Garry et al.,
2003a).
1.10 AMPA RECEPTOR INVOLVEMENT IN OTHER FORMS OF ACTIVITY-DEPENDENT
CENTRAL SENSITISATION: WIND-UP AND LONG TERM POTENTIATION
Glutamate receptors play a key role in the generation of wind-up. The
ionotropic glutamate receptors have been extensively studied, particularly the NMDA
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R. Treatment with NMDA R antagonists has been shown to attenuate wind-up (Woolf
and Thompson, 1991), (King and Lopez-Garcia, 1993).
It has been suggested that co-activation of mGluRs and iGluRs may be
required for wind-up. In vivo studies have demonstrated that induction of wind-up is
enhanced by application of ACPD an mGluR group I agonist. In addition, electrically
evoked wind-up was reduced by application of an mGluR group I antagonist. It was
suggested that the mGluR acts to facilitate the response of iGluR to stimuli, as there
was also an increase in the neuronal response to iGluR agonists (Budai and Larson,
1998). There are clearly some similarities between wind-up and central sensitisation
in the spinal cord, but the two processes are distinct (Meller et al., 1993).
LTP refers to activity dependant changes in the efficacy of synaptic
9+
communication. Increases in postsynaptic [Ca ]j are sufficient to generate LTP. For
the majority of glutamatergic synapses this can be achieved by calcium influx through
9"F
NMDA Rs, but voltage-gated Ca channels, calcium-permeable AMPA Rs or
calcium release from intracellular stores (via activation of mGluRs) may all play a
role (references in (Sandkuhler, 2000)). Enhanced excitatory transmission during LTP
reflects greater responsiveness of post synaptic AMPA Rs caused by increased
sensitivity of each receptor and / or insertion of more AMPA Rs into the postsynaptic
membrane (Malenka and Nicoll, 1999). After induction of LTP, AMPA R
responsiveness increases over about 30 minutes in the CA1 region of the
hippocampus (Soderling and Derkach, 2000). It appears likely that this increase in the
AMPA R response to glutamate is due partly to phosphorylation of GluRl (Derkach
et al., 1999).
It can be seen that LTP requires post-translational modification of AMPA Rs
and an increase in AMPA R delivery to the synapse, very much like central
sensitisation. Indeed, an LTP-like process has been demonstrated in the spinal cord.
Following a brief period of very rapid C fibre stimulation (100Hz), the AMPA R
mediated responses of a subgroup of lamina I neurons expressing the NKj R increased
for tens of minutes. However, as the frequency of stimulation required to cause these
changes is outside the physiological range, its functional significance is unclear (Ji et
al., 2003), (Yang et al., 2004a).
It is important to appreciate the differences between LTP and central
sensitisation when developing practical therapies to treat chronic pain. Treatments
which are effective in blocking both LTP and central sensitisation, such as the NMDA
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antagonist ketamine, tend to have unacceptable neuropsychiatric side effects (Hocking
and Cousins, 2003). Ideally, central sensitisation in the spinal cord could be
prevented, but memory formation left intact.
1.11 Transcription dependent central sensitisation
In parallel with neuronal plasticity occurring via synaptic receptor recruitment
and post-translational modification, long lasting changes in neuronal excitability
occur which involve the activation of transcription factors via complex signal-
transduction pathways, altering gene expression and protein synthesis in the DRG and
DH (Hokfelt et al., 1994), (Ji and Woolf, 2001).
The dramatic effects of nerve damage on gene expression have been recently
demonstrated using a cDNA microarray. Changes in levels of 14 channels, 25
receptors and 42 signal-transduction related molecules occurred in rat dorsal spinal
cord 14 days after peripheral axotomy. These regulated genes include calcium and
sodium channel subunits, AMPA R GluR3 and 4 subunits (however GluRl and 2
were not tested), GABAa receptor subunits, nicotinic acetylcholine receptors, PKCa,
|3 and 8 isozymes, JNK1-3, ERK2-3, and p38 MAPK protein kinases (Yang et ah,
2004b). Studies based on human DRG specimens following brachial plexus avulsion
injury have revealed equally complex changes in gene expression. The expression of
91 genes were altered following injury, some of which are known to be involved in
neurotransmission, trophism, cytokine functions, signal transduction, myelination,
transcription regulation, and apoptosis (Rabert et ah, 2004).
Peripheral nerve injury results in injury signals mediated by kinases, such as
extracellular signal-regulated kinases (ERKs) and PKG, which regulate gene
transcription (Sung and Ambron, 2004). Key among such transcription-regulating
messengers are the mitogen-activated protein (MAP) kinase family of serine /
threonine kinases (Widmann et ah, 1999). The family has multiple members, 3 of
which are considered here: the ERKs, c-Jun N-terminal kinase (JNK) and p38 MAPK.
The role of ERKs in a number of processes involving neuronal plasticity has
been clearly demonstrated. Activation of these kinases is dependant upon NMDA R
• • 9_i_ . . # .
activation and Ca influx in neurons and is required for LTP (Bading and Greenberg,
1991), (Rosen et ah, 1994), (Impey et ah, 1999). ERK activation by phosphorylation
also occurs following central sensitisation by capsaicin and noxious thermal and
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mechanical stimuli (Ji and Woolf, 2001). Some of these changes occur within 30-
60mins and are therefore probably transcription independent.
In addition, some activated ERK translocates to the nucleus and
phosphorylates key transcription factors such as the cAMP-response-element-binding
protein (CREB) (Impey et al., 1998), (Widmann et al., 1999). This transcription factor
has been implicated in the regulation of several genes involved in long-term neuronal
plasticity (Bonni et al., 1995), (Impey et al., 1996). Other transcription factors such as
c-Fos, c-Jun, Elk-1 may collaborate with CREB to regulate pain related gene
transcription (Ji and Woolf, 2001).
JNK is also activated following peripheral axotomy in DRG. The delay in
activation was dependant upon the distance of injury from DRG suggesting a
retrogradely transported signal molecule was involved (Kenney and Kocsis, 1998). In
addition, p38 MAPK is activated by peripheral inflammation and nerve injury in
spinal microglia and has been shown to mediate NGF-induced CREB activation (Xing
et al., 1998), (Kim et al., 2002). Several genes coding for proteins important in pain
processing, such as TNF-a and IL-lp, are positively regulated by this kinase
(Widmann et al., 1999).
As is clear from the above studies, transcription dependant central sensitisation
represents a complex and expanding field of research, which will not be considered
further here.
1.11.1 Neurotrophic factors and neuropathic pain
Neurotrophins constitute a family of molecules including nerve growth factor
(NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and
neurotrophin-4/5 (NT-4/5) (Thoenen, 1991). Neurotrophins signal by binding to low
and high affinity receptors. The p75 receptor binds all three neurotrophins, with low
affinity, whereas the trkA (NGF), trkB (BDNF and NT4/5) and trkC (NT-3) tyrosine
kinase receptors show high affinity and selective interactions with particular ligands
(references in (Mendell et al., 2001)).
In a spinal nerve ligation model of neuropathic pain, intrathecal treatment with
anti-BDNF antibody attenuated thermal hyperalgesia for 2 to 4 hours, and local
application of anti-NGF antibody to the L4 spinal nerve beside the L5 spinal nerve-
ligation site prevented the development of thermal hyperalgesia for 6 days following
ligation. This study demonstrates the importance of both BDNF and NGF in the
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development of thermal hyperalgesia after spinal nerve ligation (Fukuoka et al.,
2001). NGF is thought to be critical for gene activation in the DRG, it induces an
increased expression of SP, CGRP and BDNF (Lindsay and Harmar, 1989), (Michael
et al., 1997). It has also been suggested that up regulation of BDNF expression in
undamaged neurons following CCI may play an important role in the development of
neuropathic pain (Obata et al., 2003).
1.11.2 The interaction between injured and non-injured axons in neuropathic
pain
Central sensitisation may be described as a state of abnormal central
processing maintained by continuing peripheral input (Gracely et al., 1992). It has
been demonstrated that ectopic action potentials occur in damaged nerves which may
contribute to central sensitisation (Sotgiu et al., 1994), (Liu et al., 2000). In addition to
these abnormal stimuli, the importance of sensory input through undamaged axons
and nerves has become apparent.
Using a spinal nerve ligation model of peripheral neuropathy, it has been
found that noxious and innocuous sensory input from undamaged nerves is important
in determining the severity of mechanical hyperalgesia resulting from the injury. In
addition to tight ligation of the left L5 and L6 spinal nerves, the intact L4 spinal nerve
was manipulated either by gentle repeated stretching of the L4 spinal nerve
immediately after L5 and L6 SNL or by intermittent mechanical stimulation to the
ipsilateral paw during the first week after SNL. It was found that both mild immediate
stretch of L4 spinal nerve and application of mechanical stimuli to the ipsilateral paw
significantly increased the development of mechanical allodynia after SNL. It may be
that L4 stretch resulted in trauma to the nerve causing further ectopic discharges, but
it is clear that moderate stimulation to skin served by undamaged adjacent nerve roots
augmented the development of a sensitised state. Both these stimuli are mediated in
part via AMPA Rs (Lee et al., 2003).
In the na'ive animal, sciatic dorsal horn WDR neurons (L5/6) do not respond to
stimulation of the saphenous nerve (L2). However, 4 to 14 days after sciatic CCI, 90%
of sciatic (L5/6) neurons responded to saphenous (L2) stimulation ipsilateral to the
injury. There was no L5/6 response to saphenous stimulation contralateral to injury
(Sotgiu and Biella, 1995). This interesting finding suggests that input from adjacent
undamaged spinal segments may impinge upon damaged neurons after nerve injury.
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These abnormal inputs play a role in central sensitisation as stimulation of
saphenous (L2) fibres increased the electrophysiological responses of sciatic neurons
following sciatic CCI. Strengthening of such 'improper' neuronal connections is
likely to be due to AMPA R recruitment and AMPA R activation by non-noxious and
noxious stimuli. Abnormal sensory input from adjacent segments appears to be
important in the development of electrophysiological changes typical of thermal
hyperalgesia, as sectioning of the saphenous nerve prevented these changes (Sotgiu
and Biella, 1997).
Interactions may also occur between damaged and undamaged axons within a
single nerve. The type of sensory changes found after CCI would also seem to be
dependent upon the proportion of damaged and undamaged neurons. Utilising
activating transcription factor 3 (ATF3) expression as a marker of neuronal injury in
DRG cells, Obata et al demonstrated that at least 12.5% of DRG neurons must be
damaged for the development of thermal hyperalgesia. Mechanical hyperalgesia
occurred only when 12.5%-25% of DRG neurons demonstrated damage. This equates
to approximately 30-40% of sciatic axons undergoing axotomy. Interestingly, the
same study revealed that the neurotrophic factor BDNF was upregulated in
undamaged small and medium diameter neurons ipsilateral to injury whereas ATF3-
IR was increase in large diameter cells. It had been suggested that small diameter
DRG neurons mediate thermal hyperalgesia and large diameter mechanical allodynia
(Ossipov et al., 2000), (Obata et al., 2003). These diverse lines of evidence all suggest
that afferent input and neurochemical release from undamaged nerve fibres is
important in the development of neuropathic pain after nerve injury.
In addition to interactions between adjacent nerve roots and within individual
nerves, the activity of pairs of nociceptive and wide dynamic range neurons in the
superficial (I-IIo) and deep (V) laminae of the dorsal horn, in response to supra-
threshold electrical stimuli, was shown to be linked using cross-correlation
techniques. Activity in one neuron was predictably linked to activity in the other
(Biella et al., 1997). After CCI, there was no correlation between the
electrophysiological activity of the pairs of cells, suggesting that the functional
connections between superficial dorsal horn nociceptive neurons and deep dorsal horn
WDR neurons are either inactive or rearranged in the nerve-injured rats. This change
may underlie a reduced degree of functional coherence in the modulation of
nociceptive spinal inputs in chronic pain.
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1.11.3 Anatomical changes in neuropathic pain
In addition to the complex changes in neurotransmitter and receptor levels in
neuropathic pain (Hokfelt et al., 1994), it had been suggested that significant
anatomical changes also occur in the dorsal horn. In the resting state, the central
arborisations of large myelinated Ap cutaneous afferent fibres extend as far dorsally
as the ventral part of lamina II in rat spinal cord. Woolf et al reported that six to
twelve weeks after sciatic nerve axotomy approximately 30% of studied Ap afferents
sprouted into lamina I and the dorsal part of lamina II (Woolf et al., 1992). It would
seem reasonable to assume that the sprouting of AP fibres, which normally transmit
innocuous stimuli, into regions of the dorsal horn involved in nociceptive
transmission would result in these innocuous stimuli being interpreted as painful,
resulting in allodynia.
These findings are currently in doubt, however, as the evidence for sprouting
was based on the use of cholera toxin B subunit (CTb) as a selective tracer for A
fibres. The selectivity of this tracer has recently been disproved, and C fibres have
also been shown to transport CTb after axotomy (Shehab et al., 2003). The original
study has recently been repeated using intra-axonal Neurobiotin as a label for sciatic
Ap fibres in intact and axotomised nerves. No fibres were found to extend further
dorsally than the ventral part of lamina II in either experimental group (Hughes et al.,
2003).
Despite this lack of firm evidence for sprouting of Ap fibres, it would seem
that these neurons do undergo functional changes after sciatic nerve transection. It has
been demonstrated in a cord slice preparation that large myelinated Ap fibres establish
functional synaptic contact with interneurons and transmit innocuous information to
the substantia gelatinosa following sciatic nerve section. This represents a marked
functional alteration in spinal cord circuitry and may account in part for the sensory
abnormalities occurring in neuropathic pain (Okamoto et al., 2001). It would seem
that new and inappropriate synaptic connections might be made between Ap fibres
and neurons in the superficial dorsal horn in neuropathic pain even if extensive fibre
sprouting does not occur.
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1.11.4 Neuronal disinhibition and central sensitisation
Inhibitory mechanisms are active in nociception, both locally within the dorsal
horn and from descending pathways (Sotgiu, 1993), (see section 1.3.7). It has been
suggested that loss of this inhibitory input onto excitatory neurons may play a role in
central sensitisation. It is interesting to note that the majority of dorsal horn neurons
expressing the GluRl subunit co-express GABA and some may play an inhibitory
role (Spike et al., 1998). In addition it has been suggested that at least some inhibitory
neurons express calcium-permeable AMPA Rs (ie: lacking the GluR2 subunit)
(Albuquerque et al., 1999), (see section 1.6.4).
There is evidence to suggest that changes in the expression of AMPA R
subunits may be important in neuronal disinhibition in central sensitisation
independent of GABAergic function. This possibility has been explored in a recent
study of cultured dorsal horn neurons immunolabelled with GluRl, GluR2 and GAD
67 (glutamic acid decarboxylase, an enzyme essential for GABA synthesis). GluRl
and GAD 67 are often co-expressed within individual neurons, suggesting that GluRl
expressing cells also synthesize the inhibitory neurotransmitter GABA (Vikman et al.,
2003). Cultured cells were treated with the pro-inflammatory cytokine interferon-y
(IFN-y) for two weeks. This cytokine is known to trigger spontaneous pain when
injected intrathecally (Robertson et al., 1997). Post treatment, it was found that the
number of GluRl immunofluorescent puncta associated with dendrites was
significantly decreased, and that number of spontaneous EPSCs (excitatory
postsynaptic currents) within the cultured cells was increased. This increase in
excitation was shown to be independent of GABA function, suggesting that the down-
regulation of GluRl subunits was the cause of the disinhibition found after IFN-y.
This cytokine may also play a role in neuropathic pain, as knockout mice lacking the
gene for IFN-y did not display autotomy after sciatic nerve section (Robertson et al.,
1997).
After prolonged noxious input, it has been suggested that excessive synaptic
glutamate release may lead to the excitotoxic death of certain neurons, altering the
balance between excitatory and inhibitory processes. Such stimulation-induced cell
death may potentially contribute to the development of persistent pain. The region of
the dorsal horn affected by cell death was shown to expand from lamina III in the
naive animal, to include lamina I and II after nerve injury (Coggeshall et al., 2001).
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Indeed, there is evidence from several studies to suggest that the number of tonic
inhibitory neurons containing GABA or glycine decreased significantly on both sides
of the spinal cord after CCI. Bilateral loss of GABA-IR cells by the third day after
CCI has been demonstrated (84% reduction in proportion of cells ipsilaterally and
25% reduction contralaterally) (Ibuki et al., 1997). This reduction in GABA-IR cell
numbers was statistically significant bilaterally by week two following CCI.
Interestingly, complete recovery was seen by week 7 contralateral to injury and partial
recovery (to 45% of pre-injury levels) on the ipsilateral side. This recovery suggests
that significant cell death was unlikely to be occurring, at least contralateral to injury.
Moore et al investigated excitatory and inhibitory postsynaptic potentials in
lamina II neurons after sciatic nerve transection, sciatic nerve CCI and spared nerve
injury (SNI) (Moore et al., 2002). This study demonstrated a significant decrease in
the incidence, amplitude and duration of inhibitory postsynaptic currents following
CCI and SNI. There was no change in excitatory potentials. Evidence was provided
that the reduction in inhibition was due to a decrease in GABAa mediated currents.
There was also a small but significant decrease in the expression of the GABA-
synthesizing enzyme, GAD65 ipsilateral to CCI as measured by Western blotting by
day 6 which returned to pre-injury levels by 4 weeks. It would seem that a
subpopulation of inhibitory cells demonstrated a temporary decrease in GABA
production as a result of partial nerve injury. Very few cells appeared to have
undergone cell death ipsilateral to injury. These TUNEL-positive profiles with
pyknotic nuclei were found at day 7 post SNI (1.5 profiles per section). Many of these
were not neurons, as they did not express NeuN. However a very small number
(approximately 0.16 per slice) of NeuN and TUNEL-positive profiles were seen in
laminae I and II. The findings that GAD65 expression recovers with time and that
very few neurons demonstrated signs of cell death following CCI suggest that loss of
inhibitory neurons is not critical to the development of neuropathic pain.
Interestingly, a recent investigation of cell death following CCI has reported a
dramatic cell loss of 38±5% of all neurons in lamina II. This cell loss was found
ipsilateral to injury 3 days post CCI, and occurred bilaterally by day 7. This decrease
in cell numbers was prevented in animals treated with MPEP (mGlu5 receptor
antagonist, intra peritoneal twice daily) at day 3 post-injury, but this protective effect
was lost by day 7. This study suggests that spinal cord neuron loss may be triggered
by an apoptotic process involving glutamate mGlu5 receptors, and that these receptors
79
are involved transiently, as their blockade with MPEP was no longer cytoprotective
by day 7 post injury (de Novellis et ah, 2004). However, this study did not determine
whether the lost cells were functional neurons. Such widespread loss of cells by day 3
post CCI does not correlate well with the development of behavioural signs in this
model. Also, abnormal behaviour is only noted ipsilateral to the injury, so a major
bilateral change in cell numbers would be difficult to explain (almost 50% loss
bilaterally by day 7). Approximately 12 cells per spinal cord slice were TUNEL-
positive ipsilateral to CCI, suggesting that these cells were undergoing apoptosis. It
was not clear whether these cells were neurons. Also, the expression of several
molecules thought to be involved in apoptosis did not change following CCI in this
study, suggesting that they are not significantly involved in the process.
In contrast to the findings of these studies, work by Polgar et al has suggested
that GABAergic cells are not lost during central sensitisation caused by CCI. This
carefully conducted study revealed no decrease in the proportion of cells
demonstrating GABA- and / or glycine-immunoreactivity in laminae I, II or III of the
rat dorsal horn was found two weeks after CCI when thermal hyperalgesia was well
developed (Polgar et al., 2003). It remains possible that cell loss was occurring in the
above study, but GABA-immunopositive, glycine-immunopositive and other neurons
would have to be lost in equal proportions. Also, several studies have demonstrated
that GABA expression returns to pre-injury levels with recovery from CCI,
suggesting that loss of entire cells is unlikely (Ibuki et al., 1997).
From the studies considered above, there is no clear consensus regarding the
degree of loss of GABA expression and cell death in neuropathic pain. It would seem
that cell death is less significant than was previously thought, but more work needs to
be done to clarify the importance of this processes. However, it would seem likely
that the balance between excitatory and inhibitory inputs into the dorsal horn might be
disturbed in central sensitisation (Dickenson, 1996).
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1.12 Aims of the current study
The current study was designed to investigate the role of key receptors in the
generation and maintenance of central sensitisation underlying neuropathic pain. It is
clear that several receptor types are involved in altering the sensitivity of dorsal horn
neurons, including ionotropic and metabotropic glutamate receptors and peptidergic
receptors.
Firstly, the roles of NMDA, AMPA, mGlu group I and VPAC2 Rs were
studied. The behavioural reflex responses of naive rats to intrathecal administration of
low doses of these receptor agonists, singly or in combinations were investigated. It is
known that there are synergistic relationships between glutamate receptors in the
generation of sensitised states, but the effects of activation of combinations of
ionotropic and metabotropic glutamate receptors in addition to peptidergic receptors
have not been investigated in a behavioural paradigm in vivo (Cerne and Randic,
1992), (Jones and Headley, 1995), (Meller et al., 1996).
The sciatic chronic constriction injury (CCI) model of neuropathic pain was
adopted for the current study (Bennett and XIE, 1988). The expression of AMPA
receptor GluRl and GluR2 subunits in the superficial dorsal horn in neuropathy was
studied using confocal immunofluorescence. The effects of CCI neuropathy on the
proportion of cells expressing these AMPA R subtypes and the degree of
colocalisation of GluRl and GluR2 receptor subtypes within individual neurons was
investigated. It is known that levels of GluRl and GluR2 expression in the dorsal horn
vary in a number of pain paradigms, but the anatomical location of these changes has
not been investigated in the intact spinal cord using immunofluorescence (Harris et
al., 1996), (Grossman et al., 1999), (Helgren et al., 1999), (Garry et al., 2003b).
The relationship between the presynaptic marker protein, Bassoon and GluRl-
immunopositive cells following CCI was studied as a measure of the inclusion of
GluRl subunits into synapses in neuropathic pain. This protein has not been
previously used to assess this process in the spinal cord (Friedman et al., 2000).
The subcellular distribution of AMPA R subunits was also investigated in the
superficial dorsal horn of intact rats following CCI and in response to acute intrathecal
AMPA treatment. The effects of AMPA R antagonists and a combination of other key
receptor antagonists on the subcellular location of AMPA Rs were investigated in
animals with established neuropathy.
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The study was designed to add to understanding of the interactions between
key receptors in neuropathic pain, and to shed light on the differential role of AMPA
R subtypes in this process. It is becoming clear that AMPA Rs play an important role
in the development of abnormal pain states (Mao et al., 1992a), (Garry et al., 2003b).
This study may aid the development of novel therapies, designed to target either
specific receptor subtypes or a combination of receptors at low dose in order to




• Halothane (Zeneca Ltd., Cheshire, UK)
2.2 Sciatic nerve constriction surgery
• 4/0 chromic gut (Ethicon Ltd., Edinburgh UK)
• 5/0 Vicryl (Ethicon)
• Hibitane (Zeneca Ltd., Cheshire, UK)
• Sterile gowns, masks, drapes and gloves (Hospital Management and Supplies,
Glasgow, UK)
2.3 Intrathecal drug injections
• Syringe, 1ml (Becton Dickinson, Plymouth, UK)
• Needle 25G (Terumo, Belgium)
2.3.1 Drugs used
Vehicle
• Sterile saline 0.9% (Sigma Chemical Co, Poole, UK) used as vehicle for all
drugs other than PG 99-465, which was prepared in 0.06%
dimethylformamide in saline.
Agonists
• a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (Tocris
Cookson Inc., Bristol, UK)
• 3,5-dihydroxyphenylglycine ((±) DHPG), a metabotropic glutamate receptor
subgroup 1 and 5 agonist (mGluRl/5) (Tocris Cookson Inc.)
• N-methyl-D-aspartate (NMDA) (Sigma)
• Ro 25-1553, a VPAC2 R agonist (gift from P. Robberecht, Free University of
Brussels, Belgium).
Antagonists
• (R)-CPP (NMDA R antagonist) (Tocris Cookson Inc.)
• PG 99-465 (VPAC2 R antagonist) (gift from P. Robberecht, Free University of
Brussels, Belgium)
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• MPEP (mGluR5 antagonist) (Tocris Cookson Inc.)
• LY 376385 (mGluRl antagonist) (Tocris Cookson Inc.)
• NBQX (l,2,3,4-Tetrahydro-6-nitro-2, 3-dioxo-benzo[f]quinoxaline-7-
sulfonamide, AMPA R antagonist) (Tocris Cookson Inc.)
2.4 Behavioural reflex testing
• Thermal stimulus (Hargreaves-Plantar apparatus, Ugo Basile, Italy)
• Von Frey filaments (Stoelting Co., Wood Dale, Illinois, USA)
2.5 IMMUNOHISTOCHEMISTRY
• Agar 0.25% (Becton Dickinson)
• Di-sodium hydrogen orthophosphate dihydrate (Merck, VWR, Poole, UK)
• Fish skin gelatin (Diagnostics Scotland, Edinburgh, UK)
• Freezing microtome: Leitz Kryomat 1700 (Leitz, Germany)
• Glass slides (Merck)
• Glutaraldehyde (Sigma)
• Heparin (Sigma)
• Leica confocal microscope (Leica Microsystems Semiconductor GmbH,
Wetzlar, Germany)
• Normal goat serum (Diagnostics Scotland, Edinburgh, UK)
• Paraformaldehyde (Sigma)
• Saturated solution ofpicric acid in water (Becton Dickinson)
• Perfusion pump (Watson-Marlow Ltd., UK)
• Scalpel blades size 10 (Swann-Morton, Sheffield, UK)
• Sodium chloride (Merck)
• Sodium dihydrogen orthophosphate dihydrate (Merck)
• Sucrose (Sigma)
• To-Pro3 cyanine nucleic acid stain (Molecular Probes Europe BV, The
Netherlands)
• Triton X-100 (Sigma)
• Vecta-Shield (Vector Laboratories, Burlingame, CA)
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2.6 Stock solutions
• 0.2M Phosphate buffer (PB): Approximately 470mls 0.2M sodium dihydrogen
orthophospahte dihydrate was added to 1500mls 0.2M di-sodium hydrogen
orthophosphate dihydrate, yielding a buffer mixture of pH 7.4.
• 0.1M Phosphate buffered saline (PBS): 0.2M PB was diluted with an equal
volume of distilled water (dH20) and 9g/l sodium chloride added
• Heparinised vascular flush: 0.6mg/ml heparin (Sigma) was added to 0.9%
saline solution to give 100 iu/ml heparin.
• Fixative, 4% paraformaldehyde in 0.1M PB with 12.5% picric acid and 0.1%
gluteraldehyde: 48g paraformaldehyde was dissolved in 400mls dH20 at 60°C.
The solution was cleared with a drop of molar sodium hydroxide and then
filtered. To this solution, 600mls of 0.2M PB was added. After cooling, this
was combined withl50mls saturated picric acid. 50mls were removed for post-
fixation prior to the addition of 4.8mls of gluteraldehyde (25%). The solution
was then made up to 1200mls with dH20.
• Buffered sucrose solutions: 5%, 10% and 30% sucrose solutions were made up
by adding 2.5g, 5g or 15g sucrose to 50mls 0.1M PBS.
• Blocking serum: Specimens were blocked in 4% fish skin gelatin, 10% normal
goat serum and 0.2% Triton X-100 in 0.1 M PBS. This solution was made up
using 17.2mls PBS, 2mls normal goat serum, 0.8mls fish skin gelatin solution
and 40pl Triton X-100.
• Antibody solutions: Primary and secondary antibodies were made up in a
similar solution, containing Triton X-100 and fish skin gelatin as above, with
4% normal goat serum.
2.7 Antibodies
2.7.1 Primary antibodies
• Rabbit polyclonal anti-GluRl (Upstate Ltd., Milton Keynes, UK)
• Mouse monoclonal anti-GluR2 (Chemicon International Ltd., Harlow, UK)
• Mouse monoclonal anti-synaptophysin (Becton-Dickinson)




• Alexa Fluor 488 goat anti mouse (Molecular Probes)
• Alexa Fluor 568 goat anti rabbit (Molecular Probes)
2.8 Miscellaneous
2.8.1 Image analysis and statistical analysis
• Image Tool for Windows v3.00 for cell counting (The University of Texas
Health Science Centre, US).
• Leica Confocal Software v2.00 for cell length and brightness measurements
(Leica Microsystems, Heidelberg, GmbH, Germany).
• Minitab Statistical Software vl3.1 (Minitab Inc.) and SigmaStat for windows
v2.03 (SPSS Inc.) for statistical analysis.
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Chapter 3: The effects of intrathecal administration of specific
receptor agonists on somatosensory behavioural reflexes
3.1 Aims
This study was designed to investigate the role of AMPA, NMDA, mGlu
group I and VPAC2 Rs in the generation of the state of behavioural reflex
hypersensitivity, thought to parallel the process of central sensitisation in the spinal
cord in neuropathic pain. Low doses of specific receptor agonists were administered
to naive rats via the intrathecal route. The effects of individual agonists, and
combinations of multiple agents on the behavioural reflex responses to thermal and
mechanical stimuli were investigated.
3.2 Methods
3.2.1 Experimental animals
All studies were carried out on adult male Wistar rats (Charles River, UK).
Animals were housed in groups of three to five per cage. The cages contained bedding
and a cardboard tube to provide environmental enrichment. Free access to water and
food pellets was provided. Animal room temperature was controlled to 22-24°C with
a twelve-hour light / dark cycle. All experiments were carried out in accordance with
local ethical policy and within the constraints of the Animals (Scientific Procedures)
Act (1986).
3.2.2 Behavioural reflex testing
To investigate the effects of the drug combinations on thermal hyperalgesia
and mechanical allodynia, behavioural testing was carried out as described below.
Following a 20-minute recovery period post injection, animals were tested every ten
minutes for seventy minutes.
Thermal hyperalgesia
Animals were placed on a glass table in Perspex cages with adequate
ventilation holes and permitted to acclimatise to their environment. Hargreaves'
apparatus (Ugo Basile plantar test device, Italy) was used to determine paw
withdrawal latency (PWL) (Hargreaves et al., 1988) (see Figure 3.1a). This consists of
a moveable infra red heat source beneath the table, connected to a thermal detector
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and electronic tinier. The heat source was placed beneath the animal's hind paw and
activated, causing the timer to start and heat source to activate. As soon as the animal
lifts its paw from the hot surface, radiation is no longer reflected back onto the
detector and the timer and heat source are cut off. This allows an objective
measurement of paw withdrawal latency to the nearest 0.1 second. The heat source
was cut off at a 20 second limit to prevent tissue damage in the event that the animal
did not respond. Testing was carried out on each paw alternately, with the mean of
three consecutive measurements noted. A minimum of five minutes was allowed
between tests on the same paw. Mean latency was recorded every ten minutes during
intrathecal drug injection studies, or daily to assess the development of hyperalgesia
in animals following chronic constriction injury (CCI) surgery.
Mechanical allodynia
Mechanical allodynia was assessed using von Frey filaments (Semmes-
Weinstein Anesthesiometer Kits, Stoelting Ltd., Wood Dale, Illinois, USA), (Chaplan
et al., 1994). Each nylon filament is calibrated to exert a fixed force on the plantar
surface of the animal's hind paw before flexing. The pressure exerted depends on the
diameter of the filament and varied from 8.41 - 4831 mN/mm . Animals were placed
on a metal mesh surface covered by a transparent cage (see Figure 3.1b). This allowed
the experimenter to apply the von Frey filaments to the mid-plantar surface of the paw
until bending occurred while the animal was able to move freely. Filaments were
applied, finest first, to alternate hind paws at a lFIz rate with ten applications per paw.
Rapid elevation of the paw with or without shaking represented a nocifensive
withdrawal to a noxious stimulus. Paw withdrawal to at least fifty percent of
applications was taken as a threshold response. The test was repeated at ten-minute
intervals for intrathecal studies and daily post CCI surgery.
Statistical analysis
The effects of intrathecal agonists were assessed using a number of statistical
tests. The drug effect was calculated as the difference between the baseline and the
measured parameter at each time point. The statistical significance of the difference
between baseline and the measured parameter was assessed at each time point using a
paired Student's t-test for thermal hyperalgesia and a Wilcoxon matched pairs signed
rank sum test for mechanical allodynia (* p < 0.05, ** p < 0.01).
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As these tests do not take into account the serial nature of these data, thermal
and mechanical data were also assessed for statistical significance (f p < 0.05, ft p <
0.01) of any differences between post-injection and pre-injection baseline values
using a Friedman repeated measures ANOVA on ranks followed by Dunn's post hoc
analysis (n=6-ll) (see Figures 3.2 - 3.5). Thermal results were analysed using a
conservative non-parametric statistical test, as the data set was not normally
distributed on testing (see Figure 3.2).
When considering summary statistics of the effects of each agonist
combination, the peak effect and the area under the effect-time curve (AUC),
representing the cumulative response to the drug, were considered important features
to compare (Altman, 1999). The peak effect of each drug combination was recorded
for thermal and mechanical stimuli as the greatest decrease from baseline PWL at any
time point, (Figures 3.3a and 3.5), together with cumulative drug effect as measured
as the area of the graph between baseline PWL and measured values over the 70-
minute experimental period for thermal stimuli (see Figure 3.3b).
3.2.3 Intrathecal injection of drugs
Male Wistar rats were used for intrathecal injection of combinations of
agonists to ionotropic and metabotropic glutamate receptors and the VPAC2 R. These
animals had not undergone CCI surgery and are referred to as 'nai've' in the current
study. Behavioural tests of thermal hyperalgesia and mechanical allodynia were
carried out daily to achieve stable baseline values prior to drug administration. The
experimental animals were injected intrathecally at the L4 level under halothane
anaesthesia with 0.05mls of drug or saline vehicle using a 25G needle. The
experimenter was blind to the pharmacological agent or vehicle to be injected in the
majority of cases. There were a minimum of six animals in each experimental group,
no one animal being used for more than three injections. In cases where animals were
injected on more than one occasion, the experiments were carried out with a minimum
48-hour interval. Pre-injection behavioural measurements were taken each time to
ensure that there were no residual effects from previous drug administration.
Following intrathecal injection of a drug, behaviours were monitored until recovery to
baseline values was observed following the drug effect.
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3.2.4 Drug combinations for intrathecal administration
All drugs were made up in sterile saline (0.9%). 50pl was injected
intrathecally and the rats ranged between 250-330g weight. The concentrations at
which drug solutions were made were estimated according to the known relative
affinity of the drugs for their target receptors. Every attempt was made to avoid
excessive concentrations where overlap onto other non-specific targets might occur.
Throughout this thesis, drug doses are given as the concentration of the solution used
and the volume of solution injected. Unless otherwise stated, 50pl of solution was
used. The absolute doseage may then be calculated from these figures. The AMPA R
agonist was AMPA (50pM). NMDA (25pM) was used as the NMDA R agonist. The
mGluRl/5 agonist used was DHPG, (30mM). The VPAC2 R agonist was Ro25-1553,
(6|liM). Normal saline (0.9%) was the vehicle solution. Combinations of multiple
drugs were given at the same doses in a 50pl volume. Agonists were given singly and
then subsequently in double, triple and quadruple combinations. All possible
combinations of one, two and three drugs were given, other than those including both
AMPA and NMDA. The study was designed to compare the development of
behavioural reflex sensitisation via the action of other iGluRs, mGluRs and peptide
receptors on NMDA Rs, versus direct activation of the NMDA R itself. For this
reason, the drug combinations were divided into two groups, one with NMDA R
activation by NMDA and one with AMPA R activation. The relative efficacy of these
two groups of agonists in triggering behavioural reflex sensitisation could then be
compared. Finally, the quadruple combination contained all four agonists, giving 13
drug combinations in total.
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Figure 3.1 Shows the behavioural testing apparatus used, a) Hargreaves' apparatus for
measuring paw withdrawal latencies to noxious cutaneous thermal stimuli, b) von Frey
filaments and testing apparatus for measurement of filament indentation pressure thresholds
for paw withdrawal to mechanical stimuli, c) Tank for measurement of suspended paw
elevation time (SPET) to a cold water stimulus, d) Animal exhibiting paw withdrawal response





Dose-finding studies were carried out with individual agonists to achieve a
small but significant reduction in PWL to a thermal stimulus assessed using
Hargreave's apparatus (see Figure 3.1a). The aim was to use as low a dose as possible
to achieve a measurable, sub maximal, statistically significant effect. When
combinations of several drugs were used, this approach was intended to minimise the
possibility of ceiling effects being observed and obscuring the evidence for synergistic
effects. The effect of adding each agonist to a combination would be apparent, as each
drug alone produced only a small behavioural change. Doses were selected using tests
of thermal hyperalgesia only, since the drugs generally produced less consistent
effects on mechanical allodynia.
All drug combinations were investigated for development of thermal
hyperalgesia using behavioural reflex testing (n=6-ll). The majority of drug
combinations were also investigated for the development of mechanical allodynia.
However, because the results were generally less clear and consistent, the number of
animals used in each mechanical allodynia experiment was low for some drug
combinations (n=2-7) and statistical testing was not always appropriate.
3.3.2 Drug induced changes in behavioural reflex responses
Thermal hyperalgesia
a) Single agonists
After intrathecal injection of individual agonists under brief halothane
anaesthesia, animals were allowed to recover for 20 minutes prior to behavioural
testing (n=7-9). The saline treated group demonstrated a small (2.06 ± 0.58secs) but
significant (* p < 0.05) increase in PWL at 20 minutes post-injection. None of the
other single agonists had an effect at the 20-minute time point. These findings suggest
an artifactual increase in the first PWL measurement, possibly due to residual
anaesthesia or the disturbance of transferring the animals to the experimental
apparatus.
Thermal hyperalgesia developed to a varying degree with all other agonist
drugs at one or more time points from 30 minutes post-injection (* p < 0.05, ** p <
0.01, paired t-test, t p < 0.05, tf p < 0.01, Friedman repeated measures ANOVA on
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ranks followed by Dunn's post hoc analysis) (see Figure 3.2a - e). The peak reduction
in mean PWL caused by these drugs was not dramatic, and varied from 2.11 ± 0.69sec
for AMPA (see Figure 3.2b, Figure 3.3) to 3.67 ± 0.59secs for Ro 25-1553 (see Figure
3.2d, Figure 3.3). Compared to a mean pre-drug baseline of 12.00 ± 0.15sec. The
mGluRl/5 agonist, DHPG (peak effect DHPG, 3.54 ± 0.64secs) and the VPAC2 R
agonist Ro 25-1553 (peak effect Ro 25-1553, 3.67 ± 0.59secs) had a more marked
effect than the other two drugs up to the 60-minute time point (see Figure 3.2c,d). The
measurements ceased at 90 minutes post injection, as all PWLs were returning
towards baseline. At this time point Ro 25-1553 (* p < 0.05), NMDA + Ro 25-1553
(* p < 0.05), and NMDA + Ro 25-1553 + DHPG (** p < 0.01) continued to cause a
significant reduction in PWL (see Figure 3.2e).
b) Combinations of two agonists
Combinations of two of the agonist drugs were administered to five groups of
naive rats (n=7-ll) (see Figure 3.2f - j). Of the double combinations, adding DHPG
(peak effect NMDA + DHPG, 3.56 ± 0.48secs) or Ro 25-1553 (peak effect NMDA +
Ro 25-1553, 3.46 ± 0.45secs) to NMDA demonstrated an increase in peak effect over
NMDA alone (peak effect NMDA, 2.70 ± 0.58secs) (see Figure 3.2f, g). These
combined effects were not greater than additive, and post hoc analysis did not reveal
any statistically significant differences from single drug effects (Friedman repeated
measures ANOVA on ranks followed by Dunn's post hoc analysis).
Similar changes occurred when DHPG (peak effect AMPA + DHPG, 3.08 ±
0.56secs) or Ro 25-1553 (peak effect AMPA + Ro 25-1553, 3.15 ± 0.40secs) were
added to AMPA (peak effect AMPA, 2.11 ± 0.69secs) (see Figure 3.2h, i). Overall,
the peak and cumulative effect (measured as the area of the graph between baseline
PWL and measured experimental values over a 70-minute period for thermal stimuli)
of double drug combinations did not differ significantly from single agonists, and
there were no significant differences between the combinations (Friedman repeated
measures ANOVA on ranks followed by Dunn's post hoc analysis) (see Figure 3.3a,
b).
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c) Combinations of three or four agonists
Combinations of three or four of the agonist drugs were administered to three
groups of naive rats (n=6-10) (see Figure 3.2k - m). The combination of NMDA +
DHPG + Ro 25-1553 had no greater peak or cumulative effect than double drug
combinations with NMDA as a component (see Figure 3.2k, 2).
In contrast, adding AMPA to the double combination of DHPG + Ro 25-1553
had a dramatic effect (see Figure 3.21, Figure 3.3a). Intrathecal injection of AMPA +
DHPG + Ro 25-1553 was the only experimental intervention to cause a significant
decrease in PWL from baseline at the 20 minute time point (** p < 0.01).
Adding AMPA (peak effect 2.11 ± 0.69secs) to DHPG + Ro 25-1553 (peak
effect 2.97 ± 0.67secs) resulted in a greater than additive increase in peak effect
(AMPA + DHPG + Ro 25-1553 peak effect 6.80 ± 0.56secs). The sum of the mean
peak effects of AMPA alone and DHPG + Ro 25-1553 is, therefore 5.08secs versus
6.80 ± 0.56secs for the triple combination. It was not possible to compare these
findings using statistical tests, as experimental animals were not matched for the
individual treatments. However, AMPA + DHPG + Ro 25-1553 had a significantly
greater peak effect than all other combinations of drugs, excepting the quadruple
combination (tf p < 0.01, Student-Newmann-Keuls ANOVA) (see Figure 3.3a).
Interestingly, the peak effect of the quadruple combination of agonists (peak
effect 6.33 ± 0.55secs) was no greater than that of the AMPA + DHPG + Ro 25-1553
triple combination (see Figure 3.2m, Figure 3.3). The quadruple combination had a
significantly greater peak effect than saline, NMDA, AMPA, AMPA + DHPG (§§ p <
0.01), and DHPG + Ro 25-1553, NMDA + Ro25-1553 and AMPA + Ro 25-1553 (§ p
< 0.05, Student-Newmann-Keuls ANOVA).
When comparing cumulative drug effects, all combinations were significantly
more effective than saline control (** p < 0.01, Student-Newmann-Keuls ANOVA vs.
saline control). Comparing cumulative effects of drug combinations to each other
revealed a significantly greater effect for AMPA + DHPG + Ro 25-1553 and the
quadruple combination over all other combinations (t p ^ 0.05, Student-Newmann-
Keuls ANOVA) (see Figure 3.3b).
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Mechanical allodynia
The marked changes in reflex response to thermal stimuli, after administration
of these drugs, were not mirrored by changes in response to mechanical stimuli (see
Figure 3.4). Analysis of data for intrathecal NMDA alone (peak effect 859 ±
206mN/mm2) and AMPA alone (peak effect 1130 ± 264mN/mm2) revealed a
significant effect of each drug at one or more time points (* p < 0.05, ** p < 0.01).
Of the single agonists, DHPG (peak effect 1400 ± 309mN/mm2) was the most
effective drug, resulting in a significant decrease in filament indentation pressure for
paw withdrawal thresholds (PWT) to cutaneous mechanical stimulation from 30 to
50minutes post injection (* p < 0.05, ** p < 0.01 Wilcoxon test, tt P - 0.01,
Friedman repeated measures ANOVA on ranks, Dunn's post hoc analysis) (see Figure
3.4c). Administration of Ro 25-1553 or saline control had no discernable effect on
filament indentation pressure thresholds.
Of the combinations of two agonists, NMDA + DHPG (peak effect 1400 ±
564mN/mm ) caused a significant decrease in mechanical threshold values (* p <
0.05). The effects of AMPA + DHPG (peak effect 1250 ± 250mN/mm2) did not reach
statistical significance (see Figure 3.4f, g). The effects of NMDA + DHPG and
AMPA + DHPG were not significantly greater than the effect of DHPG alone.
AMPA + Ro 25-1553 and NMDA + Ro 25-1553 had no discernable effect on
filament indentation pressure thresholds (see Figure 3.4h, i). It is notable that single
and double combinations of Ro 25-1553 had no discernable effect on mechanical
sensitisation, whereas the VPAC2 R agonist alone, and in combination with other
agonists had a marked effect on thermal sensitisation.
The triple combination of AMPA + DHPG + Ro 25-1553 (peak effect 1320 ±
188mN/mm2) also caused a significant decrease in mechanical threshold (* p < 0.05
Wilcoxon test) (see Figure 3.4j). The quadruple combination of agonists caused a
gradual reduction in mechanical threshold lasting approximately 30 minutes (peak
9 • • •
effect 1320 ± 282mN/mm ) with statistically significant reductions in PWT recorded
at five time points (** p < 0.01, * p < 0.05 Wilcoxon test, ft p < 0.01, Friedman
repeated measures ANOVA on ranks followed by Dunn's post hoc analysis) (see
Figure 3.4k). The peak effect of AMPA + DHPG + Ro 25-1553 was almost identical
to that of the quadruple combination (1315 versus 1318mN/mm ), but the quadruple
combination was clearly more effective.
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Peak effects of drug combinations on mechanical threshold were also
compared to saline control to reveal whether any one combination was significantly
more effective than the others (see Figure 3.5). Of the drug combinations tested
AMPA, DHPG, AMPA + DHPG, AMPA + DHPG + Ro 25-1553 and the quadruple
combination had a significantly greater effect than saline control at peak (** p < 0.01,
*
p < 0.05, Mann-Whitney rank sum test). The combination of AMPA + DHPG + Ro
25-1553 achieved a higher level of statistical significance (** p < 0.01) than other
combinations.
Due to the small sample size of the saline control group, the peak effect of
NMDA alone (p = 0.058) (peak effect 859 ± 206mN/mm2) and NMDA + DHPG
(peak effect 1400 ± 564mN/mm2) did not differ significantly from control when
comparing peak values. Intrathecal Ro 25-1553, Ro 25-1553 + AMPA and Ro 25-
1553 + DHPG had no discernable effect on von Frey response thresholds.
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Figure 3.2 Effects of intrathecal administration of ionotropic glutamate (NMDA or AMPA),
metabotropic glutamate (group I) and VPAC2 R agonists, either individually or in combination,
on paw withdrawal latencies (PWL) to cutaneous noxious thermal stimulation (a-m). PWL was
measured in naive animals before and at ten-minute intervals after intrathecal administration
of single or combinations of two to four drugs. Data are shown as mean ± SEM. Statistical
significance of any differences between pre-injection values and post-injection values and
was determined at each time point by paired Student's t-test (* p < 0.05, ** p < 0.01), and
Friedman repeated measures ANOVA on ranks followed by Dunn's post hoc analysis (t p <
0.05, ff p < 0.01) (n=6-11). All single agonists and combinations of two agonists had a
significant effect on behavioural reflex sensitivity at the low doses used in this study. The
mGlu1/5R agonist DHPG (c), and the VPAC2 R agonist Ro 25-1553 (d) had the greatest
effects of single agonists. Combinations of two agonists had a greater effect, although this
was not synergistic ie: not significantly greater than single agonists or the sum of single
agonist effects. The saline control group demonstrated an increase in PWL at 20mins (*
p<0.05) (e). The triple combination of NMDA, DHPG and Ro25-1553 (k) had a similar effect to
combinations of two agonists. However, triple and quadruple combinations containing AMPA
caused a significantly greater peak reduction in paw withdrawal latency than single and
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Figure 3.3 a) Histogram showing the peak effects of intrathecal administration of
combinations of ionotropic glutamate (NMDA or AMPA), metabotropic glutamate group I and
VPAC2 R agonists. Peak reduction in paw withdrawal latency to cutaneous noxious thermal
stimulation was measured in naive animals after intrathecal injection of drug combinations.
Data are shown as mean ± SEM and statistical significance (* p < 0.05, ** p < 0.01) of any
differences between peak reduction in PWL and saline control values were determined by
Student's t test for each combination of agonists. The triple combination of AMPA + DHPG +
Ro 25-1553 caused a significantly greater peak reduction in PWL than all other combinations
excepting the quadruple combination of agonists (tt p < 0.01 Student-Newman-Keuls one¬
way ANOVA). The combination of all four agonists showed no greater peak effect than the
triple combination of AMPA + DHPG + Ro 25-1553 (§§ see Section 3.3.2 Student-Newman-
Keuls one-way ANOVA). b) Histogram showing cumulative effects of intrathecal injection of
combinations of ionotropic glutamate (NMDA or AMPA), metabotropic glutamate group I and
VPAC2 R agonists. Cumulative effect was calculated as the area under the mean PWL versus
time graph from 20 to 90mins after drug administration. The data are shown as mean ± SEM.
Statistical significance of any differences between total reduction in PWL and saline control
values were determined by Student's t test for each combination of agonists (* p < 0.05, ** p <
0.01). AMPA triple and quadruple combinations of agonists had a significantly greater
cumulative effect than all other combinations (t P ^ 0.05 Kruskal-Wallis ANOVA on ranks

























































































































NMDA triple = NMDA+DHPG+Ro 25-1552
AMPA triple = AMPA+DHPG+Ro 25-1553
Quadruple = NMDA+AMPA+DHPG+Ro 25-1553
Figure 3.4 Effects of intrathecal administration of combinations of ionotropic glutamate
(NMDA or AMPA), metabotropic glutamate group I and VPAC2 R agonists on paw withdrawal
threshold (PWT) responses to cutaneous mechanical stimulation using von Frey filaments (a-
k). Thresholds were measured in naive animals before and at ten-minute intervals after
intrathecal administration of single or combinations of two to four drugs. Data are shown as
mean ± SEM and statistical significance of any difference between pre-injection values and
post-injection values was determined by Wilcoxon matched pairs signed rank sum test (** p <
0.01. * p < 0.05) and Friedman repeated measures ANOVA on ranks with Dunn's post hoc
analysis (tf p < 0.01 see Section 3.3.2). Saline control had no effect on paw withdrawal
threshold (e). All single agonists except Ro 25-1553 exhibited a statistically significant
reduction in PWT. NMDA + DHPG had a similar effect, but AMPA + DHPG and double
combinations containing Ro 25-1553 failed to show statistical significance. The AMPA +
DHPG + Ro 25-1553 and quadruple combinations produced statistically significant reductions
in PWT. The quadruple combination was particularly effective, with statistically significant
reductions in PWT at five time points (k).
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Figure 3.5 Histogram showing peak effects of single intrathecal injections or combinations of
two to four ionotropic glutamate, metabotropic glutamate and VPAC2 receptor agonists on
PWT responses to cutaneous mechanical stimulation using von Frey filaments in naive
animals. Data shown as mean ± SEM and statistical significance of any differences between
peak reduction in mechanical threshold and saline control values for each combination of
agonists were determined using a Mann-Whitney rank sum test. The peak effects of
combinations including DHPG, AMPA, AMPA + DHPG, AMPA + DHPG + Ro 25-1553 and
AMPA + DHPG + Ro 25-1553 + NMDA were significantly greater than the effect of saline
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There is a great deal of evidence to suggest that the activation of multiple
receptor types occurs in neuropathic pain, resulting in central sensitisation and
abnormal pain sensations such as hyperalgesia and allodynia.
Co-activation of iGluRs and mGluRs has been shown to generate behavioural
responses suggestive of central sensitisation in naive rats and mice. The non-selective
mGluR agonist trans-ACPD potentiates the effects of NMDA R agonists in producing
thermal hyperalgesia in rats (Meller et al., 1996). In vivo electrophysiological studies
have revealed that mGluR activation by the non-selective agonist trans-ACPD or the
group I mGluR agonist DHPG potentiated the electrophysiological responses of rat
dorsal horn cells to AMPA, NMDA and kainate (Jones and Headley, 1995). However,
the level of enhancement was identical for all three agonists and was thought to be
due to a non-specific increase in cell excitability, probably due to mGluR group I -
mediated depolarisation, rather than any specific functional interaction with the role
of iGlu Rs.
Activation of mGluRs resulted in similar effects on acutely isolated DH
neurons using whole-cell voltage clamp techniques. ACPD-induced mGluR activation
potentiated the effects of glutamate, AMPA, and NMDA but did not alter the effect of
kainate on dorsal horn neurons (Cerne and Randic, 1992). It is difficult to explain how
ACPD had a selective effect on AMPA and NMDA, but not kainate, without
postulating that there is a specific interaction between mGluR and iGluR, unless
perhaps the kainate-responsive iGluRs are located substantially on different cells from
the AMPA and NMDA Rs.
There is also evidence for the interaction of iGluRs and mGluRs in the
generation of central sensitisation due to noxious inflammatory peripheral stimuli. It
has been demonstrated that intrathecal pre-treatment with NMDA and ACPD but not
AMPA enhanced the spontaneous pain behaviour following intraplantar formalin
injection in the rat. Although AMPA given alone had no effect on spontaneous pain
behaviour following formalin injection, the effect of NMDA was enhanced by
combined administration with AMPA or ACPD, suggesting that AMPA and mGluRs
may increase the activity of NMDA Rs in inflammatory pain (Coderre and Melzack,
1992). The role of non-NMDA iGluRs and mGluRs in activation of the NMDA R has
been discussed elsewhere in this thesis (see section 1.5.1). In a rat model of
inflammatory hyperalgesia, the NMDA R antagonist (D-AP5) prevented the
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additional hyperalgesia effect of a mGluR agonist (trans-ACPD), suggesting that
mGluR may also modulate the effect produced by activated NMDA R in
inflammation (Boxall and Tolle, 1998). In addition to the previously demonstrated
interactions between mGluR and iGluR in the induction and maintenance of central
sensitisation, it is clear that peptide neurotransmitters also play a significant role
(Cumberbatch et ah, 1995), (Dickinson and Fleetwood-Walker, 1999).
Following nerve injury the expression of certain peptide neurotransmitters is
markedly altered, and it would appear that they play a significant role in the
transduction of prolonged noxious stimuli (Hokfelt et ah, 1994), (Dickinson et ah,
1999). For example, levels of SP, CGRP and somatostatin decrease, whereas VIP and
PACAP increase in small diameter, nociceptive neurons in the DRG following nerve
injury (WiesenfeldHallin et ah, 1990). The expression of VIP increases gradually after
injury in the superficial dorsal horn of the rat and remains elevated for several weeks
(Nahin et ah, 1994), (Zhang et ah, 1995b). Following CCI, the electrophysiological
response of DH neurons to the iontophoretic application of the VPAC2 R agonist Ro
25-1553 was dramatically augmented (Dickinson et ah, 1999). These findings suggest
that the VPAC2 R may play a specific role in the transmission of noxious stimuli in
neuropathic pain. As this peptide plays relatively little role in the transmission of
acute noxious and non-noxious stimuli, and has a marked increase in functional
significance following peripheral mononeuropathy, it would seem to be an ideal target
for investigation of the induction of a sensitised state in naive animals. The effect of
co-activation of mGluR, iGluR and peptide receptors, on nociceptive behavioural
reflexes, has not yet been described in naive animals.
3.4.1 AMPA and NMDA receptors
It is known that AMPA R activation plays a role in initiating thermal
hyperalgesia seen following nerve injury, which may then be maintained by NMDA R
activation (Mao et ah, 1992a). In addition to its role in neuropathic thermal
hyperalgesia, co-activation of non-NMDA iGluRs and mGluRs has been shown to
produce mechanical hyperalgesia (Meller et ah, 1993).
The current study revealed that all agonist combinations resulted in significant
thermal hyperalgesia. This was to be expected as this sensory modality was used in
the initial dose-finding studies. The effect of the agonists on mechanical hyperalgesia
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was less marked, however. It is known that different neurotransmitter systems may be
involved in differing aspects of sensory sensitisation.
Previous work suggested that thermal hyperalgesia may be mediated by
NMDA R activation and AMPA appeared not to play a role (Meller et ah, 1996).
However, this study utilised lumbar intrathecal catheters inserted via the atlanto-
occipital membrane, used very small doses of drug (1 pmol NMDA) and found only
transient (less than 5 minutes) effects. In addition, when larger doses of AMPA (100-
200pmol) were given, spontaneous nociceptive behaviour was noted for up to 30mins,
suggesting that a narrow dose range would be required for the analysis of the effects
of AMPA in this experimental paradigm. Similar effects of higher doses of AMPA
were noted in the current study (dose finding study, data not shown). There is
evidence that AMPA Rs may be important in thermal hyperalgesia in a CCI model of
neuropathy, with a greater role in its initiation than in its maintenance (Mao et al.,
1992a). This may explain why the AMPA agonist produced only modest thermal
hyperalgesia at the doses used (2.5nmol), although additional factors are likely to be
important.
Further evidence for a significant role for AMPA Rs in the spinal cord in
mediating the sensitised nociceptive transmission that occurs following peripheral
nerve damage has been provided by a recent study (Garry et al., 2003b). The effect of
intrathecal injection of the AMPA/kainate receptor antagonist NBQX and the highly
selective AMPA R antagonists NS-257 and SYM 2206 on rats at the peak of
behavioural reflex sensitisation by CCI was investigated. It was demonstrated that
these antagonists attenuated the ipsilaterally sensitised behavioural measures of
thermal hyperalgesia and had similar but less marked effects on mechanical allodynia
following CCI. This suggests that AMPA Rs may play a significant role in both
thermal hyperalgesia and mechanical allodynia following CCI.
In the current study, the effects of AMPA on mechanical allodynia were less
marked than those on thermal hyperalgesia. This is perhaps surprising in the light of
previous studies, which suggest that AMPA Rs play an important role in the
generation of acute mechanical hyperalgesia to noxious stimuli (stimulation of rat tail
by von Frey filaments). These sensory changes have been demonstrated following
intrathecal delivery of the non-NMDA iGluR and mGluR agonist quisqualate via an
indwelling intrathecal catheter (Meller et al., 1993). The induction of mechanical
hyperalgesia in this model was blocked by inhibition of either AMPA R or mGluR
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with selective antagonists. This suggests that mechanical hyperalgesia requires the
activation of both AMPA Rs and mGluRs. However, this study used very small drug
doses (AMPA l-100pmol) and found a transient effect (less than 5 minutes).
However, the findings of the current study are consistent with a recent study
demonstrating that AMPA R blockade resulted in a less marked reduction in
mechanical allodynia than thermal hyperalgesia in rats at peak behavioural reflex
sensitisation by CCI (Garry et al., 2003b).
It has also been demonstrated that intrathecal pre-treatment with Joro spider
toxin, a specific antagonist at Ca2+ permeable AMPA Rs prevented the development
of mechanical allodynia following a mild burn (Sorkin et al., 1999). This finding
raises the possibility that AMPA R subunit composition may be important in
determining the role of this receptor in nociception.
The above studies and the results of the current investigation suggest that
NMDA and AMPA Rs are involved in both mechanical allodynia and thermal
hyperalgesia following central sensitisation due to prolonged noxious stimuli.
However, the significance of each receptor type and its associated intracellular
consequences in the induction of abnormal pain states may vary with the mechanism
of induction (inflammation versus nerve damage) and the sensory modality involved
(mechanical allodynia versus thermal hyperalgesia).
3.4.2 Group I mGlu receptors
It has been demonstrated that intrathecal injection of high doses of the mGluR
group I agonist DHPG (25nmol) resulted in SNB for 30minutes. Although the dose
used in the current study was much smaller (1.5nmol), activation of mGluR group I
resulted in the most marked decrease in paw withdrawal threshold of the single
agonists, with significant effects up to 50minutes after injection (see Figure 3.4c).
3.4.3 VPAC? receptors
The VPAC2 R agonist Ro 25-1553 (0.3nmol) had a prolonged, significant
effect on PWL to a noxious thermal stimulus but no discernable effect on paw
withdrawal threshold to a mechanical stimulus. Indeed, the double combinations of
AMPA + Ro 25-1553 and DHPG + Ro 25-1553 also had no effect on mechanical
allodynia, whereas AMPA alone and DHPG alone caused a significant decrease in
paw withdrawal thresholds. The triple combination of AMPA + DHPG + Ro 25-1553
113
reduced paw withdrawal threshold significantly at a single time point only. These
findings suggest that activation of the VPAC2 R agonist Ro 25-1553 may have an
antiallodynic effect to mechanical stimuli, but causes hyperalgesia to noxious thermal
stimuli.
This apparent differential effect of the VPAC2 R has been demonstrated using
VIP as an agonist at VPAC Rs. In the rat tail flick test to a thermal stimulus,
intrathecal VIP (6.5nmol) had a pronociceptive effect, decreasing reaction time to
37% of control value at lmin after injection (Cridland and Henry, 1988). In agreement
with the current study, VIP did not result in mechanical allodynia after intrathecal
administration.
The PAC and VPAC R agonist PACAP has been shown to have differing
effects depending on the dose. Low dose PACAP applied intrathecally (10-100pmol)
has been shown to increase mouse tail flick latency in a hot plate test, whereas high
dose regimes (200-2000pmol) resulted in scratching and biting pain related behaviour
(Narita et al., 1996). In addition, electrophysiological studies have demonstrated that
the VPAC2 R plays relatively little role in sensory transmission in the normal animal,
but is important in the transmission of prolonged noxious stimuli (such as mustard oil
application) following nerve injury (Dickinson et al., 1999). These studies suggest
that the PAC and VPAC Rs may have complex roles in the generation of sensitised
states, depending upon the dose and sensory modality involved.
3.4.4 Synergy between AMPA, DHPG and Ro 25-1553
The combined effects of DHPG, AMPA and Ro 25-1553 on thermal
hyperalgesia revealed a degree of interaction between these receptor agonists that has
not been previously demonstrated (see Figure 3.21 and Figure 3.3a and b). Adding
AMPA to DHPG + Ro 25-1553 resulted in a greater than additive increase in peak
effect on thermal hyperalgesia. AMPA + DHPG + Ro 25-1553 had a significantly
greater peak effect than all other combinations of drugs, excepting the quadruple
combination (tt p < 0.01, Student-Newmann-Keuls ANOVA) (see Figure 3.3a).
When comparing the cumulative effect of drug combinations, AMPA + DHPG + Ro
25-1553 and the quadruple combination had a significantly greater effect on thermal
hyperalgesia than all other combinations (f p ^ 0.05, Student-Newmann-Keuls
ANOVA) (see Figure 3.3b). These findings suggest that activation of AMPA Rs in
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addition to group I mGluRs and peptide VPAC2 Rs results in a synergistic interaction
in the induction of thermal hyperalgesia.
The addition of NMDA to the triple combination of AMPA + DHPG + Ro 25-
1553 made no significant difference to the peak or cumulative effect of the drug
combination on thermal hyperalgesia (see Figure 3.3a and b). This suggests that
activation of the other receptor subtypes is sufficient to create a sensitised state, and
that the NMDA R may have been activated by removal of the magnesium ion block as
a consequence of depolarisation resulting from activating these receptors. The NMDA
R would then be responsive to glutamate released from primary sensory neurons by
innocuous and noxious peripheral stimuli.
3.4.5 Mechanical allodynia
The effect of drug combinations on mechanical allodynia was less marked
than that on thermal hyperalgesia. In a practical sense this may have been due to the
use of thermal hyperalgesia in determining the optimal dose of the agonist drugs. It is
possible that a dose adequate to produce mild thermal hyperalgesia would not produce
mechanical allodynia. Also, although there is no simple division of function, it is clear
that certain receptors would seem to be involved to differential extents in either
thermal hyperalgesia or mechanical allodynia, as was demonstrated by Ro 25-1553
(Cridland and Henry, 1988). It is possible that AMPA R play a less significant role in
mechanical allodynia than in thermal hyperalgesia. In support of this suggestion, it
has recently been demonstrated that specific AMPA R antagonists are less effective in
reversing mechanical allodynia than thermal hyperalgesia in a CCI model of
neuropathic pain (Garry et al., 2003b). Finally, the use of von Frey filaments to test
the threshold for paw withdrawal involved discrete, large changes in stimulus
intensity rather than the continuous scale used for PWL from a noxious thermal
stimulus. This technique may render subtle changes in paw withdrawal threshold
undetectable.
It proved impractical to test animals for cold allodynia following intrathecal
injection, as the effects of the agonist combinations were bilateral and did not result in
a clear pattern of behavioural change in the cold-water tank. There was also no
apparent effect of acetone application to either hindpaw (data not shown).
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3.4.6 Summary
It is clear from these results that AMPA Rs play an important role in thermal
hyperalgesia and mechanical allodynia in the intact rat. Activation of AMPA Rs in
addition to group I mGluRs and peptide VPAC2 Rs results in a synergistic interaction
in the induction of thermal hyperalgesia, possibly by inducing activation of NMDA
Rs. In order to study the effect of neuropathic pain on the expression and subcellular
location of AMPA GluRl and GluR2 Rs, a well-characterised model of peripheral
mononeuropathy in the rat was utilised (see Chapter 4).
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Chapter 4: Neuropathic pain and localisation of AMPA receptor
expression in the spinal dorsal horn
4.1 Aims and introduction
These experiments were carried out to investigate the effect of an animal
model of chronic, neuropathic pain due to peripheral nerve injury on the expression
and subcellular location of AMPA R GluRl and GluR2 subunits in the dorsal horn of
spinal cord. The model used in this study was the chronic constriction injury (CCI)
model of Bennett and Xie (Bennett and Xie, 1988), which involved loose ligation of
the common sciatic nerve in the rat. Neuropathy developing after surgery was
quantified using tests of behavioural reflex function.
In the current study AMPA R GluRl and GluR2 subunit expression was
assessed using immunofluorescence techniques under a number of different
experimental conditions. The proportion of neurons expressing these subunits in the
superficial dorsal horn, and the subcellular distribution of subunits was investigated in
nai've animals, animals demonstrating peak behavioural reflex changes following CCI,
and animals after sham surgery and after recovery from CCI. A second group of nai've
animals were treated with AMPA 50pM in 0.2mls saline (0.9%) or 0.2mls saline
(0.9%) intrathecally, 35 minutes prior to perfusion. In addition to the subcellular
location of AMPA R subunits, the co-expression of GluRl and GluR2 by superficial
dorsal horn neurons was investigated following nerve injury.
In addition to changes in AMPA subunit expression, levels of key synaptic
proteins also change in models of neuropathic pain, suggesting that synaptogenesis
may be occurring in this abnormal pain state. The presynaptic vesicle protein
synaptophysin was first isolated in 1985 (Wiedenmann and Franke, 1985) and has
proved useful in the identification of synaptogenesis in several areas of the CNS
(Bergmann et al., 1997).
Bassoon is a presynaptic nerve terminal protein, which shares features with
both cytoskeleton-associated and peripheral membrane proteins (Sanmarti-Vila et al.,
2000). In the current study, both synaptophysin and Bassoon were utilised as markers
for regions of synaptic activity in dorsal horn neurons. To investigate the inclusion of
AMPA Rs into synapses in the CCI model of neuropathic pain, the relationship
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between the subcellular location of synaptic proteins Bassoon and synaptophysin and
GluRl subunits was assessed in dorsal horn cells.
The effect of intrathecal treatment with specific antagonists on the subcellular
location of AMPA R GluRl subunits was studied using animals with well-established
behavioural reflex changes following nerve injury. Antagonists to AMPA R alone,
and to NMDA R, mGluR and VPAC2 R in combination were given intrathecally. This
study was designed to investigate the relative importance of different receptor signals
in GluRl subunit trafficking.
4.2 Methods
4.2.1 Chronic constriction injury surgery
Surgical procedures were carried out in an aseptic manner, operators wearing
gowns, filter masks and sterile gloves. Surgical instruments were autoclaved prior to
use. Induction and maintenance of anaesthesia was provided by vaporised halothane
at 2-4%. The carrier gas was compressed medical oxygen at a flow rate of 2-41/min.
Depth of anaesthesia was assessed using respiratory rate and pattern and response to
surgery. After shaving the right hind limb, the skin was cleaned with chlorhexidine
(0.5% in 70% alcohol), and a small (4-5mm) skin incision made over the sciatic
nerve. The nerve was identified by blunt dissection and freed from surrounding
tissues. Using a x40 operating microscope, four 4.0 chromic gut sutures were loosely
tied around the nerve at 1mm intervals, proximal to its trifurcation. The sutures were
tightened sufficiently to prevent slippage but not to occlude the vasa nervorum. The
wound was sutured with 5.0 vicryl using a continuous subcutaneous technique with
the suture ends buried. Postoperatively, adequate recovery from surgery and
anaesthesia was ensured prior to return to their original cages. The animals were
checked each day for three to five days before behavioural testing commenced (n = 15
animals). During sham surgery the nerve was exposed before wound closure without
sciatic ligation (n = 3 animals).
Behavioural reflex testing
Tests were designed to highlight the occurrence of behavioural changes
thought to represent neuropathic pain in experimental animals. Animals were tested
pre-operatively and every few days post-operatively from day three. Animals were
examined daily for the presence of autotomy. Gait was inspected and the posture and
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condition of the affected hind limb noted. Abnormal behaviours such as repeatedly
licking the affected limb, jumping, biting, or vocalising were also noted. In all cases,
the ipsilateral operated limb was compared to the contralateral non-operated side.
Thermal hyperalgesia and mechanical allodynia were assessed as described above
(section 3.2.3).
The sensory stimulus used to detect cold allodynia in animals post CCI
surgery was ice-cold water. The testing apparatus consisted of a transparent Perspex
box with an aluminium floor plate submerged in water in equilibrium with ice in the
base of the cage to give a water temperature of 3-4°C. The water depth was
approximately 1cm; sufficient to cover both the hairy and glabrous skin of the rats'
paws. Once placed in the box, animals were given a ten second acclimatisation period
before measurement began. After acclimatisation, the time spent with each paw
elevated out of the water (suspended paw elevation time - SPET), was noted over a
twenty second period. This produced a score of 0 to 20 for each paw. This test was
shown to be suitable for animals post CCI surgery, as there was a clear difference
between the limb ipsilateral to surgery (marked withdrawal responses) and the normal
limb (where there was minimal tendency to raise the limb).
Statistical analysis
Behavioural data were acquired on days 3, 6, 9 and 14 after CCI injury. Data
were pooled for each day and the mean and SEM values calculated (see Figure 4.1).
Development of thermal hyperalgesia was assessed using a paired Student's t-test to
determine the statistical significance of any differences between the mean ipsilateral
and contralateral hind paw values at each time point (**p < 0.01, * p < 0.05, n = 8).
Student-Newmann-Keuls repeated measures ANOVA was then used to determine the
statistical significance of differences between group values at each time point when
compared to pre-operative control values (ft p < 0.01, t p < 0.05, n = 8) (see Figure
4.1a). Mechanical allodynia and cold allodynia were investigated using the equivalent
non-parametric tests. Ipsilateral and contralateral sides were compared at each time
point using a Wilcoxon test (** p < 0.01, * p < 0.05, n = 8). Statistically significant
differences from pre-operative baseline were determined using a Friedman repeated
measures ANOVA on ranks followed by Dunn's post hoc test (ft p < 0.01, t p <
0.05, n = 8) (see Figure 4.1b and c).
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4.2.2 General immunohistochemistry methods
Experimental animals were deeply anaesthetised with halothane before being
transcardially perfused with 150mls heparinised vascular flush consisting of 0.9%
saline with 0.6mg/ml heparin (Sigma) using a small rotary pump at 30mls/minute
(Watson-Mariow Ltd., UK.). The heparinised flush solution was followed by 300mls
fixative solution containing 4% paraformaldehyde (Sigma), 0.1% gluteraldehyde
(Sigma) and 12.5% picric acid (Becton Dickinson, UK) in 0.1M phosphate buffer at
pH 7.4. After perfusion, the lumbar spinal cord was dissected out under an operating
microscope and placed in a post-fix solution containing 4% paraformaldehyde, and
12.5% picric acid in 0.1M phosphate buffered normal saline (PBS). The tissue was
post-fixed at 4°C for 24hours before being transferred through increasing
concentrations of sucrose to a 30% solution in PBS for cryoprotection overnight.
Tissue sectioning was carried out on a Leitz Kryomat 1700 freezing
microtome. Blocks of tissue 2-3mm long were cut from the lumbar enlargement of the
spinal cord approximately at the L4-L5 level, with a scalpel blade, care being taken to
maintain the orientation of the tissue. The blocks were then placed on the freezing
microtome and embedded in 0.25% agar (Becton Dickinson, UK) prior to freezing at
-20°C. If the tissue was derived from a CCI animal, a small pinhole was made in the
contralateral ventral horn to aid recognition of the ipsi- and contralateral dorsal horns.
Sections 40pm thick were cut and stored briefly in 0.1 M PBS at 4°C.
Spinal cord sections were washed in PBS prior to suspension in a blocking
solution containing 10% normal goat serum (Diagnostics Scotland), 4% fish skin
gelatin (Sigma) and 0.2% Triton X-100 (Sigma) in 0.1M PBS for 1 hour at room
temperature. Both primary and secondary antibodies were diluted in a solution
containing 4% normal goat serum, 4% fish skin gelatin, and 0.2% Triton X-100 in
0.1M PBS. After removing the blocking solution, the sections were incubated in
primary antibody solution overnight at 4°C. The sections were then washed in PBS
once more prior to incubation at room temperature with fluorescent secondary
antibodies for two hours. During secondary antibody incubation, pots containing
sections were gently agitated in the dark. After a final wash in PBS, sections were
treated with To-Pro3, a cyanine nucleic acid stain, (Molecular Probes) 1:1000 for two
minutes prior to cover-slipping with Vecta Shield (Vector Laboratories). Cover slips
were sealed using clear varnish and the slides were stored at 4°C in the dark prior to
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confocal microscopy. Control sections were processed as above omitting primary or
secondary antibodies.
Antibodies
Primary antibodies were used at the following concentrations: rabbit
polyclonal anti-GluRl (1:100, Upstate Biotech Inc); mouse monoclonal anti-GluR2
(1:200, Chemicon). Secondary fluorescent antibodies were used at 1:1000: Alexa
Fluor goat anti-mouse 488nm (green fluorescence) (Molecular Probes) and Alexa
Fluor 568nm goat anti-rabbit (red fluorescence) (Molecular Probes).
4.2.3 GluRl and GluR2 AMPA receptor subunit expression in the spinal dorsal
horn in a neuropathic pain state
To investigate the effect of neuropathic pain on AMPA R subunit expression,
four experimental groups were used (n = 3-6): naive animals; those exhibiting peak
sensitisation due to CCI surgery as assessed by behavioural reflex testing at post
operative day 14; sham-operated animals and animals demonstrating behavioural
recovery from CCI surgery.
Confocal microscopy and image analysis
Slides produced using the above technique were examined using a Leica TCS
NT confocal system (Leica Microsystems Heidelberg GmbH, Germany). Digital
images were stored on TDK CD-R media for display and analysis using 'LCS Lite',
imaging software. Each image was labelled with a code name to facilitate blinding
during analysis. Single optical section x20 images were acquired from both dorsal
horns for each cord slice. Images were 500 x 500pm square, and included laminae I to
III of the dorsal horn (see Figure 4.2a). Between six and twenty image slices were
analysed for each experimental group. The lateral aspect of the dorsal horn was
included on each image, where the superficial laminae curve steeply in a ventral
direction. As a result, the extreme medial part of the dorsal horn was often omitted.
Cells were counted from the medial cut-off of the dorsal hom to the start of the
steeply curved section. In this manner, the region of afferent input from the hind limb
was the focus of attention (Swett and Woolf, 1985). The experimenter was blinded to
the treatment group and the side of dorsal horn for cell counting. GluRl-
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immunopositive cells (red) and GluR2-immunopositive cells (green) were counted in
each of the three outer dorsal horn laminae.
The definition of dorsal horn laminae was based around the location of lamina
II for this study, as this region had the clearest neuropil labelling (Spike et al., 1998).
Lamina II was taken as the region of dorsal horn with neuropil labelled with GluR2 in
its inner- and mid-portion, and GluRl in its mid- and outer-portion. This lamina
comprised a band of dense neuropil and small somata running from approximately 60-
120pm below the surface of the dorsal horn, measured midway through its
mediolateral aspect. This defined a region of the dorsal horn which was consistent
with that described by Molander et al (Molander et al., 1984). Lamina I was defined
as the region from outer lamina II extending dorsally for 30pm. Lamina III was taken
as the region 100pm ventrally from inner lamina II. Measurements of the thickness of
the superficial laminae were based upon these criteria generated using a group of
naive animals (n=3, 3 slices per animal). Lamina I measured 29.6 ± 1.5pm in depth,
and lamina II was approximately twice as deep, measuring 61.7 ± 3.2pm using the
fixing protocol described. Lamina IV and V showed little GluRl/2 labelling and were
not investigated further in the current study.
Where labelling was less clearly defined, immunofluorescent objects with
greater than twice background intensity were recorded as cells, if they were typically
cell-shaped and were associated with cyanine dye nuclear staining with To-Pro3. This
nucleic acid-binding cyanine dye causes far-red fluorescence of nuclei when excited
at 633nm, which has been artificially coloured blue in the current study. The total
number of cells in each lamina was noted by counting all To-Pro3 stained nuclei. The
proportion of GluRl- or GluR2-immunopositive cells was then calculated for each
lamina by dividing the number of immunopositive cells by the total number of nuclei.
Statistically significant differences between the mean percentage of GluRl- and
GluR2-immunopositive cells on ipsilateral and contralateral sides of the dorsal horn
were determined for each lamina using a chi-squared test (** p < 0.01). All
experimental groups were then compared to the naive control group (ANOVA
followed by Dunnetts'spost hoc analysis, tt p < 0.01) (see Figures 4.3 and 4.4).
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4.2.4 Comparison of GluRl/2 localisation with that of presynaptic markers
Spinal cord tissue from naive animals and animals at peak behavioural
sensitisation due to CCI surgery was prepared as above (n=3) (Section 4.2.2).
Sections were labelled with GluRl primary antibodies and also mouse monoclonal
anti-Bassoon (1:500, Stressgen) or mouse monoclonal anti-synaptophysin (1:200,
Pharmingen). Alexa Fluor secondary antibodies were applied as described above
(Section 4.2.2).
Confocal microscopy and image analysis
Stacks of confocal optical sections were acquired using a x63 oil immersion
lens. Image stacks consisted of 7-12 150pm optical slices, l-2pm apart centred on
the midpoint of the dorsal horn within lamina II. Single low magnification optical
sections of dorsal horns labelled with anti-Bassoon antibodies were also acquired
using a xlO lens.
Low magnification images were used to compare levels of Bassoon
immunofluorescence between ipsilateral and contralateral dorsal horns after CCI
surgery. Regions of interest in the medial, mediolateral and far lateral dorsal horn of
lamina II measuring 50x50pm were analysed to give a mean fluorescence intensity
value. The mean intensity values for each region of the dorsal horn ipsilateral and
contralateral to CCI surgery were compared using a paired Student's t test (see Figure
4.5b, Figure 4.6b).
Bassoon immunofluorescence was punctate in appearance, with some puncta
clustered near GluRl-immunopositive cells (see Figure 4.5b). For the purpose of
analysis, a Bassoon 'punctum' was defined as a group of 9 or more pixels with a
green fluorescence intensity level of 75%-l 00% of the maximum found on that image,
provided that this was at least twice the background level of green fluorescence. The
number of Bassoon immunopositive puncta per GluRl-immunopositive cell was
determined by counting all puncta within 0.5pm of a cell. A single mid-cell optical
slice was used for this analysis, and the cell marked to prevent double counting. The
mean number of puncta per mid-cell slice was determined for nai've animals and ipsi-
and contralateral to CCI injury. Statistical significance of any difference between
ipsilateral and contralateral sides was determined by a Mann-Whitney U test (* p <
0.05). All three experimental groups were compared using a Kruskal-Wallis one-way
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ANOVA on ranks followed by Dunn's post hoc analysis (** p < 0.01) (see Figure
4.5a).
Synaptophysin immunofluorescence was less clearly defined than that of the
Bassoon antibody and it was not possible to define synaptophysin puncta as precisely.
Any green synaptophysin labelling within 0.5pm of a GluRl-immunopositive cell
was counted as a punctum. As for Bassoon immunohistochemical analysis, a single
mid-cell optical slice was used for counting synaptophysin puncta. The mean number
of puncta per mid-cell slice was determined for naive animals and ipsi- and
contralateral to CCI injury. Statistical significance of any difference between
ipsilateral and contralateral sides in CCI animals was determined by a Mann-Whitney
test (see Figure 4.7).
4.2.5 AMPA receptor subunit colocalisation in the spinal dorsal horn in a
neuropathic pain state
Spinal cord tissue from naive animals and animals at peak behavioural
sensitisation post CCI (n = 3) was prepared using the technique outlined above
(section 4.2.2). Confocal images of both dorsal horns from each spinal cord slice were
obtained with a x40 objective lens (see Figure 4.8b). The images consisted of a stack
of 7-12 optical slices (approximately 0.5pm thick), from a 40pm tissue section, each
spaced l-2pm apart and approximately 250pm of an area centred on the central part
of lamina II of the dorsal hom. This region is known to receive afferent input from
branches of the sciatic nerve including the superficial peroneal and the sural nerves
(Swett and Woolf, 1985). The images of the cord slices were scanned from the surface
down to loss of antibody penetration. For each GluRl- or GluR2-immunopositive
cell, red and green fluorescent intensity was measured using 'LCS Lite' software
across a single mid-section optical slice on a scale of 0-255units. Peak red (GluRl)
and green (GluR2) intensity along the longest axis was noted for each
immunopositive cell. Background and peak levels of red GluRl fluorescence and
green GluR2 fluorescence were measured for each slice in the stack. Red and green
fluorescence was graded as absent, low or high. Absent fluorescence was defined as
being less than twice baseline levels. Low fluorescence was defined as twice baseline
to 75% of maximum intensity for that slice. High fluorescence was defined as
intensity from 75-100% of maximum for that slice. The selection of these levels of
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fluorescence as 'high' and 'low', although arbitrary, resulted in a division of the cells
into two discrete categories.
Comparisons between groups were made using Chi-Squared tests. The
proportion of cells expressing GluRl alone, GluR2 alone or both, was compared
between experimental groups (see Figure 4.8a). Changes in the level of fluorescence
expressed by cells were investigated for GluRl and GluR2 separately (see Figure 4.9).
The degree of colocalisation demonstrated by cells brightly labelled (>75% of
maximal value for that image) with either antibody was also compared.
4.2.6 The influence of specific receptor agonists and CCI on the subcellular
distribution of AMPA receptor subunits
To investigate the effect of neuropathic pain on AMPA R subunit subcellular
distribution, the following experimental groups were used: nai've animals; those
exhibiting peak behavioural sensitisation following CCI surgery (post-operative day
14); sham-operated animals (post-operative day 14) and animals demonstrating
behavioural recovery from CCI surgery (n=3-6) (12 weeks post-operative). Two
further groups of anaesthetised naive animals were treated with either AMPA 50pM
in 0.2mls saline (0.9%) or 0.2mls saline (0.9%) intrathecally, 35 minutes prior to
perfusion (n=3). Spinal cord tissue from experimental animals was prepared as above
(Section 4.2.2).
Confocal microscopy and image analysis
Confocal images of both dorsal horns from each spinal cord slice were
obtained using a x40 lens (see Figure 4.2b). Image stacks were acquired, consisting of
7-12 250pm optical slices, l-2pm apart centred on the mediolateral dorsal horn
within lamina II. The subcellular distribution of AMPA R subunits was investigated
by measuring immunopositive cells in the dorsal horn using 'LCS Lite' software. The
GluRl-immunopositive region of each cell was measured along its longest axis
choosing the optical slice nearest to its midpoint. Each cell was marked after GluRl
measurement to prevent double counting. The nucleus was also measured and the data
used to calculate the GluRl-immunopositive length to nuclear-diameter ratio. There
were sufficient GluRl-immunopositive cells to analyse data for all experimental
groups for laminae I, II and III (see Figures 4.10a-e, 4.6a). GluR2
immunofluorescence was less discrete and fewer cells were measurable, limiting
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analysis of data to lamina II (see Figure 4.11). Statistically significant (** p < 0.01, *
p < 0.05) differences between the median length of the GluRl-immunopositive
regions of cells in each experimental group was investigated using a Kruskal-Wallis
one-way ANOVA on ranks followed by Dunn's post hoc analysis for lamina I, II and
III. The same statistical tests were applied to GluR2 data for lamina II.
4.2.7 The effect of specific receptor antagonists on the subcellular distribution of
AMPA receptor subunit in neuropathic pain
Male Wistar rats exhibiting peak behavioural sensitisation following CCI
surgery (post-operative day 14) were used for this study. Animals were anaesthetised
with halothane prior to slow intrathecal injection of either 0.2mls of AMPA R
antagonist or 0.2mls of a combination of antagonists to NMDA R, mGluRl. mGluR5
and VPAC2 R (n=3). These animals were kept warm and anaesthetised for 35minutes
prior to perfusion. Spinal cord slices were labelled with antibodies to GluRl and
nuclei were stained with To-Pro3 as above (Section 4.2.2).
Specific receptor antagonists
All drugs were administered intrathecally to anaesthetized animals in 200pl
sterile saline (0.9%) unless stated otherwise. The AMPA R antagonist was NBQX
(sodium salt), IOOjjM. The combination of antagonists included: (R)-CPP (NMDA R
antagonist), lOpM; LY 376385 (mGluRl antagonist), lOmM; MPEP (mGluR5
antagonist), lOpM and PG 99-465 (VPAC2 R antagonist), 2pM in 0.06%
dimethylformamide in saline.
Confocal microscopy and image analysis
Confocal image stacks were acquired with a x40 lens and analysed as above
(Section 4.2.6.1). GluRl-immunopositive cells from the mediolateral region of lamina
II alone were analysed for this study (see Figure 4.12b). Statistically significant
differences between the median linear extent of the GluRl-immunopositive regions of
cells in each experimental group were investigated using a Mann-Whitney rank sum
test (see Figure 4.12).
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4.3 Results
4.3.1 Chronic constriction injury
General observations
The vast majority of animals developed behavioural changes characteristic of
CCI injury (12 of 15animals) and any that did not were excluded from further analysis
(n=3). Following CCI, the operated limb was held flexed and the animals tended to
favour the contralateral hind paw in locomotion with the affected paw held inverted
and in plantar flexion with claws tightly clasped. On some occasions animals held the
affected paw away from the surface completely. Other than developing a 'hopping'
gait, there were no other changes in the speed or pattern of locomotion. Post-operative
animals appeared healthy and had no gross signs of weight loss or neglect and could
be handled without any distress being evident. During the study, no animals
developed autotomy. Sham-operated animals did not develop any behavioural signs of
neuropathic pain.
Thermal hyperalgesia
Thermal hyperalgesia assessed using Hargreaves' apparatus (see Figure 3.1a)
developed to a varying degree in all animals post-operatively. Mean pre-operative
baseline PWL were measured as ipsilateral, 15.29 ± 0.74 sees and contralateral 14.77
± 0.86 sees (all data mean ± SEM). At all time points from the third post-operative
day the animals showed significantly reduced PWL ipsilateral to the injury and as
compared to the contralateral side (p < 0.01, paired Student's t test) and to all other
time points (p < 0.01, Student-Newmann-Keuls repeated measures ANOVA) (see
Figure 4.1a). Although there was a trend for the contralateral PWL to decrease in
parallel with the ipsilateral side, this was not statistically significant. The animals
reached a peak of thermal hyperalgesia at varying times, the median being post¬
operative day 9 when the ipsilateral latency was 7.64 ± 0.78secs and the contralateral
12.50 ± 0.68secs.
The behaviour of the animals also altered qualitatively with the development
of thermal hyperalgesia. In pre-operative animals the response to a noxious thermal
stimulus consisted of a rapid flick of the hind paw with a return to the resting posture.
After CCI surgery, animals tended to hold the limb elevated for a longer period of
time, or shake or lick the affected paw.
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Mechanical allodynia
Prior to CCI injury, animals displayed a mean paw withdrawal threshold
pressure of 4830 mN/mm2 (see Figure 4.1b). This value was consistent between both
paws and for all animals. The majority of animals demonstrated an increased
sensitivity to mechanical stimuli by post-operative day 3, and by post-operative day 6
these changes were universal. From post-operative day 9 onwards, there was a
significant reduction in the withdrawal threshold of the ipsilateral hind paw (1413 ±
2 2293.3 mN/mm ) when compared with the contralateral hind limb (4830 ± 0 mN/mm";
p < 0.01, Mann-Whitney rank sum test) or pre-operative values (p < 0.01, Kruskal-
Wallis one way ANOVA on ranks). There were no significant differences between the
threshold values of the contralateral hind limb in the nerve-injured animals compared
to pre-surgery values at any time point. The rats were responding to previously
innocuous stimuli with behaviour indicative of pain-related withdrawal reflex
activation, suggesting that CCI injury leads to the development of mechanical
allodynia on the nerve-injured side, which is in agreement with previous reports using
this model.
Cold Allodynia
Cold allodynia was a marked feature of CCI injury. Naive rats showed no
change in observed behaviour when placed in the shallow cold water bath (see Figure
3.1c). Their general level of activity remained as before and they showed no aversive
response to the cold stimulus. From post-operative day 3, nerve injured animals
exhibited altered behaviour, lifting the affected hind paw out of the water and keeping
it elevated or shaking or licking it. As the cold stimulus did not evoke any pain-related
behaviour in naive animals, but had a clear aversive paw withdrawal effect after nerve
injury, it can be defined as a form of allodynia where a previously innocuous stimulus
triggers pain behaviour following CCI.
Initially, the affected paw was only briefly elevated, but by post-operative day
9, animals were maintaining this abnormal posture for the majority of the time (see
Figure 4.1c). Most animals demonstrated marked effects by post-operative day 14
(SPET 15.8 ± 1.99 sees), with 50% of the animals keeping the affected paw elevated
for the full 20-second test period accompanied by occasional vocalising. Once
removed from the bath after a total of 30sec, normal behaviour resumed almost
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immediately, suggesting that the pain related behaviour was dependent on the cold
stimulus and no continuing pain was experienced. As animals were used for perfusion
experiments at this time point, it was not possible to collect recovery data.
4.3.2 AMPA receptor subunit expression in the spinal dorsal horn
General considerations
Both GluRl and GluR2 were strongly expressed in the superficial dorsal horn
(see Figure 4.2a), with a larger proportion of cells labelled with GluR2, in agreement
with previous findings as reviewed in (Coggeshall and Carlton, 1997). Both
antibodies labelled cell bodies and proximal processes, and neuropil between cells.
The marked labelling of neuropil, consisting of fine cellular processes between cell
bodies, has been noted in many previous studies (Coggeshall and Carlton, 1997). In
general, GluRl-immunofluorescence was strongest in lamina I and outer-to-mid
lamina II and GluR2-immunofluorescence was strongest in lamina II and less marked
in lamina I and III. The distribution of GluRl and GluR2 immunoreactivity matched
that seen by Todd et al using immunoperoxidase staining and immunofluorescent
labelling (Spike et al., 1998), and also Popratiloff using immunoperoxidase
(Popratiloff et al., 1996). For each experimental group, 6 to 20 optical slices were
analysed. Only the region of dorsal horn supplied by the sciatic nerve was analysed
(see section 4.2.3). Within this region, each slice contained 37 ± 2.6 cells in lamina I,
70 ± 4.7 cells in lamina II and 48 ± 3.0 cells in lamina III (all data shown as mean ±
SEM).
a) GluRl expression
In naive animals, 27.1 ± 1.9% of cells in lamina I were labelled with GluRl
antibody (see Figure 4.3). In lamina II, roughly the same percentage of cells was
GluRl-immunopositive (24.6 ± 1.7%). Fewer cells were GluRl-immunopositive in
lamina III (12.8 ±1.7%). There was no difference in the percentage of GluRl-positive
cells in laminae I or III between any of the experimental groups (ANOVA).
The most notable finding was a marked difference in the percentage of GluRl-
immunopositive cells between ipsilateral (13.4 ± 0.99%) and contralateral (23.62 ±
2.34%) sides of the spinal cord in lamina II found in animals at peak behavioural
sensitisation following CCI surgery (** p < 0.01 Chi-squared test, See Figure 4.3c).
When all experimental groups were compared to nai've animals, the percentage of
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GluRl-immunopositive cells in lamina II of the dorsal horn ipsilateral to injury was
significantly lower (ff p < 0.01 ANOVA versus naive control followed by Dunnett's
post hoc test). There was no difference between the ipsilateral and contralateral sides
for recovered and sham animals in any of the three laminae investigated (Chi-squared
test, See Figure 4.3).
b) GluR2 expression
In naive animals, labelling of neuropil was virtually absent in lamina I.
Compared to GluRl, there were 1/3 fewer cells being labelled in this lamina (18.3 ±
3.0% of all cells). GluR2 labelling of both cells and neuropil was more marked and
more focussed in Lamina II. Some 26.9 ± 2.8% of cells were immunopositive, the
majority being within mid- and inner part of lamina II. Fewer cells were GluR2-
immunopositive in lamina III (15.6 ± 1.8%) (see Figure 4.4).
There was no detectable difference between the ipsilateral and contralateral
sides for recovered animals, sham-operated animals and animals at peak behavioural
sensitisation following CCI, as determined by behavioural sensory reflex testing, in
any of the three laminae investigated (Chi-squared test, See Figure 4.4). None of the
experimental conditions differed from control when compared with naive animals
(ANOVA).
4.3.3 Colocalisation with presynaptic markers
Bassoon and GluRl expression in the spinal dorsal horn in a neuropathic pain
state
Labelling with anti-Bassoon antibody revealed bright, punctate
immunofluorescence throughout the superficial dorsal horn. Labelling was
particularly marked in a band along mid- and inner lamina II. There appeared to be a
complex network of Bassoon-immunopositive elements within the dorsal horn,
surrounding the shadows of cells with small, bright puncta superimposed on the
background immunofluorescence (see Figure 4.5b). GluRl-immunopositive cells
were clearly visible within the dorsal horn and their appearance was not altered by the
presence of Bassoon immunofluorescence.
There were significantly more puncta associated with each lamina II GluRl-
immunopositive cell ipsilateral to injury (4.1 ± 1.0 per cell) as compared to the
contralateral side (2.7 ± 0.7per cell) (* p < 0.05, Mann-Whitney test, See Figure 4.5a),
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and as compared to naive animals (2.1 ± 0.5 per cell) (ft p < 0.01, Kruskal-Wallis
one-way ANOVA on ranks followed by Dunn's post hoc analysis).
Overall Bassoon immunofluorescence was also compared for three regions of
interest from lamina II of dorsal horns on each side of the spinal cord in animals
showing peak behavioural sensitisation due to CCI (see Figure 4.5c). There was no
significant difference in the intensity of Bassoon immunofluorescence between the
two sides of the cord in sensitised animals, suggesting that Bassoon expression itself
was not altered by nerve injury.
Synaptophysin and GluRl expression in the spinal dorsal horn in a neuropathic
pain state
Synaptophysin immunofluorescence was less discrete and less bright than
Bassoon. The antibody did not penetrate well into the tissue slices, leaving only the
upper few layers of each image stack for analysis. However, brighter puncta of
synaptophysin were clearly visible, some of which were associated with GluRl -
immunopositive cells (see Figure 4.7b). There was no significant difference in the
number of synaptophysin puncta associated with each lamina II GluRl -
immunopositive cell ipsilateral to injury (1.3 ± 0.22 per cell) as compared to the
contralateral side (1.8 ± 0.27per cell) (Mann-Whitney test, See Figure 4.7a).
As synaptophysin immunofluorescence was incompletely developed through
the surface layers of the spinal cord slices, it appeared patchy on any given optical
slice. This prevented comparison of overall synaptophysin immunofluorescence
between the ipsilateral and contralateral sides of the spinal cord.
4.3.4 Colocalisation of AMPA receptor subunits in the spinal dorsal horn
When considering all immunopositive cells in lamina II in naive animals, 21.1
+ 2.7% appear to express GluRl alone, 23.2 ± 3.1% appear to express GluR2 alone
and the remainder express both subunits (55.8 ± 3.8%). The proportion of cells
appearing either GluRl-immunopositive or GluR2-immunopositive, or co-expressing
both GluRl and GluR2 did not differ significantly between naive animals and animals
at peak behavioural sensitisation following CCI (Chi-squared test, n=3), suggesting
that the subunit composition of AMPA Rs here is not markedly altered in response to
CCI (see Figure 4.8a).
131
However, there was a significant difference in the proportion of cells
expressing low and high levels of GluRl -fluorescence between experimental groups
(see Figure 4.9a) (* p < 0.05 Chi-squared test). These two levels of fluorescence were
defined as follows: low fluorescence was defined as twice background to 75% of peak
fluorescence for GluRl on that optical slice; high fluorescence was defined as 75% -
100% of peak fluorescence in arbitrary units (0-255) (see section 4.2.5). The same
definitions of high and low fluorescence were applied to GluR2 expression. For naive
animals, a greater proportion of cells tended to express GluRl at a high, rather than
low, level (45.1 ± 5.0% high versus 29.7 ± 4.8% low). The same pattern was noted for
cells contralateral to CCI injury (58.0 ± 2.0% high versus 18.0 ± 3.7% low).
Ipsilateral to CCI injury, this finding was reversed, and the majority of GluRl
expression was at a low level (28.0 ± 4.9% high versus 40.0 ± 7.1% low) (n=3). This
represents a significant reduction in the proportion of cells labelled with high levels of
GluRl immunofluorescence ipsilateral to CCI injury (* p = 0.0377, Chi-squared test,
see Figure 4.9). No such suggestion of a change in the pattern of labelling intensity
was seen for GluR2 fluorescence, and there was no apparent difference between the
experimental groups in the proportion of cells expressing high and low levels of
GluR2 (see Figure 4.9b).
4.3.5 Receptors influencing the subcellular distribution of AMPA receptor
subunits
Subcellular GluRl distribution
Several distinct patterns of GluRl distribution occurred within
immunopositive dorsal horn cells of nai've animals. In one population, the GluRl-
immunopositive region closely surrounded the nucleus in a ring-shape, with
occasional projections indenting it deeply (see Figure 4.10e, lamina I, CCI con).
Often, the GluRl-immunopositive region was thicker towards one end of the cell (see
Figure 4.10e, lamina II, nai've). Less commonly, GluRl-immunopositive cytoplasm
was seen streaming away from the nucleus, towards processes, up to 40pm long (see
Figure 4.10e, lamina II, AMPA or CCI ips). In a number of cells, labelling appeared
punctate (see Figure 4.10e, lamina II, CCI ips), whilst in others the distribution of
GluRl immunoreactivity appeared more homogeneous (see Figure 4.10e, lamina 1,
naive).
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The ring-shaped perinuclear GluRl pattern may represent the resting state,
whereas redistribution of GluRl subunits reflects trafficking of GluRl further from
the nucleus towards sites of synaptic plasticity during sensitisation. This change in the
pattern of subcellular GluRl immunoreactivity caused the linear extent of GluRl -
immunopositive cytoplasm to increase. The mean linear extent of GluRl -
immunopositive cytoplasm within the dorsal horn cell (as a multiple of nuclear
diameters) was evaluated, potentially as a measure of the degree of redistribution of
AMPA R subunits.
There was no significant difference in the mean length of GluRl -
immunopositive cytoplasm in lamina I cells in dorsal horns of na'ive animals, those
treated with AMPA or those ipsilateral or contralateral to nerve injury (1.40 ± 0.02
nuclear diameters) (see Figure 4.10a).
Major changes in subcellular GluRl subunit distribution occurred at peak
behavioural sensitisation following CCI in lamina II. There was a marked increase in
the mean length of GluRl-immunopositive cytoplasm in lamina II dorsal horn cells on
the side ipsilateral to CCI injury when compared to the contralateral side (2.00 ± 0.06
nuclear diameters versus 1.62 ± 0.03 nuclear diameters). There was also a similar
increase in GluRl-immunopositive cytoplasm length within the dorsal hom cells after
intrathecal AMPA treatment (1.97 ± 0.04 nuclear diameters) (** p < 0.01 Kruskal-
Wallis one-way ANOVA on ranks followed by Dunn's post hoc test).
There was no difference in the mean length of GluRl-immunopositive
cytoplasm between lamina II dorsal horn cells of naive animals, those contralateral to
injury and animals treated with intrathecal saline (mean GluRl-immunopositive
length 1.54 ± 0.02 nuclear diameters) (see Figure 4.10b).
The mean length of GluRl-immunopositive cytoplasm within cells in lamina
III was similar to that seen in lamina I (1.46 ± 0.04 nuclear diameters), and there was
no significant difference between experimental groups (see Figure 4.10c).
Subcellular GluR2 distribution
The immunofluorescence associated with GluR2 was more diffuse than
GluRl, and did not appear punctate. Cells were labelled in a perinuclear fashion and,
unlike the GluRl subunit, did not appear to include labelling of processes of any
length (see Figure 4.11b). As fewer cells throughout the dorsal horn were labelled
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clearly enough to allow accurate measurement of their length, data were collected for
lamina II only. Unlike GluRl, there was no significant difference in the mean length
of cells in lamina II of dorsal horns of naive animals, those treated with AMPA or
those ipsilateral or contralateral to nerve injury (Kruskal-Wallis one-way ANOVA on
ranks) (see Figure 4.1 la).
4.3.6 Effects of specific receptor antagonists on AMPA receptor subunit
subcellular distribution in neuropathic pain
The appearance of the GluRl immunopositive cells in this study did not differ
from that noted previously (See Figure 4.12b). After administration of the AMPA R
antagonist NBQX, overall appearances changed little. Some cells demonstrated
labelling of GluRl further from the centre of the cell along processes whereas others
demonstrated a perinuclear pattern of fluorescence (see Figure 4.12b).
Intrathecal administration of antagonists to mGlul/5R, NMDA R and
VPAC2R in combination caused a reversal in the subcellular redistribution of GluRl
that was seen in animals at peak behavioural sensitisation following CCI ipsilateral to
injury. The group receiving the combination of antagonists showed no difference in
mean length of GluRl-immunopositive cytoplasm within dorsal horn cells in lamina
II between the side ipsilateral to CCI injury and the contralateral side (1.45 ± 0.04
nuclear diameters versus 1.40 ± 0.02 nuclear diameters) (Mann-Whitney test) (see
Figure 4.12a). However, the difference in mean length of GluRl-immunopositive
cytoplasm between the two sides of the cord was not reversed by administration of an
AMPA R antagonist alone. In this experimental group, the cells on the side ipsilateral
to CCI injury (1.55 ± 0.04 nuclear diameters) had a greater mean spread of GluRl
immunopositive cytoplasm than those on the contralateral side (1.35 ± 0.03 nuclear
diameters) (**p < 0.05, Mann-Whitney test).
The above findings suggest that the change in subcellular GluRl distribution
associated with sensitisation may be reversed by administration of antagonists to
mGluRl/5, NMDA R and VPAC2 R in combination, but not by an antagonist to the
AMPA R alone. These data suggest that CCI-mediated activation of this combination
of receptors is instrumental in causing subcellular re-distribution of GluRl following
nerve injury.
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Figure 4.1 The time course of development of thermal hyperalgesia, mechanical and cold
allodynia ipsilateral to CCI injury, a) The time taken for hindpaw withdrawal from a noxious
thermal stimulus was measured before and at several time points after CCI surgery to the
sciatic nerve (n=8). Data shown as mean ± SEM. Significant differences between the
ipsilateral (o) and contralateral (■) paws were determined by paired Student's t tests (* p <
0.05, ** p < 0.01). Differences between pre-operative and post-operative values were
determined by Student-Newmann-Keuls repeated measures ANOVA (f p < 0.05, ft P ^
0.01). b) Paw withdrawal responses to von Frey filaments (n=8) were measured at the same
time points. Significant differences between ipsilateral (o) and contralateral (■) paws were
determined by a Wilcoxon test (* p < 0.05, ** p < 0.01), and differences between pre- and
post-operative values were determined by Friedman repeated measures ANOVA on ranks
followed by Dunn's post hoc test (t P ^ 0.05, tt P ^ 0.01). c) The suspended paw withdrawal
time (SPET) to a cold water stimulus (n=8) was also noted. Significant differences between
paws were determined by paired Student's t tests (* p < 0.05, ** p < 0.01). Differences
between pre-operative and post-operative values were determined by repeated measures
ANOVA followed by Dunnett's post hoc test (tt P ^ 0.01).
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Figure 4.2 Confocal microscope image of the dorsal horn of a naive animal, using x20 (a) or
x40 (b) lens to show GluR1-immunopositive cells labelled with fluorescent secondary antibody
(rabbit polyclonal anti-GluR1, Alexa Fluor 568 goat anti rabbit - red), GluR2-immunopositive
cells labelled with fluorescent secondary antibody (mouse monoclonal anti-GluR2, Alexa
Fluor 488 goat anti mouse - green) and To Pro3 nuclear marker (blue). A shows a GluR1-






« -lit: .5 <
<
» ■' w i fc
■






















Lateral « . %.
%
rik - I h.
■ * .» - J 99f a*
■i #»- <#• @ A fSt '
"• "
♦ ft • •
' * V® * ,
••" *-<*< * % * '&
, '
'•'a, - %?:. ■■ „•







Figure 4.3 a) Shows GluR1-immunopositive cells labelled with fluorescent secondary
antibody (red) and To Pro3 nuclear marker (blue) in the dorsal horn of a naive animal (x20). A
GluR1-immunopositive cell (circled). Scale bar 50pm. b)-d) GluR1-immunopositive cells were
counted and the ratio of immunopositive cells to the total number of To Pro3 positive nuclei in
laminae I, II and III was calculated as a percentage (b-d). Data are shown as mean ± SEM
(n=3-6). At peak sensitisation, as determined by behavioural sensory reflex testing, chronic
constriction injury results in a marked relative decrease in the number of GluR1-
immunopositive cell bodies in lamina II (but not I or III) of the dorsal horn ipsilateral to the
injury, compared to the contralateral side (** p < 0.01, Chi-squared test), and to recovered
animals, sham surgery animals and naive controls (ft P ^ 0.01, ANOVA versus naive control
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Figure 4.4 a) Shows GluR2-immunopositive cells labelled with fluorescent secondary
antibody (green) and To Pro3 nuclear marker (blue) in the dorsal horn of a naive animal
(x20). A indicates a GluR2-immunopositive cell (circled). Scale bar 50pm. b)-d) GluR2-
immunopositive cells were counted and the ratio of immunopositive cells to the total number
in laminae I, II and III calculated as a percentage (b-d). Data shown as mean ± SEM (n=3-6).
At peak sensitisation, as determined by behavioural sensory reflex testing, chronic
constriction injury did not result in any significant change in the number of GluR2-
immunopositive cells in laminae I to III of the dorsal horn when compared to naive animals,
animals showing behavioural recovery from CCI or animals after sham CCI surgery (Chi-
squared test was used to compare ipsilateral and contralateral sides. ANOVA was used to
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Figure 4.5 The effect of sensitisation induced by chronic constriction injury on the expression
of Bassoon, a presynaptic nerve terminal protein, associated within GluR1 immunopositive
cells (defined as the number of Bassoon immunopositive puncta within 0.5pm of a GluR1-
immunopositive cell), a) At peak sensitisation due to CCI, there was a significant increase in
the number of Bassoon-immunopositive puncta (defined as a group of 9 or more pixels with a
green intensity level of at least 75% of the maximum found on that image) associated with
each GluR1-immunopositive cell in lamina II of the dorsal horn ipsilateral to injury when
compared to the contralateral side (* p = 0.0372, Mann-Whitney test). Data are shown as
mean ± SEM. There were significantly more Bassoon puncta per cell ipsilateral to CCI injury
than in naive animals on comparing all three experimental groups (tt P ^ 0.01, Kruskal-Wallis
one-way ANOVA on ranks and Dunn's post hoc analysis), b) Images of typical cells within
lamina II ipsilateral and contralateral to CCI injury. The images show GluR1-immunopositive
cells labelled with fluorescent secondary antibody (red), Bassoon-immunopositive puncta
labelled with fluorescent secondary antibody (mouse monoclonal anti-Bassoon, Alexa Fluor
488 goat anti mouse - green), and To Pro3 nuclear marker (blue). White arrows indicate
Bassoon puncta associated with each GluR1-immunopositive cell (within 0.5pm of a GluR1-
immunopositive cell, scale bars 10pm). c) Differences in overall Bassoon
immunofluorescence between ipsilateral and contralateral dorsal horns at peak sensitisation
due to CCI were investigated in three regions of lamina II (x10) (n=3). There was no
significant difference in Bassoon immunofluorescence between the ipsilateral and
contralateral sides in any of the regions of interest (Mann-Whitney test, data shown as mean
± SEM).
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Figure 4.6 Analysis of the fluorescence intensity profile of images from dorsal horn. Leica
Confocal Software lite was used to analyse all images, a) The profile tool allows
measurement of fluorescent intensity on a scale of 0 to 255 for each red, green or blue colour
channel along a given axis. This application was used to measure the linear extent of
immunofluorescent cytoplasm within cells and the nuclear densities along the same axis. The
red dashed line indicates the extent of GluR1 immunofluorescence above baseline. The blue
dashed line indicates the extent of To Pro3 nuclear DS DNA labelling - taken as 50% of peak
blue fluorescence. The red striped area represents the extent of GluR1 immunofluorescence
within the cell body (in this case 1.2pm). b) The histogram tool measures various parameters
within a selected region of interest (ROI). The region of interest is shown on a typical x10 view
of a dorsal horn labelled with anti-Bassoon antibody and fluorescent secondary antibody
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Figure 4.7 The effect of sensitisation induced by chronic constriction injury on the expression
of synaptophysin, an integral membrane glycoprotein concentrated in presynaptic vesicles in
apposition to GluR1-immunopositive cells, a) At peak sensitisation due to CCI, there was no
difference in the number of synaptophysin-immunopositive puncta associated with each
GluR1-immunopositive cell in lamina II of the dorsal horn ipsilateral to injury when compared
to the contralateral side (Mann-Whitney test). Data are shown as mean ± SEM. b) Images of
typical cells within lamina II ipsilateral and contralateral to CCI injury. The images show
GluR1-immunopositive cells labelled with fluorescent secondary antibody (red),
synaptophysin-immunopositive puncta labelled with fluorescent secondary antibody (green),
and To Pro3 nuclear marker (blue). White arrows indicate synaptophysin puncta associated
with each GluR1-immunopositive cell. Scale bar 10pm.
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Figure 4.8 a) The proportion of GluR1-immunopositive or GluR2-immunopositive cells and
cells co-expressing both receptor subtypes in lamina II was calculated for each dorsal horn for
naive animals and animals at peak sensitisation due to chronic constriction injury, as
determined by behavioural sensory reflex testing. The proportion of each pattern of receptor
expression (ie: GluR1 only, GluR2 only or both) did not change at peak sensitisation due to
chronic constriction injury (each value is the mean ± SEM. Chi-Squared test with four degrees
of freedom (n=3) b) Shows GluR1-immunopositive cells labelled with fluorescent secondary
antibody (red), GluR2-immunopositive cells labelled with fluorescent secondary antibody
(green) and To Pro3 nuclear marker (blue). (A) Shows a GluR1-immunopositive cell (circled),
(B) shows a GluR2-immunopositive cell (circled), (C) shows a cell strongly expressing both
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Figure 4.9 a) The proportion of GluR1 and GluR2-immunopositive cells expressing high and
low levels of fluorescence (low fluorescence defined as twice baseline to 75% of maximum
intensity for that slice. High fluorescence was defined as intensity from 75-100% of maximum
for that slice) (Section 4.2.5) was noted in lamina II of the dorsal horn of naive animals and
animals at peak sensitisation due to chronic constriction injury, as determined by behavioural
sensory reflex testing. Each value is the mean ± SEM. (n=3). The proportion of GluR1-
immunopositive cells expressing high levels of fluorescence in lamina II of the dorsal horn
decreased significantly at peak sensitisation due to chronic constriction injury, as determined
by behavioural sensory reflex testing, ipsilateral to injury (p < 0.05, Chi-Squared test.). No
significant difference was noted between the experimental groups for GluR2-immunopositive
cells, b) Typical cells demonstrating high and low levels of GluR1 (red) and GluR2-
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Figure 4.10 a)-c) The linear extent of GluR1-immunopositive cytoplasm within cells in the
dorsal horn was measured as a multiple of the nuclear diameter for each immunopositive cell
at x40 or x63 magnification within laminae l-lll (a-c). GluR1 -immunofluorescence was
measured above background, and the nuclear density was measured as 50%-100% of
maximum blue fluorescence as in previous experiments (see Figure 4.6). Peak sensitisation
induced by chronic constriction injury or intrathecal AMPA administration resulted in a marked
change in the subcellular distribution of GluR1 AMPA R subunits within immunopositive cells
in lamina II, compared to naive animals and controls treated with intrathecal saline (** p <
0.01, Kruskal-Wallis one-way ANOVA on ranks followed by Dunn's post hoc test. Data are
shown as the mean ± SEM (n=3)). There were no significant differences between
experimental groups in lamina I or III. d) Redistribution of GluR1 subunits was not seen in
naive animals, animals showing behavioural recovery from CCI or animals after sham CCI
surgery in lamina II (Kruskal-Wallis one way ANOVA on ranks followed by Dunn's post hoc
test), e) To show typical cells from lamina l-lll (x40). GluR1-immunopositive cells were
labelled with fluorescent secondary antibody (red) and To Pro3 nuclear marker (blue). Scale
bars 10pm.
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Figure 4.11 a) The linear extent of GluR2-immunopositive cytoplasm within cells in lamina II
of the dorsal horn was recorded for each immunopositive cell, as a multiple of nuclear
diameters at x40 or x63 magnification. Peak sensitisation induced by chronic constriction
injury or intrathecal AMPA administration did not result in any significant change in the
subcellular distribution of GluR2 AMPA R subunits in immunopositive cells in lamina II,
compared to animals naive to any treatment and control animals given saline intrathecal^
(Kruskal-Wallis one-way ANOVA on ranks followed by Dunn's post hoc test. Data are shown
as mean ± SEM (n=3)). b) Shows typical cells from lamina II (x40). GluR2-immunopositive
cells were labelled with fluorescent secondary antibody (green) and To Pro3 nuclear marker
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Figure 4.12 a) The linear extent of GluR1-immunopositive cytoplasm within cells in lamina II
was recorded as a multiple of the nuclear diameter for animals at peak sensitisation due to
CCI, after treatment with various key antagonist drugs at x40 magnification (n=3). The
difference in mean linear extent of immunoreactivity between ipsilateral and contralateral
sides was compared after combined blockade of the mGlu1/5R, NMDA R and VPAC2R and
after AMPA R blockade alone. Blockade of all the non-AMPA Rs reversed the subcellular
redistribution of AMPA R GluR1 subunits demonstrated in cells in lamina II of the dorsal horn
ipsilateral to CCI injury (Mann-Whitney rank sum test. No difference could be detected
between ipsilateral and contralateral sides p=0.88). Blockade of the AMPA R alone did not
reverse this redistribution (a significant difference remained between ipsilateral and
contralateral sides p=0.003). b) Confocal images of typical lamina II dorsal horn cells (x40).
The images show GluR1-immunopositive cells labelled with fluorescent secondary antibody
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4.4 Discussion
These experiments were carried out to investigate the effect of an animal
model of neuropathic pain induced by chronic, peripheral nerve constriction on the
expression and subcellular location of AMPA R GluRl and GluR2 subunits.
Studies of neuropathic pain have focused on traumatic peripheral nerve injury
as a trigger for generation of central sensitisation, usually involving the rat sciatic
nerve (Boucher and McMahon, 2001). At mid-thigh level, this nerve consists of some
27000 axons consisting of 6% motor, 23% myelinated sensory, 48% unmyelinated
sensory and 23% unmyelinated sympathetic fibres (Schmalbruch, 1986). It is ideally
placed for generating models of neuropathic pain as it is accessible in the hind limb
and is large enough for easy handling. It arises from the L4 - S2 spinal roots and
contains four subdivisions (the sural, lateral sural, superficial peroneal and tibial
nerves), which may be manipulated independently. Also, the contralateral nerve may
serve as an intrinsic control in certain studies. Some models of neuropathic pain such
as the Seltzer technique of partial sciatic nerve damage result in behavioural changes,
that are partly bilateral, however (Seltzer et al., 1990).
The model used in this study was the chronic constriction injury (CCI) model
of Bennett and Xie (Bennett and Xie, 1988). This model relies on partial nerve
damage rather than complete transection, with the intact axons providing peripheral
skin sensation and also acting to increase the intensity of sensitisation (Lee et al.,
2003). The pharmacological profile of sciatic CCI is similar to that seen in human
neuropathic pain and it may be compared to direct nerve trauma in humans. The
frequency of autotomy is lower in this model than following sciatic transection, and
there was no evidence of its occurrence in the current study (Bennett and Xie, 1988),
(Attal et al., 1990). The sympathetic nervous system (SNS) appears to be affected in
CCI, as sympathectomy often improves the thermal hyperalgesia seen in this model
whereas mechanical and cold allodynia are not affected (Desmeules et al., 1995),
(Perrot et al., 1993). This model may result in thermal, mechanical and cold allodynia
to a variable extent, which parallels the variable responses of human subjects to
seemingly similar nerve injuries (see Figure 4.1).
It is known that there are changes in the spinal expression of GluRl and
GluR2 subunits in various pain paradigms including CCI, many of which may involve
central sensitisation. Decreases in GluRl and GluR2/3 were found in a model of
spinal cord injury (Grossman et al., 1999). In a model of peripheral inflammation, an
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early decrease in GluRl and GluR2/3 was demonstrated in the trigeminal nucleus
(Florenzano and De Luca, 1999). Three days after dorsal rhizotomy, GluRl and
GluR2/3 immunostaining was found to decrease in the superficial dorsal horn. This
finding may have been due to loss of receptors from primary afferents or to loss of
expression in intrinsic dorsal horn neurons (Carlton et ah, 1998). Following partial
sciatic deafferentation using pronase, an ipsilateral decrease in GluRl was
demonstrated in the sciatic nerve territory of the superficial dorsal horn (Helgren et
al., 1999). In joint inflammation a bilateral decrease in GluRl was noted (Pellegrini-
Giampietro et al., 1994).
Some studies noted an increase in AMPA R subunit expression. Following
spinal cord section, GluR2/3 expression increased in the dorsal horn (Popratiloff et al.,
1998). Harris et al reported a small but significant increase in GluRl and GluR2/3
expression in the superficial dorsal horn 14 days after CCI ipsilateral to the injury
using an avidin-biotin peroxidase technique (Harris et al., 1996). However, a similar
increase was also found after treatment with the NMDA antagonist MK-801 given in
a regime known to prevent thermal hyperalgesia in animals after CCI surgery. As the
increase in receptor expression did not alter with NMDA blockade, its functional
significance remains unclear. Recent studies have also revealed an ipsilateral increase
in GluR2 mRNA in lamina I and II dorsal horn cells in CCI, with no change in the
number of cells expressing this subunit (Garry et al., 2003b).
4.4.1 Immunohistochemisty of the superficial dorsal horn
The cytoarchitecture of the dorsal horn, and in particular lamina II is very
complex. Axons, dendrites, neuronal cell bodies and glia are closely apposed and
overlap. Quantitative analysis of confocal images of the dorsal horn using
immunofluorescent antibodies proved to be difficult as the axons and dendrites
forming the neuropil around neurons was also brightly labelled. A number of
strategies were tried to delineate the extent of individual neurons with greater clarity.
Firstly, we attempted to label the cell membrane with an antibody to the a3 subunit of
the ubiquitous Na+/K+ ATPase (rabbit anti-Na+/K+ ATPase, Upstate Ltd.). This was
unsuccessful as background labelling was excessively high. The cytoskeletal protein
MAP2 (microtubule associated protein 2, mouse anti-MAP2, Sigma Aldrich Ltd.) was
labelled in another attempt to identify the axons and dendrites of individual cells. This
technique was effective in demonstrating neuronal processes and revealed a complex
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system of fibres running perpendicular to lamina II, with occasional processes passing
dorsally into lamina I (see Figure 4.13). However, it was not generally possible to
follow the processes of individual cells any further from the nucleus using this
technique, due to overlapping of fibres from neighbouring cells.
The antibodies used to label GluRl and GluR2 have been used in many other
studies and their specificity has been confirmed (Hollmann and Heinemann, 1994),
(Agrawal and Fehlings, 1997), (Kumar et al., 2002). It has also been demonstrated
that the anti-GluRl antibody used binds both unphosphorylated and phosphorylated
forms of the receptor (Fang et al., 2003). It is clear that quantitative analysis of
immunofluorescent studies of intact spinal cord sections proved difficult, and
visualisation of individual small neuronal processes impossible. However, large
processes were visible in a number of cells.
4.4.2 AMPA receptor subtype expression in the dorsal horn
These results provide new insight into the expression and distribution of
AMPA R GluRl/2 subtypes in the dorsal horn of the rat in an experimental model of
neuropathic pain. The most notable finding was a marked decrease in the proportion
of cell bodies seen in lamina II of the DH that were GluRl immunoreactive and a
redistribution of GluRl on a subcellular level. The mean linear extent of GluRl
immunopositive cytoplasm in the longest axis of the cells was shown to be
significantly greater in cells ipsilateral to CCI in lamina II, and following AMPA
treatment (see Figure 4.10). This finding suggests that GluRl subunits may be
redistributing away from the nucleus towards more distant parts of the cell. The
proportion of GluRl immunopositive cell bodies and their subcellular distribution
both returned to normal on recovery from CCI. There was no apparent change in the
proportion of GluRl immunoreactive cell bodies in lamina I or III, following CCI.
The relative lack of changes in lamina I or III may reflect their differing roles
in sensory processing. Lamina I contains many projection neurons, which connect to
higher centres via the STT and SMT (Todd et al., 2000), (Todd, 2002). It has been
demonstrated that 75% of lamina I neurons are nocispecific, the remainder being type
II WDR neurons (Seagrove et al., 2004). Cells in lamina I may become sensitised by
increased excitatory input from altered neuronal responses in lamina II, leading to
central sensitisation (Willis et al., 1979). Unmyelinated nociceptor C fibres terminate
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predominantly in lamina II, so it is unsurprising that changes resulting from peripheral
nerve injury occur here (Willis and Coggeshall, 1991).
Lamina III receives the primary afferents (mainly large A(3 fibre) of hair
follicles, Pacinian corpuscles and rapidly adapting low threshold mechanoreceptors.
Second order neurons send dendrites from lamina III to laminae I and IV, in addition
to ascending tracts (Brown et al., 1981). Ap fibre mechanoreceptor neurons undergo
functional changes after sciatic nerve transection, establishing functional synaptic
contact with intemeurons in lamina II and transmitting innocuous information to the
substantia gelatinosa (Okamoto et al., 2001). This represents a marked functional
alteration in spinal cord circuitry and may account in part for the sensory
abnormalities occurring in neuropathic pain (see section 1.11.3). It is possible that
these changes occur via mechanisms which do not involve redistribution of AMPA
Rs. The somatosensory output from lamina III neurons may remain relatively
unchanged in neuropathic pain, and abnormal signal modification via sensitised
lamina I neurons, or novel connections within lamina II, result in the interpretation of
innocuous stimuli as noxious and the sensation of allodynia.
In contrast to the changes seen in GluRl, the expression of GluR2 subunits
appeared unaltered by CCI. These findings are open to a number of possible
interpretations. There may be a decrease in overall expression levels of GluRl within
cells, resulting in the cytoplasm becoming immunonegative. It is know that neurons
may rapidly change their subunit composition in response to stimulation, becoming
less Ca2+ permeable and incorporating more GluR2 into the receptors (Liu and Cull-
Candy, 2000). Any reduction in GluRl expression would result in a shift in the ratio
of receptor subtype expression towards GluR2, as we have shown that approximately
50% of DH neurons coexpress GluRl and GluR2. This change may lead to an overall
decrease in AMPA R Ca2+ permeability. Since there is some evidence that a major
proportion of GluRl is expressed in inhibitory cells (Spike et al., 1998), this may
represent a loss of function of inhibitory cells or perhaps a compensatory decrease in
the function of excitatory cells in response to CCI (see section 1.6.4). Either of these
potential mechanisms may occur, as the majority of cells expressing Ca2+ permeable
AMPA Rs would seem to play an inhibitory role but a significant minority of neurons
expressing this receptor subtype have a modulatory or excitatory role in nociceptive
transmission. The possibility that the apparent decrease in GluRl represents a loss of
inhibitory function is supported by some studies (see section 1.11.4) (Robertson et al.,
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1997). The apparent decrease in GluRl expression could be investigated further using
Western Blotting techniques. Contrary to the above hypothesis, some studies have
reported an increase in GluRl expression ipsilateral to CCI, although this finding
could not be reproduced in our lab (unpublished data) (Harris et al., 1996).
Another possibility is that it is loss of entire cells that causes disinhibition.
GluRl has been shown to be coexpressed with GABA on inhibitory cells in the DH
(Spike et ah, 1998), and loss of GABA IR has been recorded in CCI (Ibuki et ah,
1997). It has been suggested that apoptotic cell death in response to prolonged
noxious stimuli may underlie the loss of inhibitory function (Coggeshall et ah, 2001).
The role of cell death is far from clear, however, and although Moore et al
demonstrated a significant decrease in GABAa mediated currents and a small but
significant decrease in the expression of a GABA synthesizing enzyme (GAD65), less
than two cells per spinal dorsal horn were found to have undergone apoptosis (Moore
et ah, 2002). In addition, a recent study did not demonstrate any evidence of cell loss
or of decreasing GABA expression in CCI (Polgar et ah, 2003).
It is important to note that the proportion of immunopositive cell bodies was
found to return to pre-operative levels on recovery from CCI. This finding links
changes in GluRl expression to the behavioural changes found following CCI, and
suggests that it is unlikely that a large proportion of cells are undergoing apoptosis in
this process.
Although there was an apparent decrease in the proportion of cells expressing
GluRl, there was no obvious decrease in the overall level of GluRl
immunofluorescence ipsilateral to CCI. This leads to an alternative interpretation of
the experimental findings. The level of fluorescence of neuropil in the superficial
laminae of the DH did not appear to differ markedly between both sides of the cord.
This was not measured quantitatively here, but protein expression levels could be
assessed using Western Blotting. It is possible that overall expression of GluRl did
not change, and that the apparent decrease in the proportion of GluRl immunopositive
cell bodies was due to the redistribution of GluRl subunits to areas of synaptic
plasticity in the axons and dendrites of the neuron and away from the perinuclear
region. Once redistributed to peripheral parts of the cell, the GluRl
immunofluorescence may have been lost against the background neuropil, leaving the
perinuclear region GluRl immunonegative and dark.
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The results of the current study demonstrate that there are significant changes
in GluRl distribution within cells in the CCI model of neuropathic pain.
Redistribution of mGluRs in the dorsal horn following application of DHPG has been
previously reported (Yashpal et al., 2002), but the subcellular redistribution of GluRl
in the CCI model of neuropathic pain is a novel finding.
Changes in the subcellular distribution of GluRl subunits were also apparent
following intrathecal administration of AMPA (see Figure 4.10). These changes were
very similar in appearance and extent to those found following CCI, with the mean
linear extent of GluRl immunopositive cytoplasm shown to be significantly greater in
lamina II neurons following AMPA treatment, suggesting that GluRl subunits may be
redistributing away from the nucleus. It is known that activation of AMPA Rs causes
spontaneous nociceptive behaviour at higher doses, but it has not been previously
demonstrated that this finding is associated with a subcellular redistribution of GluRl
in vivo (Meller et al., 1996).
In contrast to GluRl subunits, GluR2 appeared relatively inert. No change in
the number of cells expressing GluR2 was noted in the current study, nor was there
any discernable change in the subcellular location of this subtype in neurons in lamina
II These differences in GluRl and GluR2 expression in CCI may be explained by
their differing mechanisms of trafficking to the membrane. GluRl is known to move
to sites of synaptic plasticity (Aicher et al., 2002), in response to specific stimuli and
is inserted into synapses in a tightly controlled manner (Hayashi et al., 2000),
(Passafaro et al., 2001). In contrast, GluR2 is known to cycle constitutively (Shi et al.,
2001), (Borgdorff and Choquet, 2002), and to be inserted directly into synapses from
an intracellular pool beneath the membrane (references in (Bredt and Nicoll, 2003)).
Recent studies have shown an increase in the expression of GluR2 following CCI,
with no increase in the number of cells expressing this subunit. It was also found that
GluR2 moved from the membrane compartment into the intracellular compartment
ipsilateral to nerve injury (Garry et al., 2003b). This may represent GluR2 trafficking
over very small distances, resulting in an important functional redistribution of
AMPA Rs, which was not visible on confocal microscopy at the magnification used in
the current study.
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Figure 4.13 a) Shows GluR1-immunopositive cells labelled with fluorescent secondary
antibody (red) and To Pro3 nuclear marker (blue) in the dorsal horn of a naive animal (x63).
Axons, cytoplasm and dendrites are labelled with MAP2 (microtubule associated protein 2)
antibody and fluorescent secondary antibody (green). The image is centred on lamina II, with
lamina I towards the top left and lamina III towards the bottom right. Scale bar 10pm.
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4.4.3 Expression of Bassoon and synaptophysin in the dorsal horn
These results demonstrate that there is an increased association between
GluRl receptors and Bassoon puncta ipsilateral to nerve injury (see section 4.3.3).
This may represent increased GluRl density at synaptic sites. Bassoon is thought to
be involved in the structural organisation of the neurotransmitter release site (Wilson,
2003). In situ hybridisation has revealed that Bassoon transcripts are widely
distributed in the brain and occur primarily in excitatory neurons, but examples of
GABAergic neurons expressing Bassoon have also been detected. In cultured
hippocampal neurons, Bassoon was found to colocalise with GABAa and glutamate
(GluRl) receptors. These data indicate that Bassoon is a component of the presynaptic
apparatus of both excitatory and inhibitory synapses (Righter et al., 1999). Studies of
synaptogenesis have revealed that Bassoon would appear to cluster in new synaptic
boutons within 30minutes of their formation, suggesting that it would act as a marker
of both newly formed and established synapses (Friedman et al., 2000).
The image magnification available using confocal laser microscopy did not
allow examination of synaptic structures on a nanometre scale. Further studies using
electron microscopy would be required to investigate the subcellular location of
GluRl. It is also possible that many more Bassoon immunopositive puncta were
associated with GluRl on neuronal processes distant from the nucleus, which were
not visible due to the complex cytoarchitecture of lamina II.
No change was noted in the overall level of Bassoon-immunofluorescence on
either side of the cord in established neuropathy. Levels of protein expression could
be assessed in a more quantitative fashion using techniques such as Western Blotting.
Although we found no obvious change in Bassoon expression, there is evidence to
suggest that other synaptic proteins may be upregulated following nerve injury. For
example, synaptophysin levels were increased in the ipsilateral dorsal horn with a
peak level on day 14 and returned to baseline on day 21 post injury using
immunohistochemistry, Western immunoblotting and densitometry (Chou et al.,
2002). Levels of this synaptic marker increased in parallel to the emergence of
thermal hyperalgesia, but not mechanical allodynia in this study. The authors suggest
that this may represent synaptogenesis occurring ipsilateral to nerve injury. In the
current study, the immunofluorescent labelling of synaptophysin was not as consistent
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as that for Bassoon and it was not possible to assess overall levels of expression of
this protein.
4.4.4 Colocalisation of GluRl/2 in the dorsal horn
In addition to the subcellular location of AMPA R subunits, the co-expression
of GluRl and GluR2 by superficial dorsal horn neurons was investigated. It is known
that GluRl and GluR2 AMPA R subunits may be expressed within the same cell
(Zhang et al., 1995a), (Aicher et al., 2002) but their expression in the superficial
dorsal horn is generally limited to separate bands (Tolle et al., 1993), (Coggeshall and
Carlton, 1997). AMPA Rs can also rapidly change their subunit composition in
response to stimulation (Liu and Cull-Candy, 2000). The current study was designed
to determine whether the co-expression of GluRl and GluR2 in lamina II of the dorsal
horn changes as a result of CCI.
On initial inspection, GluRl and GluR2 appear to occur in different cell
populations, divided into bands in the superficial dorsal horn (Furuyama et al., 1993),
(Tolle and et al, 1993). However, the present study revealed that in lamina II of the
spinal dorsal horn in nai've animals, only 21% of all immunopositive cells expressed
GluRl alone and 25% expressed GluR2 alone. The majority of cells (56%)
coexpressed both receptor subtypes. This finding is in keeping with previous studies
which revealed that some 50% of dendritic spines were immunopositive to both
GluRl and GluR2/3 in hippocampal cells (Bernard et al., 1997).
This finding is important as these cells are likely to demonstrate variable levels of
calcium permeability, and no generalisation as to their function can be made.
However, a significant proportion of cells do not express GluR2 and are likely to be
calcium permeable. It is interesting to note that the proportion of cells expressing both
GluRl and GluR2 did not change in neuropathy. As these measurements were made
from cytoplasmic regions near the nucleus, the possibility remains that changes in
colocalisation may have occurred at regions of synaptic connectivity distant from the
cell body. These results also show that the levels of GluRl expression were lower in
the cell bodies ipsilateral to CCI. This may represent GluRl migration away from
perinuclear areas.
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4.4.5 Reversal of GluRl redistribution
The current study revealed that the redistribution of GluRl subunits seen in
neurons ipsilateral to CCI injury in lamina II can be reversed following treatment with
a combination of antagonists to the NMDA R, mGluRl/5 and VPAC2 R. These
antagonists have previously been shown to significantly attenuate neuropathic pain
behaviour (see Figure 4.12). NMDA R blockade using systemically administered
MK-801 reversed hyperalgesia following CCI (Mao et al., 1992a). Blockade of the
VPAC2 R suppressed neuronal responses to prolonged noxious input in both normal
and nerve-injured rats (Dickinson et al., 1999). Ablation of group I mGluRs using
antibody treatment reversed cold allodynia in a CCI model of neuropathy and
blockade of mGluR5 using SIB 1757 reversed thermal hyperalgesia in a SNL model
(Dogrul et al., 2000). It is highly likely that administration of a combination of these
three antagonists would result in a particularly effective reversal of behavioural reflex
sensitisation in CCI. This finding suggests that the reversal of GluRl redistribution
would be associated with reversal of the behavioural changes seen in neuropathic
pain.
Interestingly, intrathecal treatment with the AMPA R antagonist NBQX alone
failed to reverse the redistribution of GluRl subunits at peak behavioural change
following CCI. It is known that various stimuli may cause trafficking of AMPA Rs to
and from the cell membrane (Luscher and Frerking, 2001), and that blockade of
AMPA Rs and related proteins may result in the reversal of behavioural reflex
sensitisation that is thought to reflect neuropathic pain (Mao et al., 1992a), (Garry et
al., 2003b).
The previously demonstrated reversal of thermal hyperalgesia using an AMPA
R antagonist alone (NBQX 5nmol) was relatively short lived, lasting 15-30mins post
injection (Garry et al., 2003b). It is possible that AMPA R blockade may reverse
behavioural changes as it prevents continuing stimulus from entering the dorsal horn
transiently, switching off sensitisation. It is known that AMPA R blockade may result
in the prevention of transmission of both noxious and innocuous stimuli (Dougherty et
al., 1992). The effect of AMPA R antagonism alone may be analogous to that of a
local anaesthetic agent acting through sodium channel blockade. Peripheral nerve
blockade may also be transiently effective in preventing neuropathic hyperalgesia and
allodynia, but usually fails to demonstrate long term relief (Abram, 2000).
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The spinal cord specimens used in the current study were obtained 35-40mins
following intrathecal injection of NBQX (20nmol). At this time point, the behavioural
effects of the drug found in a previous study had resolved (Garry et al., 2003b). It is
possible that transient changes in the subcellular location of GluRl may have
occurred during this period, which would not have been apparent on analysis of tissue
taken at 35mins post injection.
4.4.6 Summary
The current study has revealed significant changes in the apparent expression
and subcellular location of GluRl subunits within lamina II ipsilateral to CCI. It is
clear that changes in the function of lamina II neurons may influence the processing
of nociceptive and innocuous somatosensory information, resulting in central
sensitisation. In the context of other reports in the literature, the results are consistent
with the idea that the induction of reflex sensitisation may result from both an
increase in excitatory function and a decrease in inhibitory function of lamina II
neurons.
It was possible to reverse the redistribution of GluRl subunits within lamina II
cells demonstrated following CCI using a combination of antagonists known to
attenuate behavioural reflex sensitisation, suggesting that trafficking of GluRl
subunits may play a significant part in neuropathic pain. Also, blockade of AMPA
receptors alone was not sufficient to reverse these changes, suggesting that continued
activation of NMDA, mGluR and VPAC2 Rs is important in maintaining this
sensitised state, but continued AMPA R activation is not essential.
There were no apparent changes in the expression or subcellular distribution of
GluR2 subunits following nerve injury. This does not exclude significant functional
changes in the role of this receptor subunit in neuropathic pain, however.
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Chapter 5: Summary and conclusions
Neuropathic pain is known to involve marked plastic changes in synaptic and
neuronal structure and function including changes is neurotransmitter and receptor
expression in the DRG and dorsal hom (Hokfelt et al., 1994). However, the role of
AMPA Rs and their interaction with other neurotransmitter systems in this sensitised
state has not been fully elucidated.
5.1 Behavioural studies
The use of behavioural reflex techniques provides valuable information about
the response of the intact animal to drug treatment, potentially including the
functioning of higher brain centres and intact inhibitory mechanisms. However, this
paradigm is limited in the amount of information that can be obtained regarding the
mechanism of the processes involved in generating specific behaviours.
The most marked behavioural finding was the synergistic effect on
sensitisation of thermal nociceptive responses found between AMPA, Ro 25-1553 and
DHPG. It is possible that the activation of AMPA Rs would reproduce the effects of
ongoing noxious and innocuous sensory input thought to be required to maintain
central sensitisation, as AMPA Rs mediate the majority of monosynaptic excitatory
postsynaptic potentials (EPSP) in the dorsal horn evoked by C fibres (Gracely et al.,
1992), (Liu et al., 2000) (see Figure 3.3). This AMPA-mediated stimulus may be
sufficient to trigger central sensitisation in the spinal cord (Sotgiu et al., 1994), (Lee et
al., 2003). In addition, activation of calcium permeable AMPA Rs may have a specific
effect by triggering second messenger systems that activate many downstream
processes including phosphorylation of NMDA Rs and AMPA Rs (see section 1.6.4
(Sorkin et al., 2001)).
Although the current behavioural study has revealed that combinations of
receptors may be activated in central sensitisation, the changes occurring in the spinal
dorsal horn during neuropathic pain are somewhat different. The duration of noxious
stimulation is far longer following nerve injury, permitting transcription dependant
changes in the expression of neurotransmitters and receptors to occur over hours to
days (see section 1.11), (Hokfelt et al., 1994). Also, central sensitisation in
neuropathic pain occurs following release of glutamate and co-transmitters from
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primary sensory neurons, which would initially affect local dorsal horn neurons and
activate many more receptor types than those considered in the current study.
The duration of reflex sensitisation was limited to 90minutes following drug
treatment, in most cases, which is far shorter than the duration of sensory changes
following damage to a peripheral nerve. It is likely that the effect of intrathecal
agonist administration was terminated by local metabolism, redistribution within the
CSF or absorption into the circulation. The low frequency ongoing afferent input from
injured and uninjured axons required to maintain a neuropathic state is also lacking in
drug treatment. The absence of this afferent barrage may have allowed more rapid
recovery from sensitisation (Gracely et al., 1992), (Liu et al., 2000), (see section
1.11.2).
Long-lasting sensitisation could, potentially be triggered by increasing the
duration of exposure to the agonist drugs. This could be achieved using intrathecal
infusions of drugs delivered to experimental animals via an osmotic minipump and
intrathecal catheter. However, the current study utilised a simple intrathecal injection
technique. Halothane was used as the sole anaesthetic agent for all studies, as is does
not interact with AMPA Rs at clinically relevant concentrations, whereas certain
barbiturate anaesthetic agents may cause channel blockade (Joo et ah, 1999), (Joo et
ah, 2001). The insertion of intrathecal catheters requires more invasive surgery and
results in an inflammatory response that takes several days to recover (Dib, 1984).
Catheter insertion may also affect levels of endogenous opioids and potentially cause
long-lasting changes to the responsiveness of neurons to further stimuli (Dib et ah,
1991).
5.2 Immunocytochemistrv
The findings of the behavioural study suggested that further investigation of
the role of the AMPA Rs in neuropathic sensitisation was warranted. AMPA Rs are
involved in the fast transmission of noxious and innocuous stimuli, and mediate the
majority of monosynaptic excitatory postsynaptic potentials (EPSP) in the dorsal horn
evoked by C fibres (Procter et ah, 1998), (Stanfa and Dickenson, 1999).
The GluRl and GluR2 AMPA R subunits were chosen for further study for a
number of reasons. Firstly, they are expressed significantly by neurons in the
superficial dorsal horn of the spinal cord, and have been localised to synaptic densities
in lamina II on electron micrography (Tachibana et ah, 1994), (Popratiloff et ah,
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1996), (Todd et al., 1998). Electron microscopy has revealed that these subunits were
found between 30nm outside and 40nm inside the postsynaptic membrane of
asymmetric synapses, associated with two types of nerve terminal. GluRl subunits
were associated with CI terminal boutons and unmyelinated primary afferents, and
GluR2/3 with C2 terminal boutons and small myelinated afferents (RibeiroDaSilva
and Coimbra, 1982). It is therefore likely that these two receptor subtypes play an
important role in nociception, and their distribution in the CCI model of neuropathic
pain was investigated in detail using immunohistochemistry and confocal microscopy.
Initial experiments revealed an apparent marked decrease in the proportion of
cell bodies expressing GluRl in lamina II of the DH ipsilateral to CCI at peak
neuropathic change in reflex responses (25% to 15%) (see Figure 4.3). It would seem
likely that this is due to a redistribution of GluRl distally into regions of synaptic
connectivity or a reduction in expression rather than cell death (see section 4.4.2).
This hypothesis is supported by the finding that there was no deficit in the proportion
of cells expressing GluRl in animals showing recovery from CCI (see Figure 4.3).
The current study revealed a significant subcellular redistribution of GluRl
subunits in the dorsal horn in neuropathy (see Figure 4.10 and section 4.4.2).
Although it is known that 60-85% of total GluRl protein and 40-80% of total
GluR2/3 protein was expressed on the surface of hippocampal neurons, only a very
small proportion of these receptors are localized at synapses (Hall and Soderling,
1997), (Grosshans et al., 2002). A study of apical dendrites in hippocampal cells
revealed 71% of GluRl subunits to be localised intracellularly in the dendritic shafts,
20% on the dendritic shaft surface, 8% in spines and only 3% in postsynaptic densities
(Shi et al., 1999). This suggests that there is a large pool of receptors available for
insertion into the synapse.
We also provide evidence to suggest that redistribution of GluRl is
functionally significant. Firstly, redistribution was demonstrated at peak CCI and
absent in recovered animals - this suggests that there is a functional association
between GluRl redistribution and neuropathic pain, but it was not possible to prove
causality. Receptor redistribution also occurred following high dose AMPA treatment,
which has been shown to cause behavioural reflex sensitisation (see section 3.4) and
which may be sufficient to trigger central sensitisation (see Figure 4.10).
Subcellular redistribution of GluRl was also associated with an increase in the
number of Bassoon-immunoreactive puncta in contact with each GluRl-
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immunopositive neuron (see Figure 4.5). This may reflect the movement of GluRl-
containing AMPA Rs towards sites of synaptic activity for insertion into the PSD.
AMPA Rs containing GluRl subunits are added to synapses during neuronal
plasticity; requiring an interaction between GluRl and PDZ domain proteins (Hayashi
et al., 2000). The insertion of AMPA Rs into excitatory synapses would result in an
increased number of EPSPs and play a role in the initiation of central sensitisation in
the spinal cord. In addition, insertion of AMPA Rs consisting of tetramers of GluRl
94- . • .
into the synapse would increase Ca permeability, permitting further depolarisation
and activating numerous calcium dependant second messenger systems (Sorkin et al.,
1999). Some 20% of lamina II neurons were found to express GluRl only, so the
• 94- • • • •
contribution of Ca permeable AMPA Rs to synaptic transmission in the DH may be
highly significant. However, the AMPA R subunit colocalisation study revealed that
80% of immunopositive lamina II cells expressed GluR2, suggesting that the degree
of calcium-permeability of the majority of lamina II cells is reduced. There was no
change in the proportion of colocalised cells in a neuropathic state, so it was not
possible to generalise as to which group of cells demonstrated GluRl redistribution.
In addition to increased excitatory transmission due to GluRl redistribution
leading to increased AMPA R insertion into synapses in excitatory neurons, GluRl
expression may decrease within inhibitory interneurons, reducing their
responsiveness. This hypothesis is supported by the finding that down regulation of
GluRl subunits following administration of the pro inflammatory cytokine IFN-y
resulted in a GABA-independent increase in spontaneous excitatory activity in
neuronal culture (Robertson et al., 1997). GluRl redistribution and down-regulation
may result in an overall change in the balance of excitatory / inhibitory function
resulting in central sensitisation (Dickenson, 1996).
The current study demonstrated the reversal of GluRl redistribution in
established neuropathy using combinations of antagonists. Whether this finding
reflects long-term reversal of behavioural reflex sensitisation and long-term analgesia
remains to be determined. Also, the current study does not provide evidence for a
causal role for GluRl redistribution in central sensitisation.
Blockade of AMPA Rs alone was not effective in restoring pre-injury GluRl
distribution (see Figure 4.12). It is possible that blockade of AMPA Rs alone is not
sufficient to release AMPA Rs containing GluRl subunits from the PSD, where they
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are bound via the C-terminal tail to the postsynaptic density protein SAP-97, and
actin-associated protein 4. IN, which has been shown to increase AMPA R density at
postsynaptic sites in cell cultures (Shen et al., 2000), (Rumbaugh et al., 2003). AMPA
Rs containing GluR2 are also stabilised at the PSD by ABP and GRIP (Osten et al.,
2000). The interaction between GluR2 and PICK1 has also been shown to be
important in the maintenance of thermal hyperalgesia in neuropathic pain (Garry et
al., 2003b) (see section 1.9.4). It is possible that blockade of mGluR, VPAC2 R and
NMDA Rs is sufficient to release GluRl and possibly GluR2 containing AMPA Rs
from the PSD, reversing the redistribution of GluRl in established neuropathy. This
may reflect a long-term reversal of central sensitisation. This could be investigated
further using the behavioural paradigm and administering antagonists to combinations
of receptor subtypes to animals with established neuropathic sensitisation. It is
possible that combinations of multiple antagonists would lead to a prolonged and
extensive reversal of behavioural reflex sensitisation.
In contrast to the marked changes in GluRl expression revealed in the current
study, the expression and subcellular location of the GluR2 subunit did not appear to
change in response to CCI or AMPA treatment. AMPA Rs incorporating the GluR2
subunit have been shown to constitutively cycle to and from synapses in hippocampal
cells (Shi et al., 2001). Although no changes in GluR2 distribution were seen in the
current study, trafficking of this receptor is likely to be important in neuropathic pain,
as it has been recently demonstrated that blockade of GluR2 interaction with adapter
proteins in the dorsal horn results in a reduction in thermal hyperalgesia in CCI (Garry
et al., 2003b). It is known that at least 50% of AMPA Rs containing the GluR2
subunit are localised beneath the cell membrane within vesicles containing GRIP and
PICK1 in hippocampal cells (Lee et al., 2001). It is possible that insertion of GluR2
AMPA Rs occurs from these intracellular stores located close to the synapse, which
was not apparent using immunofluorescent antibodies and confocal microscopy.
There may have been significant functional changes in the role of GluR2 at peak
neuropathy, which could be more effectively investigated using electrophysiological
techniques (see section 1.6.2).
Behavioural studies revealed a synergistic interaction between AMPA Rs and
mGluR group I, and VPAC2 Rs in the generation of thermal hyperalgesia.
Behavioural sensitisation following CCI is accompanied by a redistribution of GluRl
AMPA R subunits towards sites of synaptic plasticity in lamina II of the dorsal horn.
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This redistribution may also be triggered by treatment with AMPA. GluRl
redistribution is reversed on behavioural recovery from CCI or treatment with a
combination of antagonists to NMDA Rs, mGluR group I, and VPAC2 peptide Rs. It
is suggested that reversal of GluRl redistribution by a combination of antagonists
may result in prolonged reversal of central sensitisation occurring in neuropathic pain.
In conclusion the current study provides evidence using behavioural and
immunohistochemical techniques for the importance of AMPA Rs in the induction of
central sensitisation, and the redistribution of GluRl subunits in neuropathic pain.
5.3 Therapeutic implications
Further study is required before the therapeutic potential of these findings can
be assessed. The behavioural responses of rats at peak neuropathic sensitisation, to
combinations of the antagonists used in the current study would provide useful
information as to the duration and effectiveness of reversal of neuropathic pain
behaviour. Electron microscopy may provide further information regarding the
subcellular redistribution of GluRl/2 in neuropathy. Functional investigation of the
changes in dorsal horn neuron responsiveness using electrophysiological techniques
may provide additional information as to the specific roles of GluRl and 2 subunits in
neuropathic pain.
The therapeutic potential of AMPA blockade has been assessed in a number of
paradigms. Non-specific blockade of all AMPA Rs has been shown to result in loss of
all sensory transmission and would initially be thought inappropriate in the
management of chronic pain (Dougherty et al., 1992). However, it is clear that low
doses of AMPA R antagonists can strongly inhibit neuropathic sensitisation at levels
which have no detectable effect on naive unsensitised responses (Garry et al., 2003b).
As well as their possible value in neuropathic pain such AMPA R antagonists may
have a role in suppressing excitotoxicity in other clinical situations such as head
injury (Belayev et al., 2001).
It is possible that blockade of AMPA R subtypes may be effective in
9+
alleviating certain types of pain. For example, blockade of Ca permeable AMPA Rs
using JsTx reduced mechanical allodynia following a burn injury (Sorkin et al., 1999).
Recently, the GluR2 subunit has been shown to be important in neuropathic pain.
Blockade of the interaction between GRIP / PICK1 and GluR2 resulted in a marked
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attenuation of the thermal hyperalgesia seen after induction of reflex sensitisation by
CCI (Garry et al., 2003b), (Garry and Fleetwood-Walker, 2004).
The findings of the current study suggest that there may also be therapeutic
potential in the use of multiple antagonist drugs in combination to treat neuropathic
pain. Multiple antagonist treatment may result in unbinding of AMPA Rs from the
PSD, potentially resulting in long-term pain relief. Combinations of antagonists could
be given at lower doses, resulting in fewer systemic side effects. However, as many of
the drugs used are peptides and unable to cross the blood-brain barrier, or survive
enteral dosing intact, they would have to be administered via the intrathecal route.
Non-peptide agents may of course be developed in the future. Although intrathecal
injection results in high drug concentrations focussed at the required site, it is not a
practical route of administration if long-term repeated dosing is required.
It is also of note that certain antagonists are likely to be more effective in
treating differing modalities of sensory abnormality. Attempts have been made to
rationalise the treatment of various neuropathic pain conditions. Treatments have been
targeted at specific conditions, at individual symptoms and at underlying mechanisms.
However, it would seem that there are often no clear associations between the
presenting symptoms of the condition, its aetiology or response to treatment. On
reviewing the effectiveness of drug therapies in neuropathic pain, there were no clear
relations between the mechanism of action of the drugs and their effectiveness in
distinct pain conditions, or for single drug classes and different pain conditions
(Sindrup and Jensen, 1999). Treatment based on the specific mechanisms underlying
various neuropathic pain conditions has been suggested, but it is not yet possible to
establish the underlying changes in the CNS resulting in neuropathic pain in a clinical
setting (Woolf and Mannion, 1999).
Attempts to treat specific symptoms, rather than underlying mechanisms, with
tailored therapy in neuropathic pain have been largely unsuccessful to date, possibly
because the drugs employed such as membrane stabilisers, tricyclic antidepressants,
sodium and calcium channel blockers and opioids do not target receptors linked to
specific aspects of central sensitisation. Potentially, treatment with combinations of
antagonists to particular receptors, such as those shown to play a role here, may allow
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EVIDENCE FOR SYNERGISM BETWEEN GLUTAMATE AND PEPTIDE RECEPTORS IN
THE GENERATION OF HYPERALGESIC PAIN STATES
Mark Rockett. Lesley Colvin, Sue Fleetwood-Walker (SPON: Lesley Colvin). Department of
Preclinical Veterinary Science, Royal (Dick) School of Veterinary Studies, Summerhall
Square, Edinburgh, EH9 1QH, Scotland.
Aim of investigation To determine the relationship between various key receptors in the
development of an hyperalgesia pain state in the rat.
Methods Male rats were injected intrathecal^, under brief halothane anaesthesia, with
agonists to the ionotropic glutamate receptors N-methyl-D-aspartate (NMDAR), a-amino-3-
hydroxy-5-methyl-4-'soxazolepropionic acid (AMPAR), the Group I metabotropic glutamate
(mGlu) receptors and the vasoactive intestinal polypeptide (VPAC2) peptide receptor. The
drugs were administered individually, in pairs and in triple combinations. After recovery from
anaesthesia, the latency of paw withdrawal (PWL) to a noxious thermal stimulus (Hargreaves)
and the withdrawal threshold to mechanical stimuli (von Frey) was recorded every ten
minutes for ninety minutes.
Results All individual drugs caused a statistically significant decrease in PWL for a period
after injection. Injection of pairs of agonists had a similar effect. However, injection of a triple
agonist combination of AMPA, Ro-25-1553; VPAC2 receptor agonist, and DHPG (3,5-
dihydroxyphenylglycine; mGlu Group I agonist) caused a more marked decrease in PWL than
the sum of all other combinations
Conclusions The greater than additive effect of the triple AMPA, Ro-25-1553 and DHPG
injection, suggests ;hat there may be a synergistic interaction between these three receptors
in the development of hyperalgesic states. This study suggests that there may be scope for
developing therapies directed towards more than one receptor in the treatment of chronic pain
states in humans.
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